

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Turcot, V., Lu, Y., Highland, H. M., Schurmann, C., Justice, A. E., Fine, R. S., Kee, F., Hirschhorn, J. N., & Loos, R. J. F. (2018). Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. *Nature Genetics*, 50, 26-41. <https://doi.org/10.1038/s41588-017-0011-x>

Published in:
Nature Genetics

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

© 2017 Nature America Inc., part of Springer Nature. All rights reserved.
This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure underpinning obesity

Valérie Turcot^{1*}, Yingchang Lu^{2,3,4*}, Heather M Highland^{5,6*}, Claudia Schurmann^{3,4*}, Anne E Justice^{5*}, Rebecca S Fine^{7,8,9*}, Jonathan P Bradfield^{10,11}, Tõnu Esko^{7,9,12}, Ayush Giri¹³, Mariaelisa Graff⁵, Xiuqing Guo¹⁴, Audrey E Hendricks^{15,16}, Tugce Karaderi^{17,18}, Adelheid Lempradl¹⁹, Adam E Locke^{20,21}, Anubha Mahajan¹⁷, Eirini Marouli²², Suthesh Sivapalaratnam^{23,24,25}, Kristin L Young⁵, Tamuno Alfred³, Mary F Feitosa²⁶, Nicholas GD Masca^{27,28}, Alisa K Manning^{7,24,29,30}, Carolina Medina-Gomez^{31,32}, Poorva Mudgal³³, Maggie CY Ng^{33,34}, Alex P Reiner^{35,36}, Sailaja Vedantam^{7,8,9}, Sara M Willems³⁷, Thomas W Winkler³⁸, Goncalo Abecasis²⁰, Katja K Aben^{39,40}, Dewan S Alam⁴¹, Sameer E Alharthi^{22,42}, Matthew Allison⁴³, Philippe Amouyel^{44,45,46}, Folkert W Asselbergs^{47,48,49}, Paul L Auer⁵⁰, Beverley Balkau⁵¹, Lia E Bang⁵², Inês Barroso^{15,53,54}, Lisa Bastarache⁵⁵, Marianne Benn^{56,57}, Sven Bergmann^{58,59}, Lawrence F Bielak⁶⁰, Matthias Blüher^{61,62}, Michael Boehnke²⁰, Heiner Boeing⁶³, Eric Boerwinkle^{64,65}, Carsten A Böger⁶⁶, Jette Bork-Jensen⁶⁷, Michiel L Bots⁶⁸, Erwin P Bottinger³, Donald W Bowden^{33,34,69}, Ivan Brandslund^{70,71}, Gerome Breen^{72,73}, Murray H Brilliant⁷⁴, Linda Broer³², Marco Brumat⁷⁵, Amber A Burt⁷⁶, Adam S Butterworth^{77,78}, Peter T Campbell⁷⁹, Stefania Cappellani⁸⁰, David J Carey⁸¹, Eulalia Catamo⁸⁰, Mark J Caulfield^{22,82}, John C Chambers^{83,84,85}, Daniel I Chasman^{7,86,87,88}, Yii-Der Ida Chen¹⁴, Rajiv Chowdhury⁷⁷, Cramer Christensen⁸⁹, Audrey Y Chu^{87,90}, Massimiliano Cocca⁹¹, Francis S Collins⁹², James P Cook⁹³, Janie Corley^{94,95}, Jordi Corominas Galbany^{96,97}, Amanda J Cox^{33,34,98}, David S Crosslin⁹⁹, Gabriel Cuellar-Partida^{100,101}, Angela D'Eustacchio⁸⁰, John Danesh^{15,77,78,102}, Gail Davies^{94,95}, Paul IW de Bakker^{68,103}, Mark CH de Groot^{104,105}, Renée de Mutsert¹⁰⁶, Ian J Deary^{94,95}, George Dedoussis¹⁰⁷, Ellen W Demerath¹⁰⁸, Martin den Heijer¹⁰⁹, Anneke I den Hollander⁹⁷, Hester M den Ruijter¹¹⁰, Joe G Dennis¹¹¹, Josh C Denny⁵⁵, Emanuele Di Angelantonio^{77,78}, Fotios Drenos^{112,113}, Mengmeng Du^{114,115}, Marie-Pierre Dubé^{1,116}, Alison M Dunning¹¹⁷, Douglas F Easton^{111,117}, Todd L Edwards¹³, David Ellinghaus¹¹⁸, Patrick T Ellinor^{7,24,30}, Paul Elliott¹¹⁹, Evangelos Evangelou^{84,120}, Aliko-Eleni Farmaki^{107,121}, I. Sadaf Farooqi^{53,54}, Jessica D Faul¹²², Sascha Fauser¹²³, Shuang Feng²⁰, Ele Ferrannini^{124,125}, Jean Ferrieres¹²⁶, Jose C Florez^{7,24,29,30}, Ian Ford¹²⁷, Myriam Fornage¹²⁸, Oscar H Franco³¹, Andre Franke¹¹⁸, Paul W Franks^{129,130,131}, Nele Friedrich¹³², Ruth Frikke-Schmidt^{57,133}, Tessel E. Galesloot⁴⁰, Wei Gan¹⁷, Ilaria Gandin¹³⁴, Paolo Gasparini^{75,135}, Jane Gibson¹³⁶, Vilmantas Giedraitis¹³⁷, Anette P Gjesing⁶⁷, Penny Gordon-Larsen^{138,139}, Mathias Gorski^{38,66}, Hans-Jörgen Grabe^{140,141}, Struan FA Grant^{10,142,143}, Niels Grarup⁶⁷, Helen L Griffiths¹⁴⁴, Megan L Grove⁶⁴, Vilmundur Gudnason^{145,146}, Stefan Gustafsson¹⁴⁷, Jeff Haessler³⁶, Hakon Hakonarson^{10,142}, Anke R Hammerschlag¹⁴⁸, Torben Hansen⁶⁷, Kathleen Mullan Harris^{138,149}, Tamara B Harris¹⁵⁰, Andrew T Hattersley¹⁵¹, Christian T Have⁶⁷, Caroline Hayward¹⁵², Liang He^{153,154}, Nancy L Heard-Costa^{90,155}, Andrew C Heath¹⁵⁶, Iris M Heid^{38,157}, Øyvind Helgeland^{158,159}, Jussi Hernesniemi^{160,161,162}, Alex W Hewitt^{163,164,165}, Oddgeir L Holmen¹⁶⁶, G Kees Hovingh¹⁶⁷, Joanna MM Howson⁷⁷, Yao Hu¹⁶⁸, Paul L Huang²⁴, Jennifer E Huffman¹⁵², M Arfan Ikram^{31,169,170}, Erik Ingelsson^{147,171}, Anne U Jackson²⁰, Jan-Håkan Jansson^{172,173}, Gail P Jarvik^{76,174}, Gorm B Jensen¹⁷⁵, Yucheng Jia¹⁴, Stefan Johansson^{159,176}, Marit E Jørgensen^{177,178}, Torben Jørgensen^{57,179,180}, J Wouter Jukema^{181,182}, Bratati Kahali^{183,184,185,186}, René S Kahn¹⁸⁷, Mika Kähönen^{188,189}, Pia R Kamstrup⁵⁶, Stavroula Kanoni²², Jaakko Kaprio^{154,190,191}, Maria Karaleftheri¹⁹², Sharon LR Kardia⁶⁰, Fredrik Karpe^{193,194}, Sekar Kathiresan^{7,24,88}, Frank Kee¹⁹⁵, Lambertus A Kiemeny⁴⁰, Eric Kim¹⁴, Hidetoshi Kitajima¹⁷, Pirjo Komulainen^{196,197,198}, Jaspal S Koener^{83,85,199,200}, Charles Kooperberg³⁶, Tellervo Korhonen^{191,201,202}, Peter Kovacs⁶¹, Helena Kuivaniemi^{81,203}, Zoltán Kutalik^{59,204}, Kari Kuulasmaa¹⁹¹, Johanna Kuusisto²⁰⁵, Markku Laakso²⁰⁵, Timo A Lakka^{196,197,198}, David Lamparter^{58,59}, Ethan M Lange²⁰⁶, Leslie A Lange²⁰⁶, Claudia Langenberg³⁷, Eric B Larson^{76,207,208}, Nanette R Lee^{209,210}, Terho Lehtimäki^{161,162}, Cora E Lewis²¹¹, Huaixing Li¹⁶⁸, Jin Li²¹², Ruifang Li-Gao¹⁰⁶, Honghuang Lin²¹³, Keng-Hung Lin²¹⁴, Li-An Lin¹²⁸, Xu Lin¹⁶⁸, Lars Lind²¹⁵, Jaana Lindström¹⁹¹, Allan Linneberg^{180,216,217}, Ching-Ti Liu²¹⁸, Dajiang J Liu²¹⁹, Yongmei Liu²²⁰, Ken Sin Lo¹, Artitaya Lophatananon²²¹, Andrew J Lotery¹⁴⁴, Anu Loukola^{154,190}, Jian'an Luan³⁷, Steven A Lubitz^{7,24,30}, Leo-Pekka Lyytikäinen^{161,162}, Satu Männistö¹⁹¹, Gaëlle Marenne¹⁵, Angela L Mazul⁵, Mark I McCarthy^{17,193,194}, Roberta McKean-Cowdin²²², Sarah E Medland¹⁰¹, Karina Meidtner^{223,224}, Lili Milani¹², Vanisha Mistry^{53,54}, Paul

Mitchell²²⁵, Karen L Mohlke²⁰⁶, Leena Moilanen²²⁶, Marie Moitry^{227,228}, Grant W Montgomery^{101,229}, Dennis O Mook-Kanamori^{106,230}, Carmel Moore^{78,231}, Trevor A Mori²³², Andrew D Morris²³³, Andrew P Morris^{17,93}, Martina Müller-Nurasyid^{157,234,235}, Patricia B Munroe^{22,82}, Mike A Nalls^{236,237}, Narisu Narisu⁹², Christopher P Nelson^{27,28}, Matt Neville^{193,194}, Sune F Nielsen^{56,57}, Kjell Nikus¹⁶⁰, Pål R Njølstad^{158,159}, Børge G Nordestgaard^{56,57}, Dale R Nyholt^{101,238}, Jeffrey R O'Connell²³⁹, Michelle L. O'Donoghue²⁴⁰, Loes M Olde Loohuis²⁴¹, Roel A Ophoff^{187,241}, Katharine R Owen^{193,194}, Chris J Packard¹²⁷, Sandosh Padmanabhan¹²⁷, Colin NA Palmer²⁴², Nicholette D Palmer⁶⁹, Gerard Pasterkamp^{110,243}, Aniruddh P Patel^{7,24,88}, Alison Pattie⁹⁵, Oluf Pedersen⁶⁷, Peggy L Peissig⁷⁴, Gina M Peloso²¹⁸, Craig E Pennell²⁴⁴, Markus Perola^{191,245,246}, James A Perry²³⁹, John RB Perry³⁷, Tune H Pers^{67,247}, Thomas N Person⁷⁴, Annette Peters^{224,235,248}, Eva RB Petersen²⁴⁹, Patricia A Peyser⁶⁰, Ailith Pirie¹¹⁷, Ozren Polasek^{233,250}, Tinca J Polderman¹⁴⁸, Hannu Puolijoki²⁵¹, Olli T Raitakari^{252,253}, Asif Rasheed²⁵⁴, Rainer Rauramaa^{196,197,198}, Dermot F Reilly²⁵⁵, Frida Renström^{129,256}, Myriam Rheinberger⁶⁶, Paul M Ridker^{87,88,240}, John D Rioux^{1,116}, Manuel A Rivas^{7,257}, David J Roberts^{78,258,259}, Neil R Robertson^{17,193}, Antonietta Robino⁸⁰, Olov Rolandsson^{172,260}, Igor Rudan²³³, Katherine S Ruth²⁶¹, Danish Saleheen^{254,262}, Veikko Salomaa¹⁹¹, Nilesh J Samani^{27,28}, Yadav Sapkota¹⁰¹, Naveed Sattar¹²⁷, Robert E Schoen²⁶³, Pamela J Schreiner²⁶⁴, Matthias B Schulze^{223,224}, Robert A Scott³⁷, Marcelo P Segura-Lepe⁸⁴, Svati H Shah²⁶⁵, Wayne H-H Sheu^{266,267,268}, Xueling Sim^{20,269}, Andrew J Slater^{270,271}, Kerrin S Small²⁷², Albert Vernon Smith^{145,146}, Lorraine Southam^{15,17}, Timothy D Spector²⁷², Elizabeth K Speliotes^{183,184,185}, John M Starr^{94,273}, Kari Stefansson^{145,274}, Valgerdur Steinthorsdottir²⁷⁴, Kathleen E Stirrups^{22,25}, Konstantin Strauch^{157,275}, Heather M Stringham²⁰, Michael Stumvoll^{61,62}, Liang Sun^{153,154}, Praveen Surendran⁷⁷, Amy J Swift⁹², Hayato Tada^{240,276}, Katherine E Tansey^{113,277}, Jean-Claude Tardif^{1,116}, Kent D Taylor¹⁴, Alexander Teumer²⁷⁸, Deborah J Thompson¹¹¹, Gudmar Thorleifsson²⁷⁴, Unnur Thorsteinsdottir^{145,274}, Betina H Thuesen¹⁸⁰, Anke Tönjes²⁷⁹, Gerard Tromp^{81,280}, Stella Trompet^{181,281}, Emmanouil Tsafantakis²⁸², Jaakko Tuomilehto^{191,283,284,285}, Anne Tybjaerg-Hansen^{57,133}, Jonathan P Tyrer¹¹⁷, Rudolf Uher²⁸⁶, André G Uitterlinden^{31,32}, Matti Uusitupa²⁸⁷, Sander W van der Laan¹¹⁰, Cornelia M van Duijn³¹, Nienke van Leeuwen^{288,289}, Jessica van Setten⁴⁷, Mauno Vanhala^{201,290}, Anette Varbo^{56,57}, Tibor V Varga¹²⁹, Rohit Varma²⁹¹, Digna R Velez Edwards²⁹², Sita H Vermeulen⁴⁰, Giovanni Veronesi²⁹³, Henrik Vestergaard^{67,178}, Veronique Vitart¹⁵², Thomas F Vogt²⁹⁴, Uwe Völker^{295,296}, Dragana Vuckovic^{75,135}, Lynne E Wagenknecht²²⁰, Mark Walker²⁹⁷, Lars Wallentin²⁹⁸, Feijie Wang¹⁶⁸, Carol A Wang²⁴⁴, Shuai Wang²¹⁸, Yiqin Wang¹⁶⁸, Erin B Ware^{60,299}, Nicholas J Wareham³⁷, Helen R Warren^{22,82}, Dawn M Waterworth³⁰⁰, Jennifer Wessel³⁰¹, Harvey D White³⁰², Cristen J Willer^{183,184,303}, James G Wilson³⁰⁴, Daniel R Witte^{305,306}, Andrew R Wood²⁶¹, Ying Wu²⁰⁶, Hanieh Yaghootkar²⁶¹, Jie Yao¹⁴, Pang Yao¹⁶⁸, Laura M Yerges-Armstrong^{239,307}, Robin Young^{77,127}, Eleftheria Zeggini¹⁵, Xiaowei Zhan³⁰⁸, Weihua Zhang^{83,84}, Jing Hua Zhao³⁷, Wei Zhao²⁶², Wei Zhao⁶⁰, Wei Zhou^{183,184}, Krina T Zondervan^{17,309}, CHD Exome+ Consortium, EPIC-CVD Consortium, ExomeBP Consortium, Global Lipids Genetic Consortium, GoT2D Genes Consortium, InterAct, INTERVAL Study, ReproGen Consortium, T2D-Genes Consortium, The MAGIC Investigators, Understanding Society Scientific Group, Jerome I Rotter¹⁴, John A Pospisilik¹⁹, Fernando Rivadeneira^{31,32}, Ingrid B Borecki²⁶, Panos Deloukas^{22,42}, Timothy M Frayling²⁶¹, Guillaume Lettre^{1,116§}, Kari E North^{310§}, Cecilia M Lindgren^{17,311§}, Joel N Hirschhorn^{7,9,312§}, Ruth JF Loos^{3,4,313§}

* These authors contributed equally to this work.

§ These authors jointly supervised this work.

AFFILIATIONS

1. Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, H1T 1C8, Canada
2. Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, 37203, USA
3. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
4. The Genetics of Obesity and Related Metabolic Traits Program, Icahn School of Medicine at Mount Sinai, New York, NY, 10069, USA
5. Department of Epidemiology, University of North Carolina, Chapel Hill, NC, 27514, USA
6. Human Genetics Center, The University of Texas School of Public Health, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA
7. Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
8. Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA
9. Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, MA, 02115, USA
10. Center for Applied Genomics, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
11. Quantinuum Research LLC, San Diego CA, 92101, USA
12. Estonian Genome Center, University of Tartu, Tartu, 51010, Estonia
13. Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN, 37203, USA
14. Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, 90502, USA
15. Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK
16. Department of Mathematical and Statistical Sciences, University of Colorado, Denver, CO, 80204, USA
17. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
18. Department of Biological Sciences, Faculty of Arts and Sciences, Eastern Mediterranean University, Famagusta, Cyprus
19. Max Planck Institute of Immunobiology and Epigenetics, Freiburg, 79108, Germany
20. Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, 48109, USA
21. McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO, 63108, USA
22. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
23. Department of Vascular Medicine, AMC, Amsterdam, 1105 AZ, The Netherlands
24. Massachusetts General Hospital, Boston, MA, 02114, USA
25. Department of Haematology, University of Cambridge, Cambridge, CB2 0PT, UK
26. Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, MO, 63108, USA
27. Department of Cardiovascular Sciences, Univeristy of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK
28. NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, LE3 9QP, UK
29. Department of Medicine, Harvard University Medical School, Boston, MA, 02115, USA
30. Medical and Population Genetics Program, Broad Institute, Cambridge, MA, 02141, USA
31. Department of Epidemiology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands
32. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands
33. Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA

34. Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
35. Department of Epidemiology, University of Washington, Seattle, WA, 98195, USA
36. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle WA, 98109, USA
37. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, CB2 0QQ, UK
38. Department of Genetic Epidemiology, University of Regensburg, Regensburg, D-93051, Germany
39. Netherlands Comprehensive Cancer Organisation, Utrecht, 3501 DB, The Netherlands
40. Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, 6500 HB, The Netherlands
41. School of Kinesiology and Health Science, Faculty of Health, York University, Toronto
42. Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah, 21589, Saudi Arabia
43. Department of Family Medicine & Public Health, University of California, San Diego, La Jolla, CA, 92093, USA
44. INSERM U1167, Lille, F-59019, France
45. Institut Pasteur de Lille, U1167, Lille, F-59019, France
46. Universite de Lille, U1167 - RID-AGE - Risk factors and molecular determinants of aging-related diseases, Lille, F-59019, France
47. Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands
48. Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The Netherlands
49. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK
50. Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, 53201, USA
51. INSERM U1018, Centre de recherche en Épidémiologie et Santé des Populations (CESP), Villejuif, France
52. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, 2100, Denmark
53. Metabolic Research Laboratories, University of Cambridge, Cambridge, CB2 0QQ, UK
54. NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK
55. Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, 37203, USA
56. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2730, Denmark
57. Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark
58. Department of Computational Biology, University of Lausanne, Lausanne, 1011, Switzerland
59. Swiss Institute of Bioinformatics, Lausanne, 1015, Switzerland
60. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, 48109, USA
61. IFB Adiposity Diseases, University of Leipzig, Leipzig, 04103, Germany
62. University of Leipzig, Department of Medicine, Leipzig, 04103, Germany
63. Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, 14558, Germany
64. School of Public Health, Human Genetics Center, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA
65. Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030 USA
66. Department of Nephrology, University Hospital Regensburg, Regensburg, 93042, Germany

67. The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2100, Denmark
68. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
69. Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
70. Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, 7100, Denmark
71. Institute of Regional Health Research, University of Southern Denmark, Odense, 5000, Denmark
72. MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, SE5 8AF, UK
73. NIHR Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London, BR3 3BX, UK
74. Marshfield Clinic Research Institute, Marshfield, WI, 54449, USA
75. Department of Medical Sciences, University of Trieste, Trieste, 34137, Italy
76. Department of Medicine, University of Washington, Seattle, WA, 98195, USA
77. MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK
78. NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
79. American Cancer Society, Epidemiology Research Program, Atlanta, GA, 30303, USA
80. Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, 34137, Italy
81. Weis Center for Research, Geisinger Health System, Danville, PA 17822
82. NIHR Barts Cardiovascular Research Unit, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
83. Department of Cardiology, London North West Healthcare NHS Trust, Ealing Hospital, Middlesex, UB1 3HW, UK
84. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK
85. Imperial College Healthcare NHS Trust, London, W12 0HS, UK
86. Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
87. Division of Preventive Medicine, Brigham and Women's and Harvard Medical School, Boston, MA, 02215, USA
88. Harvard Medical School, Boston, MA, 02115, USA
89. Medical department, Lillebaelt Hospital, Vejle, 7100, Denmark
90. NHLBI Framingham Heart Study, Framingham, MA, 01702, USA
91. Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, 34100, Italy
92. Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA
93. Department of Biostatistics, University of Liverpool, Liverpool, L69 3GL, UK
94. Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
95. Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
96. Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, 6500 HB, The Netherlands
97. Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, 6500 HB, The Netherlands
98. Menzies Health Institute Queensland, Griffith University, Southport, QLD, Australia
99. Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, 98195, USA
100. Diamantina Institute, University of Queensland, Brisbane, Queensland, 4072, Australia
101. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, 4006, Australia

102. British Heart Foundation Cambridge Centre of Excellence, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK
103. Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands
104. Department of Clinical Chemistry and Haematology, Division of Laboratory and Pharmacy, University Medical Center Utrecht, Utrecht, 3508 GA, The Netherlands
105. Utrecht Institute for Pharmaceutical Sciences, Division Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, 3508 TB, The Netherlands
106. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, 2300RC, The Netherlands
107. Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, 17671, Greece
108. Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, 55454, USA
109. VU University Medical Center, Department of Internal Medicine, Amsterdam, 1007 MB, The Netherlands
110. Laboratory of Experimental Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands
111. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK
112. Institute of Cardiovascular Science, University College London, London, WC1E 6JF, UK
113. MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, BS8 2BN, UK
114. Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA, 98109, USA
115. Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, 10017, USA
116. Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal, Quebec, H3T 1J4, Canada
117. Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK
118. Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany
119. Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, W2 1PG, UK
120. Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, 45110, Greece
121. Department of Health Sciences, University of Leicester, Leicester, LE1 7RH, UK
122. Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, 48104, USA
123. Department of Ophthalmology, University of Cologne, Cologne, 50937, Germany
124. CNR Institute of Clinical Physiology, Pisa, Italy
125. Department of Clinical & Experimental Medicine, University of Pisa, Italy
126. Toulouse University School of Medicine, Toulouse, TSA 50032 31059, France
127. University of Glasgow, Glasgow, G12 8QQ, UK
128. Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA
129. Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmo, SE-20502, Sweden
130. Department of Nutrition, Harvard School of Public Health, Boston, MA, 02115, USA
131. Department of Public Health and Clinical Medicine, Unit of Medicine, Umeå University, Umeå, 901 87, Sweden

132. Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, 17475, Germany
133. Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, 2100, Denmark
134. Ilaria Gandin, Research Unit, AREA Science Park, Trieste, 34149, Italy
135. Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy
136. Centre for Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, SO17 1BJ, UK
137. Geriatrics, Department of Public Health, Uppsala University, Uppsala, 751 85, Sweden
138. Carolina Population Center, University of North Carolina, Chapel Hill, NC, 27514, USA
139. Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, 27514, USA
140. Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, 17475, Germany
141. German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, 17475, Germany
142. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
143. Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, USA
144. Vision Sciences, Clinical Neurosciences Research Group, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK
145. Faculty of Medicine, University of Iceland, Reykjavik, 101, Iceland
146. Icelandic Heart Association, Kopavogur, 201, Iceland
147. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, 751 41, Sweden
148. Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam, Amsterdam, 1081 HV, The Netherlands
149. Department of Sociology, University of North Carolina, Chapel Hill, NC, 27514, USA
150. Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, National Institutes of Health, Bethesda, MD, 20892, USA
151. University of Exeter Medical School, University of Exeter, Exeter, EX2 5DW, UK
152. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
153. Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, NC, 27708, USA
154. Department of Public Health, University of Helsinki, Helsinki, FI-00014, Finland
155. Department of Neurology, Boston University School of Medicine, Boston, MA, 02118, USA
156. Department of Psychiatry, Washington University, Saint Louis, MO, 63110, USA
157. Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, 85764, Germany
158. Department of Pediatrics, Haukeland University Hospital, Bergen, 5021, Norway
159. KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, 5020, Norway
160. Department of Cardiology, Heart Center, Tampere University Hospital, and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, 33521, Finland
161. Department of Clinical Chemistry, Fimlab Laboratories, Tampere, 33521, Finland
162. Department of Clinical Chemistry, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere 33014, Finland
163. Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria, 3002, Australia

164. Centre for Ophthalmology and Vision Science, Lions Eye Institute, University of Western Australia, Perth, Western Australia, 6009, Australia
165. Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, 7000, Australia
166. K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health, NTNU, Norwegian University of Science and Technology, Trondheim, 7600, Norway
167. AMC, Department of Vascular Medicine, Amsterdam, 1105 AZ, The Netherlands
168. Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, People's Republic of China, Shanghai, 200031, China
169. Department of Neurology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands
170. Department of Radiology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands
171. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, 943 05, USA
172. Department of Public Health & Clinical Medicine, Umeå University, Umeå, SE-90185, Sweden
173. Research Unit Skellefteå, Skellefteå, SE-93141, Sweden
174. Department of Genome Sciences, University of Washington, Seattle, WA, 98195, USA
175. The Copenhagen City Heart Study, Frederiksberg Hospital, Frederiksberg, 2000, Denmark
176. Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, 5021, Norway
177. National Institute of Public Health, University of Southern Denmark, Copenhagen, 1353, Denmark
178. Steno Diabetes Center Copenhagen, Gentofte, 2800, Denmark
179. Faculty of medicine, Aalborg University, Aalborg, DK-9000, Denmark
180. Research Center for Prevention and Health, Capital Region of Denmark, Glostrup, DK-2600, Denmark
181. Department of Cardiology, Leiden University Medical Center, Leiden, 2333, The Netherlands
182. The Interuniversity Cardiology Institute of the Netherlands, Utrecht, 2333, The Netherlands
183. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA
184. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA
185. Division of Gastroenterology, University of Michigan, Ann Arbor, MI, 48109, USA
186. Centre for Brain Research, Indian Institute of Science, Bangalore 560012, India
187. Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, 3584 CG, The Netherlands
188. Department of Clinical Physiology, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, 33014, Finland
189. Department of Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland
190. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, FI-00014, Finland
191. National Institute for Health and Welfare, Helsinki, FI-00271, Finland
192. Echinops Medical Centre, Echinops, Greece
193. Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LE, UK
194. Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, OX3 7LE, UK
195. UKCRC Centre of Excellence for Public Health Research, Queens University Belfast, Belfast, UK, BT12 6BJ, UK
196. Foundation for Research in Health Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, 70100, Finland
197. Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio Campus, 70210, Finland

198. Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland
199. National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, London, W12 0NN, UK
200. MRC-PHE Centre for Environment and Health, Imperial College London, London, W2 1PG, UK
201. University of Eastern Finland, Kuopio, 70210, Finland
202. University of Helsinki, Helsinki, 00100, Finland
203. Department of Psychiatry, and Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Western Cape, 7505, South Africa
204. Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, 1010, Switzerland
205. Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, 70210, Finland
206. Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599, USA
207. Kaiser Permanente Washington Health Research Institute Seattle WA 98101
208. Department of Health Services, University of Washington, Seattle WA 98101
209. Department of Anthropology, Sociology, and History, University of San Carlos, Cebu City, 6000, Philippines
210. USC-Office of Population Studies Foundation, Inc., University of San Carlos, Cebu City, 6000, Philippines
211. Division of Preventive Medicine University of Alabama at Birmingham, Birmingham, AL 35205, USA
212. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA, 94304, USA
213. Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA
214. Department of Ophthalmology, Taichung Veterans General Hospital, Taichung, Taiwan 407, Taiwan
215. Uppsala University, Uppsala, 75185, Sweden
216. Department of Clinical Experimental Research, Rigshospitalet, Copenhagen, DK-2200, Denmark
217. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark
218. Department of Biostatistics, Boston University School of Public Health, Boston, MA, 02118, USA
219. Department of Public Health Sciences, Institute for Personalized Medicine, the Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
220. Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
221. Division of Health Sciences, Warwick Medical School, Warwick University, Coventry, CV4 7AL, UK
222. Department of Preventive Medicine, Keck School of Medicine of the University of California, Los Angeles, CA, 90089, USA
223. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, 14558, Germany
224. German Center for Diabetes Research, München-Neuherberg, 85764, Germany
225. Westmead Millennium Institute of Medical Research, Centre for Vision Research and Department of Ophthalmology, University of Sydney, Sydney, New South Wales, 2022, Australia
226. Department of Medicine, Kuopio University Hospital, Kuopio, 70210, Finland
227. Department of Epidemiology and Public Health, University of Strasbourg, Strasbourg, F-67085, France
228. Department of Public Health, University Hospital of Strasbourg, Strasbourg, F-67081, France

229. Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, 4072, Australia
230. Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, 2300RC, The Netherlands
231. INTERVAL Coordinating Centre, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK
232. School of Medicine and Pharmacology, The University of Western Australia, Perth, Western Australia, 6009, Australia
233. Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH8 9AG, UK
234. Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universitat, Munich, 81377, Germany
235. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, 80802, Germany
236. Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, 20892, USA
237. data tecnica international, Glen Echo, MD, USA
238. Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, 4059, Australia
239. Program for Personalized and Genomic Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, 21201, US
240. Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
241. Center for Neurobehavioral Genetics, UCLA, Los Angeles, CA, 90095, USA
242. Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
243. Laboratory of Clinical Chemistry and Hematology, Division Laboratories and Pharmacy, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands
244. School of Women's and Infants' Health, The University of Western Australia, Perth, Western Australia, 6009, Australia
245. University of Helsinki, Institute for Molecular Medicine (FIMM) and Diabetes and Obesity Research Program, Helsinki, FI00014, Finland
246. University of Tartu, Estonian Genome Center, Tartu, Estonia, Tartu, 51010, Estonia
247. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, 2200, Denmark
248. Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, 85764, Germany
249. Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital, Vejle, 7100, Denmark
250. School of Medicine, University of Split, Split, 21000, Croatia
251. South Ostrobothnia Central Hospital, Seinäjoki, 60220, Finland
252. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, 20521, Finland
253. Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, 20520, Finland
254. Centre for Non-Communicable Diseases, Karachi, Pakistan
255. Merck, Sharp & Dohme, Genetics and Pharmacogenomics, Boston, MA, 02115, USA
256. Department of Biobank Research, Umeå University, Umeå, SE-90187, Sweden
257. Nuffield Department of Clinical Medicine, Oxford, OX37 BN, UK
258. NHS Blood and Transplant - Oxford Centre, Oxford, OX3 9BQ, UK
259. BRC Haematology Theme and Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU, UK
260. Department of Public Health and Clinical Medicine, Unit of Family Medicine, Umeå University, Umeå, 90185, Sweden

261. Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, EX2 5DW, UK
262. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
263. University of Pittsburgh Medical Center, Departments of Medicine and Epidemiology, Pittsburgh, PA, 15213, USA
264. Division of Epidemiology & Community Health University of Minnesota, Minneapolis, MN, 55454, USA
265. Duke Molecular Physiology Institute, Duke University, Durham NC, 27701
266. Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan 407, Taiwan
267. School of Medicine, National Defense Medical Center, Taipei, Taiwan 114, Taiwan
268. School of Medicine, National Yang-Ming University, Taipei, Taiwan
269. Saw Swee Hock School of Public Health, National University Health System, National University of Singapore, Singapore 117549, Singapore
270. Genetics, Target Sciences, GlaxoSmithKline, Research Triangle Park, NC, 27709, US
271. OmicSoft a QIAGEN Company, Cary, NC, 27513, US
272. Department of Twin Research and Genetic Epidemiology, King's College London, London, SE1 7EH, UK
273. Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, EH8 9JZ, UK
274. deCODE Genetics/Amgen inc., Reykjavik, 101, Iceland
275. Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, 81377, Germany
276. Kanazawa University, Kanazawa, 920-8641, Japan
277. College of Biomedical and Life Sciences, Cardiff University, Cardiff, CF14 4EP, UK
278. Institute for Community Medicine, University Medicine Greifswald, Greifswald, 17475, Germany
279. Center for Pediatric Research, Department for Women's and Child Health, University of Leipzig, Leipzig, 04103, Germany
280. Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Western Cape, 7505, South Africa
281. Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, 2333, The Netherlands
282. Anogia Medical Centre, Anogia, Greece
283. Centre for Vascular Prevention, Danube-University Krems, Krems, 3500, Austria
284. Dasman Diabetes Institute, Dasman, 15462, Kuwait
285. Diabetes Research Group, King Abdulaziz University, Jeddah, 21589, Saudi Arabia
286. Department of Psychiatry, Dalhousie University, Halifax, B3H 4R2, Canada
287. Department of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, 70210, Finland
288. Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, 1081BT, The Netherlands
289. Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, 2333ZC, The Netherlands
290. Central Finland Central Hospital, Jyväskylä, 40620, Finland
291. USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, 90033, USA
292. Department of Obstetrics and Gynecology, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN, 37203, USA
293. Research Center on Epidemiology and Preventive Medicine, Department of Medicine and Surgery, University of Insubria, Varese, 21100, Italy
294. Merck, Sharp & Dohme, Cardiometabolic Disease, Kenilworth, NJ, 07033, USA

295. DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Greifswald, 17475, Germany
296. Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, 17475, Germany
297. Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle, NE2 4HH, UK
298. Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Uppsala, 752 37, Sweden
299. Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, 48104, USA
300. Genetics, Target Sciences, GlaxoSmithKline, King of Prussia, PA, US
301. Departments of Epidemiology & Medicine, Diabetes Translational Research Center, Fairbanks School of Public Health & School of Medicine, Indiana University, Indiana, IN, 46202, USA
302. Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, Auckland, New Zealand
303. Department of Human Genetics, University of Michigan, Ann Arbor, MI, 48109, USA
304. Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, 39216, USA
305. Danish Diabetes Academy, Odense, 5000, Denmark
306. Department of Public Health, Aarhus University, Aarhus, 8000, Denmark
307. GlaxoSmithKline, King of Prussia, PA, 19406, USA
308. Department of Clinical Sciences, Quantitative Biomedical Research Center, Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
309. Endometriosis CaRe Centre, Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Oxford, OX3 9DU, UK
310. Department of Epidemiology and Carolina Center of Genome Sciences, Chapel Hill, NC, 27514, USA
311. Li Ka Shing Centre for Health Information and Discovery, The Big Data Institute, University of Oxford, Oxford, OX3 7BN, UK
312. Departments of Pediatrics and Genetics, Harvard Medical School, Boston, MA, 02115, USA
313. The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10069, USA

Correspondence to:

Ruth J. F. Loos (ruth.loos@mssm.edu)

Joel N. Hirschhorn (joelh@broadinstitute.org)

ABSTRACT

Genome-wide association studies (GWAS) have identified >250 loci for body mass index (BMI), implicating pathways related to neuronal biology. Most GWAS loci represent clusters of common, non-coding variants from which pinpointing causal genes remains challenging. Here, we combined data from 718,734 individuals to discover rare and low-frequency (MAF<5%) coding variants associated with BMI. We identified 14 coding variants in 13 genes, of which eight in genes (*ZBTB7B*, *ACHE*, *RAPGEF3*, *RAB21*, *ZFHX3*, *ENTPD6*, *ZFR2*, *ZNF169*) newly implicated in human obesity, two (*MC4R*, *KSR2*) previously observed in extreme obesity, and two variants in *GIPR*. Effect sizes of rare variants are ~10 times larger than of common variants, with the largest effect observed in carriers of an *MC4R* stop-codon (p.Tyr35Ter, MAF=0.01%), weighing ~7kg more than non-carriers. Pathway analyses confirmed enrichment of neuronal genes and provide new evidence for adipocyte and energy expenditure biology, widening the potential of genetically-supported therapeutic targets to treat obesity.

Obesity is a heritable disease and represents a major unmet public health problem with only a few safe and long-term effective therapies¹ and intervention strategies². To understand the genetic basis of obesity and identify potential targets for new therapies, genome-wide association studies (GWAS) for body mass index (BMI) and obesity risk have identified >250 common variants over the past decade³⁻⁷. Consistent with single-gene disorders of obesity⁸, tissue expression and gene-set enrichment analyses for genes in BMI-associated loci have shown that the central nervous system (CNS) plays a critical role in body weight regulation⁵. While the numerous GWAS loci have provided insight into broad biological mechanisms underlying body weight regulation, pinpointing the causal gene(s)/variant(s) remains a major challenge⁹, as GWAS-identified variants are typically non-coding and may affect genes at long distance. The association of intronic *FTO* variants with BMI illustrates the challenges of identifying causal regulatory effects. The proposed causal variant was found to regulate the expression of nearby *RPGRIP1L* in some studies¹⁰⁻¹², whereas others found that it regulates distant *IRX3/IRX5* genes in specific cell types^{13,14}.

To expedite mapping of obesity-related genes, we performed an exome-wide search for low-frequency (LF, minor allele frequency [MAF]=1-5%) and rare (R, MAF<1%) single nucleotide variants (SNVs) associated with BMI using exome-targeted genotyping arrays. A total of 125 studies ($N_{\text{individuals}}=718,734$) performed single-variant association between up to 246,328 SNVs and BMI. In addition, we performed gene-based meta-analyses to aggregate rare and LF (R/LF) coding SNVs across 14,541 genes. Using genetic, functional and computational follow-up analyses, we gained insights into the function of BMI-implicated genes, and the biological pathways through which they may influence body weight.

RESULTS

Fourteen rare and low-frequency coding variants in 13 genes

Our study comprises a discovery and a follow-up stage (**Supplementary Figure 1, Supplementary Tables 1-3, Online Methods**). In our primary analysis, the discovery stage includes data from 123 studies ($N_{\text{max}}=526,508$) across five ancestry groups, predominantly European (~85%). Each study performed

single-variant association analyses of coding variants present on the exome array, including up to 13,786 common (MAF>5%) and 215,917 R/LF coding SNVs (exons and splicing sites). Summary statistics were combined using fixed-effect meta-analyses. SNV-associations of R/LF variants that reached suggestive significance ($P<2.0\times 10^{-6}$) were taken forward for follow-up in two European cohorts, deCODE ($N_{\max}=72,613$) and UK Biobank ($N_{\max}=119,613$ [interim release]). Overall significance was assessed after combining results of discovery and follow-up studies into a final meta-analysis (all-ancestries, sex-combined, additive model, $N_{\max}=718,734$), SNV-associations that reached $P<2\times 10^{-7}$ were considered array-wide significant^{15,16} (**Table 1, Supplementary Table 4, Supplementary Figures 2-4**). In secondary analyses, we performed sex-specific analyses, analyses limited to individuals of European ancestry, and analyses using a recessive model.

In our primary analysis of R/LF variants, we identified five rare SNVs in three genes (*KSR2*, 2 in *MC4R*, 2 in *GIPR*) and nine LF SNVs in eight genes (*ZBTB7B*, 2 in *ACHE*, *RAPGEF3*, *PRKAG1*, *RAB21*, *HIP1R*, *ZFHX3*, *ENTPD6*) (**Table 1, Box 1, Supplementary Table 5, Supplementary Figure 3a**). In secondary analyses, we identified two additional LF SNVs, one in all-ancestry women-only (*ZFR2*) and one in European ancestry only analyses (*ZNF169*) (**Table 1, Supplementary Tables 6-8, Supplementary Figures 3b, 3c**). Of these 16 SNVs, located in 13 genes, the two SNVs in *MC4R* ($r^2=1$, $D'=1$) and two in *ACHE* ($r^2=0.98$, $D'=0.99$) were in high LD, whereas the two SNVs in *GIPR* ($r^2=0$, $D'=0.16$) were independent of each other. Hence, the 16 SNVs represent 14 independent SNVs (4 rare, 10 LF), of which eight locate in genes not previously implicated in BMI (*ZBTB7B*, *ACHE*, *RAPGEF3*, *RAB21*, *ZFHX3*, *ENTPD6*, *ZFR2*, *ZNF169*), and six are located in five loci that were previously identified by GWAS (*PRKAG1/BCDIN3D*, *HIP1R/CLIP1*, *MC4R*, *GIPR/QPCTL*)⁵ and/or through sequencing of severe early-onset obesity cases (*MC4R*, *KSR2*)¹⁷⁻¹⁹ (**Supplementary Figure 5**). Conditional analyses established that coding SNVs in *PRKAG1*, *MC4R* and *GIPR* are independent of the common lead variants in GWAS loci (rs7138803, rs17782313, rs2287019, respectively), whereas the SNV in *HIP1R* and GWAS locus near *CLIP1* (rs11057405) represent the same signal (**Online Methods, Supplementary Tables 9, 10, Supplementary Figure 5**).

Next, we performed gene-based association tests (SKAT, VT, broad, strict) in up to 14,541 genes²⁰ to examine whether these aggregated analyses would yield new evidence for multiple R/LF coding SNVs in the same gene affecting BMI (**Online Methods**). Using broad SNV inclusion criteria, associations for 13 genes reached array-wide significance ($P < 2.5 \times 10^{-6}$)^{15,16}, four of which had not been highlighted in single-variant analyses (**Table 2, Supplementary Table 11**). Conditional analyses showed that only for *GIPR* was the gene-based association driven by multiple SNVs (**Table 2, Supplementary Table 12**). For all other genes, associations were driven by a single SNV only, but these SNVs had not reached array-wide significance in single-variant analyses.

Taken together, we identified 14 R/LF coding SNVs in 13 genes that are independently associated with BMI, four rare SNVs in three genes, and 10 LF SNVs in 10 genes. One SNV (*ZFR2*) showed a sex-specific effect, whereas no ancestry-specific effects were observed (**Supplementary Note, Supplementary Tables 6-8, Supplementary Figure 6**). Eight (*ACHE*, *ENTPD6*, *RAB21*, *RAPGEF3*, *ZBTB7B*, *ZFH3*, *ZFR2*, *ZNF169*) of these 13 genes have not been previously implicated in body weight regulation (**Table 1**).

Novel common coding variants associated with BMI

Although the main focus of our study was on R/LF coding SNVs, we also identified 92 common coding variants ($P < 2.0 \times 10^{-7}$, **Supplementary Tables 4, Supplementary Figures 4, 7**), of which 41 were novel (**Supplementary Table 9, Supplementary Note**). These novel common loci had not been identified in previous GWAS efforts, because our current sample size is more than twice as large as the most recent GWAS meta-analysis⁵, and also because some SNVs were not tested before, as they were not present on the HapMap reference panel and/or were on the X-chromosome, which was not analyzed. Because of the increased samples size, effect sizes of the 41 novel common loci are smaller (on average 0.014 SD/allele, [range: 0.010–0.024]) than of previously established common loci (0.021 SD/allele, [0.010–0.050]) (**Supplementary Figure 7**).

Impact of R/LF SNVs on BMI and obesity risk

The minor allele for half of the 14 R/LF SNVs is associated with lower BMI (**Table 1, Figure 1**). The effects of LF SNVs range between 0.024 and 0.066 SD/allele, equivalent to ~0.11 to 0.30 kg/m² in BMI or ~0.315 to 0.864 kg in body weight for a 1.7m tall person. Effects of rare SNVs range between 0.06 and 0.54 SD per allele, equivalent to 0.26 to 2.44 kg/m² or 0.74 kg to 7.05 kg per allele (**Table 1, Figure 1**). By comparison, these rare SNV effect sizes are on average ten times larger than those for previously identified GWAS loci (effect_{mean}=0.019 SD/allele, ~0.086 kg/m² or ~0.247 kg/allele) of which the largest effect is seen for the *FTO* locus (0.08 SD/allele, ~0.35 kg/m² or 1 kg/allele) and those for other GWAS loci range between 0.010 and 0.056 SD/allele (~0.045 to 0.25 kg/m², or 0.130 to 0.728 kg)⁵.

Effect sizes increase as MAF decreases, in particular for SNVs with a MAF<0.5% (~1 heterozygote carrier in 100 people), consistent with the statistical power of our sample (**Figure 1**). For example, the nonsense p.Tyr35Ter *MC4R* SNV (rs13447324, MAF=0.01%) is present in ~1 in 5,000 individuals and results in a ~7 kg higher body weight for a 1.7m tall person. The two *GIPR* SNVs contribute independently to a *lower* body weight, carriers (1 in ~455 individuals) of p.Arg190Gln (rs139215588) weigh ~1.92 kg (0.148 SD BMI) less than non-carriers and carriers (1 in ~385 individuals) of p.Glu288Gly (rs143430880) weigh ~1.99 kg (0.153 SD BMI) less. Among 115,611 individuals of the UK Biobank, one apparently healthy 61-year-old woman, with no reported illnesses, carried both rare *GIPR* alleles and weighed ~11.2 kg less (equivalent to -0.86 SD BMI or 3.87 kg/m²) than the average non-carrier of the same height (**Supplementary Figure 8**). The possible synergistic effect of the two *GIPR* alleles needs confirmation by additional individuals that carry both variants.

Even though effect sizes of LF and, in particular, rare SNVs tend to be larger than those of common GWAS-identified loci⁵, the 14 SNVs combined explain <0.1% of BMI variation, because of their low population frequency (**Table 1, Online Methods**). Also, although the effects of the four rare SNVs (*KSR2*, *MC4R*, 2 in *GIPR*) are large by GWAS standards, penetrance for obesity is still expected to be low. Indeed, using data from the UK Biobank (N_{max}=119,781), we compared the prevalence of normal-weight (18.5 kg/m² ≤ BMI < 25 kg/m²) and obesity (BMI ≥ 30 kg/m²) between carriers and non-carriers (**Supplementary Table 13, Online Methods**). For *GIPR* (p.Arg190Gln, p.Glu288Gly), both BMI-decreasing SNVs, carriers

tended ($P < 0.05$) to have a lower obesity prevalence (21.2%, 20.1%, respectively), compared to non-carriers (25.1%, 25%). For *MC4R* p.Tyr35Ter and *KSR2* p.Arg525Gln, the prevalence of obesity between carriers (30%, 25.7%, resp.) and non-carriers (25.1%, 25.3%) was not significantly different.

We examined whether R/LF SNVs affect obesity risk early on in life by combining data from three case-controls studies of childhood obesity ($N_{cases}=4,395$, $N_{controls}=13,072$) (**Online Methods, Supplementary Table 14**). Associations for 10 of 13 SNVs were directionally consistent with those observed for BMI in adults (77%, $P_{binomial}=0.046$), three of which (*ZBTB7B*, *PRKAG1*, *RAB21*) reached nominal significance ($P < 0.05$). While no carriers of the *MC4R* mutations were available for analyses, the role of *MC4R* in body weight regulation in childhood was established almost two decades ago^{17,19,21}.

Impact of R/LF SNVs on cardiometabolic and other traits

To examine whether identified SNVs affect other traits, we obtained results from multiple large-scale genetic consortia (GIANT¹⁵, MAGIC, GoT2D/T2D-GENES¹⁶, GLGC, ICBP²², REPROGEN²³) (**Supplementary Table 15, Supplementary Figure 9**), and performed phenome-wide association (PheWAS) analyses using electronic medical record (EMR) data from BioVu and UK Biobank (**Online Methods, Supplementary Table 16**). The BMI-increasing allele of *ZBTB7B* p.Pro190Ser is associated with greater height, and those of *PRKAG1*, *ACHE*, and *RAPGEF3* SNVs are associated with shorter height, but association with other traits differ. Specifically, *PRKAG1* p.Thr38Ser Ser-allele carriers appear heavier and shorter, have lower HDL-cholesterol levels, earlier age at menarche (reported before²³) and higher systolic blood pressure, which is in agreement with PheWAS analyses showing an increased risk of “malignant essential hypertension” and “hypertension” (**Supplementary Table 16**). While carriers of the *RAPGEF3* p.Leu300Pro Pro-allele are also heavier and shorter, they have a lower WHR_{adjBMI} ²⁴ and lower fasting insulin levels (**Supplementary Table 15**), consistent with PheWAS results that show lower odds of “secondary diabetes mellitus” (**Supplementary Table 16**). Thus, while all SNVs are associated with BMI, their patterns of association with other traits suggest they may affect different physiological pathways.

Gene set enrichment analyses

To test whether the R/LF variants implicate biological pathways, we performed gene set enrichment analyses. Similar to our previous analysis of GWAS for BMI⁵, we analyzed coding variants that reached $P < 5 \times 10^{-4}$, using a DEPICT version adapted for exome-array analysis¹⁵ (**Online Methods, Supplementary Note**). We used 50 R/LF coding variants as input (all $P < 5 \times 10^{-4}$, **Online Methods**) and observed significant enrichment (**Figure 2, Supplementary Table 17, Supplementary Figure 10a**). Many of these relate to neuronal processes, such as neurotransmitter release and synaptic function (e.g. glutamate receptor activity, regulation of neurotransmitter levels, synapse part), consistent with previous findings from GWAS⁵. When we excluded variants near (+/- 1Mb) previously identified GWAS loci, we still observed 29 significantly enriched gene sets (in 12 meta-gene sets) (**Supplementary Table 18, Supplementary Figure 10b**), thereby providing an independent confirmation of the GWAS gene set enrichment results. In addition to neuronal-related gene sets, the analyses with R/LF coding variants newly identified a cluster of metabolic pathways related to insulin action and adipocyte/lipid metabolism (e.g. enhanced lipolysis, abnormal lipid homeostasis, increased circulating insulin level, **Figure 2**). Finally, we observed that R/LF BMI-associated coding variants are more effective at identifying enriched gene sets compared to common coding variants. Specifically, adding 192 common coding SNVs (all $P < 5 \times 10^{-4}$) to the analysis decreased the number of enriched gene sets from 471 (106 meta-gene sets) seen with R/LF coding SNVs to 62 (24 meta-gene sets) (**Supplementary Table 19, Supplementary Figure 10c**). We observed fewer significant genes sets with the combined common and R/LF analysis, despite including more total coding variants and a higher fraction of array-wide significant coding variants. One possible explanation is that R/LF coding variants may fall in the causal gene more often than do common coding variants, which suggests that the R/LF variants are more likely to be causal, rather than simply in LD with causal variants.

We also used gene set enrichment analysis to prioritize candidate genes. Among the genes with R/LF coding variants associated with BMI at $P < 5 \times 10^{-4}$, a subset is prominently represented in the CNS-related enriched gene sets (**Figure 2**) and is proposed to influence neurotransmission and/or synaptic organization, function and plasticity. These include genes in regions with suggestive evidence of association from GWAS (e.g. *CARTPT*, *MAP1A*, *ERC2*) and genes in regions not previously implicated by GWAS

(e.g. *CALY*, *ACHE*, *PTPRD*, *GRIN2A*). The non-neuronal metabolic gene sets implicate two genes (*CIDEA*, *ADH1B*) that are markers of brown or “beige” adipose tissue^{25,26}, providing new supporting evidence for a causal role of this aspect of adipocyte biology.

***Drosophila* fly results**

To test for potential adiposity-driving effects of gene regulation, we performed tissue-specific RNAi-knockdown experiments in *Drosophila*. We generated adipose-tissue (cg-Gal4) and neuronal (elav-Gal4) specific RNAi-knockdown crosses for nine of the 13 candidate genes for which fly orthologues exist (**Supplementary Table 20**) and performed whole body triglyceride analysis in young adult male flies. Triglycerides, the major lipid storage form in animals, were chosen as a direct measure of fly adiposity. Both neuronal and fat-body knockdown of *zfh2*, the orthologue of *ZFHX3*, resulted in significantly increased triglyceride levels. Adipose-tissue specific, but not neuronal, knockdown of *epac* (*RAPGEF3*) was lethal. Tissue-specific loss-of-function of the other seven genes tested did not affect triglyceride levels.

R/LF coding SNVs in monogenic and syndromic genes

We identified 39 genes in the literature that have been convincingly implicated in monogenic obesity or syndromes of which obesity is one of the main features (**Supplementary Table 21, 22, Supplementary Figure 11**). Of the 652 R/LF SNVs in these 39 monogenic and/or syndromic genes, five R/LF SNVs were significantly associated with BMI (Bonferroni-corrected P -value = 7.7×10^{-5} ($=0.05/652$)). Beside SNVs in *MC4R* (p.Tyr35Ter, Asp37Val) and *KSR2* (Arg525Gln), already highlighted in the single-variant analyses, we identified an additional SNV in *MC4R* (p.Ile251Leu) and one in *BDNF* (p.Glu6Lys). *MC4R* p.Ile251Leu has been previously shown to protect against obesity²⁷, whereas *BDNF* p.Glu6Lys, independent of previously GWAS-identified SNVs ($r^2=0.01$, $D'=1.0$)⁵, has not been implicated in body weight regulation before. We examined whether the 652 R/LF SNVs showed enrichment for association with BMI compared to R/LF coding SNVs in all other genes, but found no evidence to support this.

DISCUSSION

In this meta-analysis of exome-targeted genotyping data, we identified 14 R/LF coding variants in 13 genes associated with BMI. Eight of these genes (*ACHE*, *ENTPD6*, *RAB21*, *RAPGEF3*, *ZBTB7B*, *ZFHX3*, *ZFR2*, *ZNF169*) have not been previously implicated in human obesity, but evidence from animal studies provides support for a role in energy metabolism for some of these, such as *ACHE*^{28,29}, *RAPGEF3*³⁰⁻³³, and *PRKAG1*³⁴⁻³⁹. Others fall into established BMI GWAS loci (*PRKAG1/BCDIN3D*, *HIP1R/CLIP1*, *MC4R*, *GIPR/QPCTL*)⁵ and/or were previously implicated in severe early-onset obesity (*MC4R*, *KSR2*)¹⁷⁻¹⁹ and using this exome-targeted approach, we pinpoint R/LF variants in these loci that play a role in obesity in the general population. Pathway analyses confirm a key role for neuronal processes, and newly implicate adipocyte and energy expenditure biology.

Consistent with other polygenic traits^{15,23,40-43}, we show that large sample sizes are needed to identify R/LF variants. Observed effect sizes reflect the statistical power of our sample size, and are particularly large for SNVs with a MAF < 0.05%. The existence of rare alleles with larger effects on BMI than have been observed for common alleles might reflect negative or stabilizing selection on the extremes of BMI. However, rare variants with smaller effects almost certainly exist, larger samples will be needed to uncover these. Our study was limited to coding variants on the exome-array, large-scale sequencing studies will be needed to test for variants not covered by exome-arrays.

The strongest association was observed for a stop-codon (p.Tyr35Ter, rs13447324, MAF= 0.01%) in *MC4R*, with carriers weighing on average 7kg more than non-carriers. *MC4R* is widely expressed in the CNS and is an established key player in energy balance regulation^{44,45}. Mouse and human studies showed already two decades ago that *MC4R*-deficiency results in extreme obesity, mainly through increased food intake⁴⁶⁻⁴⁹. p.Tyr35Ter, which results in *MC4R*-deficiency⁵¹, was one of the first *MC4R* mutations discovered in monogenic cases of obesity^{17,19}, in whom the mutation is >20x more prevalent than in the general population^{17,50,52,53}. Here, we show that p.Tyr35Ter plays a role outside the setting of early-onset and extreme obesity. Despite its large effect, penetrance is low, and does not fit the model of a fully penetrant Mendelian variant.

While significant R/LF coding variants are strong candidates for being causal, the strongest implication of causal genes is provided by association with multiple independent coding variants, as we demonstrate for *GIPR*. We identified two rare variants in *GIPR* (p.Arg190Gln, rs139215588, MAF=0.11%, p.Glu288Gly, rs143430880, MAF=0.13%) independently associated with lower BMI, carriers of either variant weigh ~2 kg less than non-carriers. Common variants in/near *GIPR* have been found to associate with lower BMI⁵⁵ and delayed glucose and insulin response to an oral glucose challenge⁵⁴. However, the two rare variants influence BMI independently of these common ones and are not associated with type 2 diabetes or glycemic traits tested. Rodent models have provided strong evidence for a role of GIPR in body weight regulation. *Gipr*-deficient mice are protected from diet-induced obesity⁵⁶ and have an increased resting metabolic rate⁵⁷. Blocking GIP-signaling using a vaccination approach in mice on a high-fat diet reduces weight gain, mainly through reduced fat accumulation, mediated through increased energy expenditure⁵⁸. Manipulation of incretins (GIP, GLP1) and their receptors has complex effects on obesity and insulin secretion/action that may differ between human and mice⁵⁹. The human genetic data suggest that inhibition of GIPR-signaling might present a therapeutic target for the treatment of obesity⁶⁰.

A fourth rare variant, in *KSR2*, (p.Arg525Gln, rs56214831, MAF=0.82%) increases body weight by ~740g/allele. *KSR2* is another gene previously implicated in energy metabolism and obesity^{18,61,62}. In a recent study, mutation carriers were hyperphagic, had a reduced basal metabolic rate and severe insulin resistance¹⁸. Consistent with human data, *Ksr2*^{-/-} mice were obese, hyperphagic, and had a reduced energy expenditure^{18,61-63}. *KSR2* is almost exclusively expressed in the brain and interacts with multiple proteins⁶⁴, including AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis^{61,62}. Interestingly, *KSR2* is one of the first genes implicated in severe, early-onset obesity in which mutations not only affect food intake but also basal metabolic rate, and is thought to act via neuronal effects¹⁸ (**Figure 2**).

Despite convincing associations of these four rare variants in *MC4R*, *GIPR* and *KSR2*, their penetrance for obesity is low (**Supplementary Table 13**). This is consistent with the polygenic and multifactorial nature of obesity, where variants across a range of frequencies and effect sizes contribute to the phenotype in any one person. Despite low predictive power, it remains possible that the identities of

particular variants in any one person may contribute to different balances of underlying physiologies and hence, different responses to treatments. This was illustrated in two patients with monogenic obesity due to *POMC* mutations, these patients lack the main activator of MC4R and were effectively treated with an MC4R-agonist⁶⁵.

Of the coding variants in newly identified genes, some have well-known connections to obesity. For example, *PRKAG1* encodes the γ 1-subunit of AMPK, a critical cellular energy sensor³⁴. In the hypothalamus, AMPK integrates hormonal and nutritional signals with neuronal networks to regulate food intake and whole-body energy metabolism³⁵⁻³⁷. Furthermore, hypothalamic AMPK is a key regulator of brown adipose tissue in mice^{36,38,39}. The BMI-decreasing allele at the associated *PRKAG1* variant (p.Thr38Ser, rs1126930, MAF=3.22%) has additional beneficial effects on blood pressure, providing additional genetic support for modulation of AMPK as an ongoing therapeutic avenue for treatment.

ACHE, in which p.His353Asn (rs1799805, MAF=3.9%) is associated with increased BMI, is another candidate gene related to neuronal biology, involved in the signaling of acetylcholine at neuromuscular junction and brain cholinergic synapses^{67,68}. Inhibitors of ACHE, used to treat moderate-to-severe Alzheimer's Disease⁶⁹, results in weight loss in humans and Ache-deficient mice have delayed weight gain^{28,29}. However, these may be indirect consequences of adverse gastrointestinal and neuromuscular effects, respectively^{28,29,70,71}.

Another LF coding variant (p.Leu300Pro, rs145878042, MAF=1.1%) is located in *RAPGEF3*, and has strong effects on multiple other phenotypes. The BMI-increasing 300Pro-allele is associated with shorter height, lower WHR_{adjBMI} and lower insulin levels, suggesting that this variant has multiple physiologic consequences. Data from animal models also suggest complex effects of *RAPGEF3* on adipocyte biology, energy balance and glucose metabolism³⁰⁻³³. For example, in one study, global deletion of *Rapgef3* in mice on a high-fat diet are resistant to obesity due to reduced food intake and have an increased glucose tolerance³¹. However, in a similar study, *Rapgef3*^{-/-} mice develop severe obesity, increased respiratory exchange ratio and impaired glucose tolerance³³. Adipose tissue-specific *Rapgef3* knockout mice on a high-fat diet are also more prone to obesity, show increased food intake, reduced energy

expenditure, impaired glucose tolerance, and reduced circulating leptin levels⁷². More research is needed to understand the consequences of *RAPGEF3* manipulation.

The remaining genes with significant associations, *ENTPD6*, *HIP1R*, *RAB21*, *ZFR2*, *ZBTB7*, and *ZFHX3*, have no clear prior evidence for a role in energy homeostasis, and in-depth functional follow up is needed to gain insight in how they affect body weight. Here, we performed gene set enrichment analyses to better understand the biology implicated by our genetic data, and confirm the importance of neuronal processes, in particular synaptic function and neurotransmitter release, providing an independent validation of previous GWAS findings⁵. The combination of gene set enrichment and association analyses of coding variants also enables us to highlight candidate genes that are both within these gene sets and show association with BMI at R/LF coding variants. These include genes reaching array-wide significance (e.g. *ACHE*, *ZFR2*), and others with clear prior evidence for a role in body weight regulation (e.g. *CARTPT*⁷³), but that had not been highlighted in our single-variant or gene-based association analyses. Of note, the enrichment signals were stronger with R/LF coding variants only than with *all* coding variants, suggesting that R/LF variants are more likely to be causal and may more often point directly to relevant genes, whereas common coding variants may more often be proxies for common noncoding variants that affect nearby genes.

In addition, our gene set enrichment analyses now provide supporting evidence for a role of non-neuronal mechanisms as well. Specifically, *CIDEA* and *ADH1B* are both strongly predicted to be members of enriched gene sets related to insulin action and adipocyte biology, and both are markers that distinguish brown from white fat depots in mice²⁵ and humans²⁶. *CIDEA* is predominantly expressed in adipose tissue and known as a key regulator of energy metabolism²⁵. *Cidea*-deficient mice are resistance to diet-induced obesity with increased lipolysis and mitochondrial uncoupling²⁵. The connection of *ADH1B* to obesity is less clear, but the gene is highly expressed in human adipocytes, has been implicated by gene expression analyses in obesity and insulin resistance, and functions early in a potentially relevant metabolic pathway (retinoid biosynthesis)^{25,26,74,75}. Similar pathways were implicated by recent work dissecting the signal near *FTO*¹³. However, because SNV-association signals at *ADH1B* and *CIDEA* did not reach array-wide

significance, additional genetic analysis of their role in obesity would be warranted.

In summary, we performed association analyses between R/LF variants and BMI in >700,000 individuals, and identified 14 variants in 13 genes, in 5 known and 8 novel genes. While each variant contributes little to BMI variation in the general population, they may have substantial impact on body weight at an individual level. Furthermore, prior literature for these genes and unbiased gene set enrichment analysis indicate a strong role for neuronal biology and also provide new support for a causal role of aspects of adipocyte biology. The identified genes provide potential targets that may lead to new and more precise approaches for the treatment of obesity, which has seen minimal innovation in the past 30 years¹.

URLs

CDC 2000 Growth Charts: http://www.cdc.gov/growthcharts/cdc_charts.htm

CHOP cohort: <http://www.metabolic-programming.org/obesity/>

EC-DEPICT code: <https://github.com/RebeccaFine/obesity-ec-depict>

ENSEMBL: www.ensembl.org

EasyQC: www.genepi-regensburg.de/easyqc

EasyStrata: www.genepi-regensburg.de/easystrata

ExAC: <http://exac.broadinstitute.org/>

GCTA: <http://cnsgenomics.com/software/gcta/>

GTEx: <http://www.gtexportal.org/home/>

GTOOL: <http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html>

Impute2: https://mathgen.stats.ox.ac.uk/impute/impute_v2.html

INTERVAL Study: <http://www.intervalstudy.org.uk/>

PLINK v1.90: <https://www.cog-genomics.org/plink2>

QCTOOL: <http://www.well.ox.ac.uk/~gav/qctool/#overview>

RAREMETALWORKER: <http://genome.sph.umich.edu/wiki/RAREMETALWORKER>

RareMETALS: <http://genome.sph.umich.edu/wiki/RareMETALS>

RVTEST: <https://github.com/zhanxw/rvtests>

Shapeit2: https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html

UKHLS: <https://www.understandingsociety.ac.uk/>

UK10K Obesity Sample Sets - SCOOP: <http://www.uk10k.org/studies/obesity.html>

1000 Genomes Phase 1: <http://www.1000genomes.org/category/phase-1/>

ACKNOWLEDGMENTS

Alex Reiners was supported by R01DK089256. Alex Hewitt is supported by an NHMRC Practitioner Fellowship (APP1103329). Alisa Manning received funding from NIH/NIDDK K01 DK107836. Andrew Hattersley is a Wellcome Trust Senior Investigator (WT098395), and a NIH Research Senior Investigator. Andrew Morris is a Wellcome Trust Senior Fellow in Basic Biomedical Science (WT098017). Andrew Wood is supported by the European Research Council (SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC). Anne Jackson is supported by the American Heart Association (13POST16500011) and NIH (R01DK089256, R01DK101855, K99HL130580). Bratati Kahali and Elizabeth Speliotes were supported by the Doris Duke Medical Foundation, NIH (R01DK106621), the University of Michigan Internal Medicine Department, Division of Gastroenterology, the University of Michigan Biological Sciences Scholars Program and The Central Society for Clinical Research. Cristen Willer is supported by NIH (HL094535, HL109946). Daniel Liu is supported by R01HG008983 and R21DA040177. Daniel Witte is supported by the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation. Veiko Salomaa has been supported by the Finnish Foundation for Cardiovascular Research. Folkert Asselbergs is supported by a Dekker scholarship-Junior Staff Member 2014T001 Netherlands Heart Foundation and UCL Hospitals NIHR Biomedical Research Centre. Fotios Drenos is supported by the UK MRC (MC_UU_12013/1-9). Gabriela Partida received scholarship support from the University of Queensland and QIMR Berghofer. Guillaume Lettre is funded by the Montreal Heart Institute Foundation and the Canada Research Chair program. Hanieh Yaghootkar and Tim Frayling are supported by the European Research Council (323195, SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC). Iris Heid is supported by BMBF (01ER1206) and BMBF (01ER1507m), NIH and Max Planck Society. Jeff Haessler was supported by NHLBI R21HL121422. Joel Hirschhorn is supported by NIH R01DK075787. Kari North was supported by NIH (R01DK089256, R01HD057194, U01HG007416, R01DK101855), and AHA (13GRNT16490017). Manuel Rivas is supported by Nuffield Department of Clinical Medicine Award, Clarendon Scholarship. Mark McCarthy is a Wellcome Trust Senior Investigator (WT098381), and a NIH Research Senior Investigator. Mengmeng Du is supported by the NCI (R25CA94880, P30CA008748). Pal

Njolstad is supported by the European Research Council (AdG, 293574), Research Council of Norway, University of Bergen, KG Jebsen Foundation, Helse Vest, Norwegian Diabetes Association. Patrick Ellinor is supported by the NIH (1R01HL092577, R01HL128914, K24HL105780), an Established Investigator Award from the American Heart Association (13EIA14220013) and by the Foundation Leducq (14CVD01). Paul Auer was supported by NHLBI R21HL121422 and R01DK089256. Paul Huang is support by NIH (NS33335, HL57818). Rebecca Fine is supported by NIH (T32GM096911). Ruth loos is supported by the NIH (R01DK110113, U01HG007417, R01DK101855, R01DK107786). Steven Lubitz is supported by NIH (K23HL114724) and a Doris Duke Charitable Foundation Clinical Scientist Development Award. Timothy Spector holds an ERC Advanced Principal Investigator award. Trevor Mori is supported by an Australian National Health and Medical Research Fellowship (APP1042255). Tune Pers received a Lundbeck Foundation and Benzon Foundation support. Valerie Turcot is supported by a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR). Zoltan Kutalik is supported by the Leenaards Foundation, Swiss National Science Foundation (31003A-143914) and SystemsX.ch (51RTP0_151019). Part of this work was conducted using the UK Biobank resource (Project Numbers 1251, 9072). A full list of acknowledgments appears in the **Supplementary Note**.

AUTHOR CONTRIBUTIONS

Writing Group (wrote and edited manuscript)

A.E.J., A.E.L., C.M.L., C.S., G.L., H.M.H., J.N.H., K.E.N., K.L.Y., M.F.F., M. Graff, P.D., R.J.F.L., T.M.F., V.T., Y. Lu

Data preparation group (program development and quality control of data from contributing cohorts for meta-analyses)

A.E.J., A.E.L., C.S., D.J.L., E. Marouli, H.M.H., I.B.B., K.L.Y., K. Stirrups, K.S.L., M.A.R., M.C.M.G., M.C.Y.N., M. Graff, N.G.D.M., P. Mudgal, R.J.F.L., S. Feng, S.M.W., S.S., S.V., T.A., T.E., T. Karaderi, T.W.W., V.T., X.Z., Y. Lu

BMI meta-analyses (*discovery and follow-up, single-variant and gene-based*)

A.E.J., C.S., C.T.L., D.J.L., H.M.H., I.B.B., J.N.H., K.L.Y., R.J.F.L., T.M.F., V.T., Y. Lu

Childhood data (analyses and interpretation)

A.E.H., G.M., H.H., I. Barroso, I.S.F., J.P.B., S.F.A.G., V.M.

Pleiotropy working group

A.M., C.J.W., C.M.L., D.J.L., E. Marouli, F.D., G.A., G.M., G.M.P., H. Kitajima, H.M.H., J.C.F., J.P.C., J.R.B.P., J.W., K.S.R., M. Boehnke, M.I.M., P.B.M., P.D., R.J.F.L., S. Kathiresan, S.M.W., S.W., T.F.V., X.S.

Phenome-wide association studies

A.G., A.M., J.C.D., L. Bastarache, M.I.M., T.L.E.

Gene-set enrichment analyses

D.L., J.N.H., R.S.F., S.B., T.H.P., Z.K.

Monogenic and syndromic gene enrichment analyses

A.K.M., H.M.H.

Fly Obesity Screen

A. Lempradl, J.A. Pospisilik

Overseeing of contributing studies

A. Linneberg, A. Peters, A. Tönjes, A.C.H., A.D.M., A.G.U., A.H.F., A.I.d.H., A.J.L., A.M.D., A.P.M., A.P.R., A.S.B., A.T. Hattersley, A.W.H., B.B., B.G.N., C.A.B., C.C., C.E.P., C.H., C.J.W., C.L., C.M.L., C.N.A.P., D.F.E., D.F.R., D.I.C., D.M.W., D.O.M.K., D.R.N., D.R.W., D.S., D.W.B., E.B., E.B.L., E.D.A., E.F., E.I., E.K.S., E.P.B., E.Z., F. Karpe, F. Kee, F. Renström, F.W.A., G. Dedoussis, G. Tromp, G.B., G.B.J., G.K.H., G.L., G.P., G.P.J., G.W.M., H. Kuivaniemi, H.B., H.D.W., H.H., H.J.G., H.M.d.R., H.R.W., I. Barroso, I. Brandslund, I.B.B., I.F., I.J.D., I.M.H., I.R., I.S.F., J. Kaprio, J.C.C., J.C.T., J.D., J.D.R., J.F., J.G.W., J.I.R., J.M.M.H., J.M.S., J.R.O., J.S.K., J.T., K. Stefansson, K. Strauch, K.B.K., K.E.N., K.K., K.K.A., K.L.M., K.M.H., K.N., K.R.O., K.T.Z., L.E.W., L.L., L.W., M. Blüher, M. Kähönen, M. Kumari, M.A.I., M.A.R., M.B.S., M.C.H.d.G, M.d.H., M.E.J., M.F., M.H.B., M.I.M., M.L.O., M.M., M.P., M.P.D., M.S., M.U., M.V., M.W., N.D.P., N.J.S., N.J.W., N.S., N.v.L., O. Pedersen, O. Polasek, O.T.R., P. Kovacs, P.A., P.A.P., P.B.M., P.D., P.E., P.G., P.G.L., P.J.S., P.L.A., P.L.H., P.L.P., P.M.R., P.R.N., P.T.C., P.W.F., R.A.O., R.A.S., R.C., R.E.S., R.J.F.L., R.V., S. Fauser, S. Kathiresan, S.E.M., S.F.A.G., S.H. Scholte, S.J., S.L.R.K., S.M., S.P., Svati H. Shah, T.A.M., T.B.H., T.D.S., T.E., T.H., T.J., T.L., T.L.E., T.M.F., U.T., V. Gudnason, V. Salomaa, V.V., W.H.H.S., X.G., X.L., Y.Liu

Genotyping of contributing studies

A. Loukola, A. Tybjaerg-Hansen, A.B., A.D.E., A.G.U., A.I.d.H., A.J.L., A.L.M., A.M., A.M.D., A.P.G., A.P.M., A.P.R., A.R.H., A.S.B., A.V., A.W.H., A.Y.C., B.G.N., C.A.B., C.E.P., C.H., C.J.P., C.K., C.L., C.M., C.M.L., C.M.v.D., C.N.A.P., C.S., D.F.R., D.I.C., D.J.C., D.J.R., D.M.W., D.R.N., E.D.A., E.E., E.I., E.K., E.M.L., E.P.B., E.W.D., F. Karpe, F. Rivadeneira, F.S.C., G. Davies, G. Tromp, G.P.J., G.W.M., H. Kuivaniemi, H.H., H.L.G., H. Li, H.V., I.G., J. Kuusisto, J.A. Perry, J.B.J., J.C.C., J.D., J.D.F., J.G.D., J.I.R., J.M.M.H., J.S., J.S.K., J.T., K. Strauch, K.B.K., K.D.T., K.E.S., K.M., L. Milani, L. Southam, L.A. Lange, L.A.K., L.M.Y.A., L.P.L., M. Benn, M. Boehnke, M. Gorski, M. Kähönen, M. Kumari, M.B.S., M.C.H.d.G., M.C.M.G., M.F., M.H.B., M.I.M., M.L., M.L.B., M.L.G., M.L.O., M.M.N., M.P.D., M.P.S.L., N.D.P., N.G., N.J.S., N.J.W., N.v.L., O.H., P.B.M., P.G.L., P.I.W.d.B., P.T.C., P.W.F., R.A.O., R.A.S., R.E.S., R.F.S., R.J.F.L., R.L.G., R.R., R.Y., S. Kanoni, S. Kathiresan, S.C., S.F.A.G., S.F.N., S.H.V.L.B., S.L.R.K., S.S., S.W.v.d.L., T.A.L., T.B.H., T.E., T.H., T.L., U.V., V.V., W. Zhao, W.O., X.L., Y. Lu, Y.D.I.C., Y.H., Y. Liu, Y.W.

Phenotyping of contributing studies

A. Pattie, A. Peters, A.R.H., A. Robino, A.S.B., A.T. Hattersley, A. Tönjes, A. Tybjaerg-Hansen, A.U.J., A.V., A.W.H., B.B., B.G.N., B.H.T., B.K., C.A.B., C.E.L., C.E.P., C.H., C.J.P., C.K., C.M., C.M.L., C.N.A.P., C.S., D.E., D.F.R., D.I.C., D.J.R., D.R.N., D.R.V.E., D.R.W., E.C., E.D.A., E.E., E.F., E.I., E.P.B., E.R.B.P., E.T., E.W.D., F. Karpe, F. Kee, F. Renström, F. Rivadeneira, F.W., G.B.J., G.L., G.P.J., G. Tromp, G.W.M., H.B., H.D.W., H.H., H.L.G., H.Li, I.J.D., I.R., J.C., J.C.C., J.D., J.D.F., J.F., J.H.J., J. Kaprio, J. Lindström, J.M.M.H., J.M.S., J.P.B., J.S., J.S.K., K.B.K., K.E.N., K.H.L., K.K., K.K.A., K.M.H., K.N., K.R.O., K.S.L., K.S.S., K.T.Z., L.A.K., L.E.B., L.E.W., L.L., L.M.Y.A., L. Southam, L. Sun, L.W., M.A., M.A.I., M. Blüher, M. Brumat, M.C.H.d.G., M.C.M.G., M.F.F., M.I.M., M.J.C., M. Kähönen, M. Karaleftheri, M. Kumari, M.L.B., M.M., M.M.N., M.N., M.R., M.S., N.D.P., N.G., N.J.S., N.J.W., N.L., N.N., N.R.L., O.H., O.H.F., O.L.H., O. Polasek, O.R., O.T.R., P.A., P.G.L., P. Komulainen, P. Kovacs, P.L.P., P.M.R., P. Mitchell, P.R.K., P.R.N., P.T.C., P.T.E., R.d.M., R.E.S., R.F.S., R.M.C., R.R., R.S.K.,

R.V., R.Y., S.A.L., S.E.M., S.F.A.G., S. Fauser, S.H. Scholte, S.H. Shah, S.H.V., S.L.R.K., S.M., S.S., S.T., T.A.L., T.A.M., T.B.H., T.D.S., T.E.G., T.J., T.J.P., T.L., T.L.E., T.N.P., V. Giedraitis, V. Salomaa, V.T., W.H.H.S., W.O., X.L., X.S., Y. Liu, Y. Lu

Data analysis of contributing studies

A.E.H., A.E.J., A.E.L., A.G., A.J.C., A.J.S., A. Lophatananon, A.M., A.P.M., A.P.P., A. Pirie, A.R.W., A. Rasheed, A. Robino, A.S.B., A. Teumer, A.V.S., A.Y.C., B.K., C.A.B., C.A.W., C.H., C.P.N., C.S., C.T.H., C.T.L., D.F.R., D.I.C., D.J.T., D.M.W., D.S.A., D.V., E.B.W., E.E., F. Rivadeneira, G.C.P., G. Davies, G.L., G.M., G. Thorleifsson, G. Tromp, G.V., H. Li, H. Lin, H.M.S., H.P., H.R.W., H.T., H.Y., I.F., I.G., J.A. Perry, J.B.J., J.C.C., J.C.G., J.E.H., J.G., J.G.D., J.H.Z., J. Haessler, J. Hernesniemi, J.I.R., J. Kuusisto, J. Li, J. Luan, J.M.M.H., J.P.B., J.P.T., J.R.O., J.S.K., J.v.S., J.W.J., J.Y., K.B.K., K.E.N., K.E.S., K.E.T., K.L.Y., K.M., K.S.L., L.-A. Lin, L.A. Lange, L. Broer, L.F.B., L.H., L.M.O.L., L.M.Y.A., L. Moilanen, L.P.L., L. Southam, M.A.N., M.C., M.C.H.d.G., M.C.M.G., M.C.Y.N., M.D., M.F., M.F.F., M. Gorski, M. Graff, M. Kumari, M.L., M.P.S.L., M.R., M.U., M.V., N.D.P., N.G., N.G.D.M., N.J.S., N.L.H.C., N.R.R., N.v.L., O.H., P.L.A., P. Mudgal, P.S., P.Y., R.A.S., R.C., R.L.G., R.U., R.Y., S.A.L., S.E.A., S.G., S.J., S.M., S.M.W., S.P., S.S., S.V., S.W.v.d.L., T.E., T. Karaderi, T. Korhonen, T.L.E., T.M.F., T.S.C., T.V.V., T.W.W., V.M., V. Steinthorsdottir, V.T., V.V., W.G., W. Zhang, W. Zhou, W. Zhao, X.G., X.L., X.S., Y.H., Y.J., Y. Lu, Y.S., Y. Wu

REFERENCES

1. Bray, G.A. & Ryan, D.H. Update on obesity pharmacotherapy. *Ann N Y Acad Sci* **1311**, 1-13 (2014).
2. Bray, G.A., Fruhbeck, G., Ryan, D.H. & Wilding, J.P. Management of obesity. *Lancet* **387**, 1947-56 (2016).
3. Monda, K.L. *et al.* A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. *Nat Genet* **45**, 690-6 (2013).
4. Wen, W. *et al.* Meta-analysis of genome-wide association studies in East Asian-ancestry populations identifies four new loci for body mass index. *Hum Mol Genet* **23**, 5492-504 (2014).
5. Locke, A.E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206 (2015).
6. Winkler, T.W. *et al.* The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. *PLoS Genet* **11**, e1005378 (2015).
7. Akiyama, M. *et al.* Genome-wide association study identifies 112 new loci for body mass index in the Japanese population. *Nat Genet* **49**, 1458-1467 (2017).
8. van der Klaauw, A.A. & Farooqi, I.S. The hunger genes: pathways to obesity. *Cell* **161**, 119-32 (2015).
9. Edwards, S.L., Beesley, J., French, J.D. & Dunning, A.M. Beyond GWASs: illuminating the dark road from association to function. *Am J Hum Genet* **93**, 779-97 (2013).
10. Stratigopoulos, G. *et al.* Hypomorphism of Fto and Rpgrip1l causes obesity in mice. *J Clin Invest* **126**, 1897-910 (2016).
11. Stratigopoulos, G., LeDuc, C.A., Cremona, M.L., Chung, W.K. & Leibel, R.L. Cut-like homeobox 1 (CUX1) regulates expression of the fat mass and obesity-associated and retinitis pigmentosa GTPase regulator-interacting protein-1-like (RPGRIP1L) genes and coordinates leptin receptor signaling. *J Biol Chem* **286**, 2155-70 (2011).
12. Stratigopoulos, G. *et al.* Hypomorphism for RPGRIP1L, a ciliary gene vicinal to the FTO locus, causes increased adiposity in mice. *Cell Metab* **19**, 767-79 (2014).
13. Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. *N Engl J Med* **373**, 895-907 (2015).
14. Smemo, S. *et al.* Obesity-associated variants within FTO form long-range functional connections with IRX3. *Nature* **507**, 371-5 (2014).
15. Marouli, E. *et al.* Rare and low-frequency coding variants alter human adult height. *Nature* (2017).
16. Fuchsberger, C. *et al.* The genetic architecture of type 2 diabetes. *Nature* **536**, 41-7 (2016).
17. Sina, M. *et al.* Phenotypes in three pedigrees with autosomal dominant obesity caused by haploinsufficiency mutations in the melanocortin-4 receptor gene. *Am J Hum Genet* **65**, 1501-7 (1999).
18. Pearce, L.R. *et al.* KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. *Cell* **155**, 765-77 (2013).
19. Hinney, A. *et al.* Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. *J Clin Endocrinol Metab* **84**, 1483-6 (1999).
20. Purcell, S.M. *et al.* A polygenic burden of rare disruptive mutations in schizophrenia. *Nature* **506**, 185-90 (2014).
21. van den Berg, L. *et al.* Melanocortin-4 receptor gene mutations in a Dutch cohort of obese children. *Obesity (Silver Spring)* **19**, 604-11 (2011).
22. Surendran, P. *et al.* Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat Genet* **48**, 1151-1161 (2016).
23. Lunetta, K.L. *et al.* Rare coding variants and X-linked loci associated with age at menarche. *Nat Commun* **6**, 7756 (2015).
24. GIANT. Include reference to GIANT WHR paper.
25. Zhou, Z. *et al.* Cidea-deficient mice have lean phenotype and are resistant to obesity. *Nat Genet* **35**, 49-56 (2003).

26. Tews, D. *et al.* Comparative gene array analysis of progenitor cells from human paired deep neck and subcutaneous adipose tissue. *Mol Cell Endocrinol* **395**, 41-50 (2014).
27. Stutzmann, F. *et al.* Non-synonymous polymorphisms in melanocortin-4 receptor protect against obesity: the two facets of a Janus obesity gene. *Hum Mol Genet* **16**, 1837-44 (2007).
28. Lin, H.Q., Wang, Y., Chan, K.L., Ip, T.M. & Wan, C.C. Differential regulation of lipid metabolism genes in the brain of acetylcholinesterase knockout mice. *J Mol Neurosci* **53**, 397-408 (2014).
29. Vignaud, A. *et al.* Genetic ablation of acetylcholinesterase alters muscle function in mice. *Chem Biol Interact* **175**, 129-30 (2008).
30. Ji, Z., Mei, F.C. & Cheng, X. Epac, not PKA catalytic subunit, is required for 3T3-L1 preadipocyte differentiation. *Front Biosci (Elite Ed)* **2**, 392-8 (2010).
31. Yan, J. *et al.* Enhanced leptin sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking exchange protein directly activated by cyclic AMP isoform 1. *Mol Cell Biol* **33**, 918-26 (2013).
32. Almahariq, M., Mei, F.C. & Cheng, X. Cyclic AMP sensor EPAC proteins and energy homeostasis. *Trends Endocrinol Metab* **25**, 60-71 (2014).
33. Kai, A.K. *et al.* Exchange protein activated by cAMP 1 (Epac1)-deficient mice develop beta-cell dysfunction and metabolic syndrome. *FASEB J* **27**, 4122-35 (2013).
34. Hardie, D.G., Ross, F.A. & Hawley, S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat Rev Mol Cell Biol* **13**, 251-62 (2012).
35. Hardie, D.G. & Ashford, M.L. AMPK: regulating energy balance at the cellular and whole body levels. *Physiology (Bethesda)* **29**, 99-107 (2014).
36. Lopez, M., Nogueiras, R., Tena-Sempere, M. & Dieguez, C. Hypothalamic AMPK: a canonical regulator of whole-body energy balance. *Nat Rev Endocrinol* **12**, 421-32 (2016).
37. Minokoshi, Y. *et al.* AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. *Nature* **428**, 569-74 (2004).
38. Viollet, B. *et al.* The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. *J Clin Invest* **111**, 91-8 (2003).
39. Xue, B. *et al.* Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues. *Mol Cell Biol* **29**, 4563-73 (2009).
40. Warren, H.R. *et al.* Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet* (2017).
41. Chami, N. *et al.* Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. *Am J Hum Genet* **99**, 8-21 (2016).
42. Li, M. *et al.* SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function. *J Am Soc Nephrol* (2016).
43. Liu, C. *et al.* Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. *Nat Genet* **48**, 1162-70 (2016).
44. Schwartz, M.W., Woods, S.C., Porte, D., Jr., Seeley, R.J. & Baskin, D.G. Central nervous system control of food intake. *Nature* **404** 661-671 (2000).
45. Garfield, A.S. *et al.* A neural basis for melanocortin-4 receptor-regulated appetite. *Nat Neurosci* **18**, 863-71 (2015).
46. Huszar, D. *et al.* Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* **88** 131-141 (1997).
47. Fan, W., Boston, B.A., Kesterson, R.A., Hruby, V.j. & Cone, R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. *Nature* **385** 165-168 (1997).
48. Yeo, G.S.H. *et al.* A frameshift mutation in MC4R associated with dominantly inherited human obesity. *Nature Genetics* **20** 111-112 (1998).
49. Vaisse, C., Clement, K., Guy-Grand, B. & Froguel, P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. *Nature Genetics* **20** 113-114 (1998).

50. Farooqi, I.S. *et al.* Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene. *The New England Journal of Medicine* **348**, 1085-1095 (2003).
51. Lubrano-Berthelier, C. *et al.* Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. *J Clin Endocrinol Metab* **91**, 1811-8 (2006).
52. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285-91 (2016).
53. Hinney, A. *et al.* Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. *J Clin Endocrinol Metab* **88**, 4258-67 (2003).
54. Saxena, R. *et al.* Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nat Genet* **42**, 142-8 (2010).
55. Speliotes, E.K. *et al.* Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet* **42**, 937-948 (2010).
56. Miyawaki, K. *et al.* Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nat Med* **8**, 738-742 (2002).
57. Hansotia, T. *et al.* Extrapankreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. *J Clin Invest* **117**, 143-52 (2007).
58. Fulurija, A. *et al.* Vaccination against GIP for the treatment of obesity. *PLoS One* **3**, e3163 (2008).
59. Finan, B. *et al.* Reappraisal of GIP Pharmacology for Metabolic Diseases. *Trends Mol Med* **22**, 359-76 (2016).
60. Irwin, N. & Flatt, P.R. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. *Diabetologia* **52**, 1724-31 (2009).
61. Revelli, J.P. *et al.* Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2. *Obesity (Silver Spring)* **19**, 1010-8 (2011).
62. Costanzo-Garvey, D.L. *et al.* KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. *Cell Metab* **10**, 366-78 (2009).
63. Brommage, R. *et al.* High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. *Obesity (Silver Spring)* **16**, 2362-7 (2008).
64. Liu, L. *et al.* Proteomic characterization of the dynamic KSR-2 interactome, a signaling scaffold complex in MAPK pathway. *Biochim Biophys Acta* **1794**, 1485-95 (2009).
65. Kuhn, P. *et al.* Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. *N Engl J Med* **375**, 240-6 (2016).
66. Beiroa, D. *et al.* GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. *Diabetes* **63**, 3346-58 (2014).
67. Xiang, Y.Y., Dong, H., Yang, B.B., Macdonald, J.F. & Lu, W.Y. Interaction of acetylcholinesterase with neurexin-1beta regulates glutamatergic synaptic stability in hippocampal neurons. *Mol Brain* **7**, 15 (2014).
68. Bartels, C.F., Zelinski, T. & Lockridge, O. Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. *Am J Hum Genet* **52**, 928-36 (1993).
69. Farlow, M.R. *et al.* Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. *Clin Ther* **32**, 1234-51 (2010).
70. Farlow, M. *et al.* Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. *BMC Neurol* **11**, 57 (2011).
71. Tariot, P., Salloway, S., Yardley, J., Mackell, J. & Moline, M. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. *BMC Res Notes* **5**, 283 (2012).

72. Hu, Y. *et al.* Role of Exchange Protein Directly Activated by Cyclic AMP Isoform 1 in Energy Homeostasis: Regulation of Leptin Expression and Secretion in White Adipose Tissue. *Mol Cell Biol* **36**, 2440-50 (2016).
73. Altarejos, J.Y. *et al.* The Creb1 coactivator Crtc1 is required for energy balance and fertility. *Nat Med* **14**, 1112-7 (2008).
74. Winnier, D.A. *et al.* Transcriptomic identification of ADH1B as a novel candidate gene for obesity and insulin resistance in human adipose tissue in Mexican Americans from the Veterans Administration Genetic Epidemiology Study (VAGES). *PLoS One* **10**, e0119941 (2015).
75. Molotkov, A., Deltour, L., Foglio, M.H., Cuenca, A.E. & Duester, G. Distinct retinoid metabolic functions for alcohol dehydrogenase genes *Adh1* and *Adh4* in protection against vitamin A toxicity or deficiency revealed in double null mutant mice. *J Biol Chem* **277**, 13804-11 (2002).
76. G. TEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648-60 (2015).
77. Volpicelli-Daley, L.A., Duysen, E.G., Lockridge, O. & Levey, A.I. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. *Ann Neurol* **53**, 788-96 (2003).
78. Ivanenkov, V.V., Murphy-Piedmonte, D.M. & Kirley, T.L. Bacterial expression, characterization, and disulfide bond determination of soluble human NTPDase6 (CD39L2) nucleotidase: implications for structure and function. *Biochemistry* **42**, 11726-35 (2003).
79. Jain, R.N. *et al.* *Hip1r* is expressed in gastric parietal cells and is required for tubulovesicle formation and cell survival in mice. *J Clin Invest* **118**, 2459-70 (2008).
80. Engqvist-Goldstein, A.E. *et al.* RNAi-mediated *Hip1R* silencing results in stable association between the endocytic machinery and the actin assembly machinery. *Mol Biol Cell* **15**, 1666-79 (2004).
81. Tao, Y.X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. *Endocr Rev* **31**, 506-43 (2010).
82. Farooqi, I.S. *et al.* Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med* **348**, 1085-95 (2003).
83. Stutzmann, F. *et al.* Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. *Diabetes* **57**, 2511-8 (2008).
84. Vaisse, C. *et al.* Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. *J Clin Invest* **106**, 253-62 (2000).
85. Schonke, M., Myers, M.G., Jr., Zierath, J.R. & Bjornholm, M. Skeletal muscle AMP-activated protein kinase γ 1(H151R) overexpression enhances whole body energy homeostasis and insulin sensitivity. *Am J Physiol Endocrinol Metab* **309**, E679-90 (2015).
86. Pellinen, T. *et al.* Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of β 1-integrins. *J Cell Biol* **173**, 767-80 (2006).
87. Banerjee, U. & Cheng, X. Exchange protein directly activated by cAMP encoded by the mammalian *rapgef3* gene: Structure, function and therapeutics. *Gene* **570**, 157-67 (2015).
88. Rippey, C. *et al.* Formation of chimeric genes by copy-number variation as a mutational mechanism in schizophrenia. *Am J Hum Genet* **93**, 697-710 (2013).
89. Schmitz, C., Kinge, P. & Hutter, H. Axon guidance genes identified in a large-scale RNAi screen using the RNAi-hypersensitive *Caenorhabditis elegans* strain *nre-1(hd20) lin-15b(hd126)*. *Proc Natl Acad Sci U S A* **104**, 834-9 (2007).
90. Setoguchi, R. *et al.* Repression of the transcription factor Th-POK by Runx complexes in cytotoxic T cell development. *Science* **319**, 822-5 (2008).
91. Widom, R.L., Culic, I., Lee, J.Y. & Korn, J.H. Cloning and characterization of hcKrox, a transcriptional regulator of extracellular matrix gene expression. *Gene* **198**, 407-20 (1997).
92. Sun, X. *et al.* Deletion of *atbf1/zfhx3* in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways. *Neoplasia* **16**, 377-89 (2014).
93. Parsons, M.J. *et al.* The Regulatory Factor ZFH3X Modifies Circadian Function in SCN via an AT Motif-Driven Axis. *Cell* **162**, 607-21 (2015).

94. Balzani, E. *et al.* The Zfhx3-Mediated Axis Regulates Sleep and Interval Timing in Mice. *Cell Rep* **16**, 615-21 (2016).
95. Kao, Y.H. *et al.* ZFHX3 knockdown increases arrhythmogenesis and dysregulates calcium homeostasis in HL-1 atrial myocytes. *Int J Cardiol* **210**, 85-92 (2016).

FIGURE LEGENDS

Figure 1. Effect sizes (y-axis) of the 14 BMI-associated R/LF coding variants by their minor allele frequency. Effect sizes are expressed in body weight (kg) per allele, assuming a SD of 4.5 kg and an average-sized person of 1.7m tall. Solid markers indicate that the minor allele is associated with higher BMI, and clear markers indicate that the minor allele is associated with lower BMI. Variants were identified in all-ancestry analyses (light blue diamonds), the European ancestry analyses (dark blue square) and women-only analyses (pink diamond). Effect sizes for previously identified GWAS loci are shown in navy blue diamonds. The dotted line represents 80% power, assuming $\alpha = 2 \times 10^{-7}$ and $N = 525,000$ (discovery sample size).

Figure 2. Heatmap showing DEPICT gene set enrichment results for suggestive and significant rare and low-frequency coding SNVs. For any given square, the color indicates how strongly the corresponding gene (x-axis) is predicted to belong to the reconstituted gene set (y-axis), based on the gene's Z-score for gene set inclusion in DEPICT's reconstituted gene sets (red indicates a higher, blue a lower Z-score). To visually reduce redundancy and increase clarity, we chose one representative "meta-gene set" for each group of highly correlated gene sets based on affinity propagation clustering (**Online Methods, Supplementary Note**). Heatmap intensity and DEPICT *P*-values (**Supplementary Table 17**) correspond to the most significantly enriched gene set within the meta-gene set. Annotations for genes indicate (1) whether it has an OMIM annotation as underlying a monogenic obesity disorder (black/grey), (2) the MAF of the significant ExomeChip (EC) variant (blue), (3) whether the variant's *P*-value reached array-wide significance ($< 2 \times 10^{-7}$) or suggestive significance ($< 5 \times 10^{-4}$) (purple), (4) whether the variant was novel, overlapping "relaxed" GWAS signals from Locke *et al.*⁵ (GWAS $P < 5 \times 10^{-4}$), or overlapping "stringent" GWAS hits (GWAS $P < 5 \times 10^{-8}$) (pink), and (5) whether the gene was included in the gene set enrichment analysis or excluded by filters (orange/brown) (**Online Methods, Supplementary Note**). Annotations for gene sets indicate if the meta-gene set was significant (green, FDR < 0.01 , < 0.05 , or not significant) in the DEPICT analysis of GWAS results⁵. Here, two regions of particularly strong gene set membership are

shown (see full heat map in **Supplementary Figure 10a**).

TABLES

Table 1 Rare and low-frequency coding variants significantly associated with BMI

Chr:position	Variant	Coding locus	Allele		Amino acid change	EAF (%)	β (SD/allele)	SE	P-value	N	Explained variance (%)
			Effect	Other							
<u>All-ancestries additive</u>											
1:154987704	rs141845046	<i>ZBTB7B</i> *	T	C	p.Pro190Ser	2.44%	0.048	0.006	7.73E-18	718,628	0.011%
7:100490797	rs1799805	<i>ACHE</i> *	T	G	p.His353Asn	3.90%	0.029	0.005	2.82E-10	707,448	0.006%
12:48143315	rs145878042	<i>RAPGEF3</i> *	G	A	p.Leu300Pro	1.10%	0.066	0.008	1.56E-15	700,852	0.010%
12:49399132	rs1126930	<i>PRKAG1</i>	C	G	p.Thr38Ser	3.22%	0.034	0.005	3.98E-12	712,354	0.007%
12:72179446	rs61754230	<i>RAB21</i> *	T	C	p.Ser224Phe	1.74%	0.040	0.007	1.33E-09	693,373	0.005%
12:117977550	rs56214831	<i>KSR2</i>	T	C	p.Arg525Gln	0.82%	0.057	0.010	1.08E-08	655,049	0.005%
12:123345509	rs34149579	<i>HIP1R</i>	T	G	p.Cys938Phe	4.54%	-0.032	0.004	2.00E-14	716,253	0.009%
16:72830539	rs62051555	<i>ZFHX3</i> *	G	C	p.Gln1100His	4.34%	-0.024	0.004	4.01E-08	690,637	0.005%
18:58039478	rs13447324	<i>MC4R</i>	T	G	p.Tyr35Ter	0.01%	0.542	0.086	2.26E-10	631,683	0.006%
19:46178020	rs139215588	<i>GIPR</i>	A	G	p.Arg190Gln	0.11%	-0.148	0.028	1.25E-07	695,800	0.005%
19:46180976	rs143430880	<i>GIPR</i>	G	A	p.Glu288Gly	0.13%	-0.153	0.028	2.96E-08	599,574	0.006%
20:25195509	rs6050446	<i>ENTPD6</i> *	A	G	p.Lys185Glu	2.71%	-0.034	0.005	2.40E-10	717,084	0.006%
<u>All-ancestries sex-specific additive (women only)</u>											
19:3813906	rs45465594	<i>ZFR2</i> *	C	A	p.Ile718Met	2.55%	-0.040	0.008	1.94E-07	373,848	0.008%
<u>European Ancestry additive</u>											
9:97062981	rs12236219	<i>ZNF169</i> *	T	C	p.Arg381Cys	4.23%	-0.029	0.005	8.78E-10	612,396	0.007%

Array-wide significant is defined as $P < 2 \times 10^{-7}$.

Variant positions are reported according to Build 37 and their alleles are coded based on the positive strand.

Alleles (effect/other), effect allele frequency (EAF), beta (b), standard error (SE) and P values are based on the meta-analysis of Discovery Stage (GIANT) and Validations stage (deCODE, UKBiobank) studies. Effect allele is always the minor allele. Effects (b) are expressed in SD, assuming mean=0 and SD=1.

The amino acid change from the most abundant coding transcript is shown in this table (see Supplementary Table 25 for more details on protein annotation based on VEP tool and transcript abundance from GTEx database).

* Novel gene, i.e. not previously implicated in human obesity

Table 2. Genes significantly associated with BMI in a gene-based meta-analyses, aggregating R/LF coding SNVs

Gene	Location longest coding transcript	Test ^d	N variants	P-value	Conditioned P-value ^a	Single variant	
						Top variant	P-value
<u>All-ancestries sex-combined</u>							
<i>SLC6A17</i>	chr1:110693132-110744823	SKAT	13	2.73E-07	0.13	rs41313405	4.45E-07
<i>RAPGEF3</i>	chr12:48128453-48152889	SKAT	19	8.91E-15	0.20	rs145878042	5.16E-14
<i>PRKAG1</i>	chr12:49396055-49412629	SKAT	4	2.75E-12	0.53	rs1126930	2.63E-12
<i>RAB21</i>	chr12:72148643-72187256	SKAT	5	4.81E-08	0.27	rs61754230	4.96E-08
<i>KSR2</i>	chr12:117890817-118406028	SKAT	7	7.15E-09	0.19	rs56214831	4.59E-08
<i>MAP1A</i>	chr15:43809806-43823818	SKAT	25	9.42E-07	0.16	rs55707100	1.01E-06
<i>MC4R</i>	chr18:58038564-58040001	VT	4	3.72E-09	0.01	rs13447325	2.97E-11
<i>GIPR</i>	chr19:46171502-46186982	VT	10	8.24E-09	1.12E-04	rs143430880	5.76E-06
<u>All-ancestries sex-specific</u>							
<i>ALDH3A1</i> (men only)	chr17:19641298-19651746	SKAT	15	3.24E-07	0.003	rs142078447	8.62E-06
<i>ZFR2</i> (women only)	chr19:3804022-3869027	SKAT	19	1.81E-07	0.82	rs45465594	3.64E-07
<u>European sex-combined</u>							
<i>ACHE</i>	chr7:100487615-100493592	SKAT	6	3.30E-10	0.12	rs386545548	7.22E-10
<u>European sex-specific</u>							
<i>ANGPTL7</i> (men only)	chr1:11249346-11256038	VT	3	2.50E-06	0.008	rs202182115	2.56E-05
<i>ZNF169</i> (women only)	chr9:97021548-97064111	SKAT	9	1.89E-07	0.24	rs12236219	1.06E-06

Array-wide significant gene-based association is defined as $P < 2.5 \times 10^{-6}$. P-values are based on the meta-analysis of Discovery Stage studies.

Gene-based analyses were performed with SKAT and VT, results shown are from the test (SKAT or VT) for which the significance exceeded $P < 2.5 \times 10^{-6}$. Only results using the "broad" SNV inclusion criteria reached array-wide significance.

Transcript positions are reported according to Build 37 for the longest coding transcript supported by RefSeq (as displayed in UCSC Genome Browser).

^aP-value after conditioning on the most significant (top) single variant aggregated in the gene-based test.

BOX 1 – Brief description of the 13 genes (alphabetical) identified

ACHE (acetylcholinesterase). *ACHE* is mainly expressed in brain and muscle⁷⁶. Its encoded protein hydrolyzes acetylcholine (Ach) at brain cholinergic synapses and neuromuscular junctions, and thus terminates signal transmission⁶⁷. Knockout mice showed a reduction in expression of muscarinic Ach receptors in brain regions associated with learning and memory and showed lower ability to initiate the signaling cascade⁷⁷. This gene has fewer missense variants than expected and is highly intolerant to loss of function (LoF) mutations⁵².

ENTPD6 (ectonucleoside triphosphate diphosphohydrolase 6). Previously known as *Interleukin 6 Signal Transducer-2*, this gene is similar to E-type nucleotidases that participate in purine and pyrimidine metabolism, calcium ion binding, hydrolase activity, magnesium ion binding and nucleoside-diphosphatase activity⁷⁸. It is widely expressed in many different tissues, in particular in the brain⁷⁶.

GIPR (gastric inhibitory polypeptide receptor). *GIPR* encodes a G-protein coupled receptor for gastric inhibitory polypeptide that is secreted by intestinal K-cells after food ingestion⁵⁹. *GIPR* activation stimulates insulin secretion from pancreatic β -cells and mediates fat deposition by increasing lipoprotein lipase activity, lipogenesis, fatty acid and glucose uptake in adipocytes. *GIPR* is mostly expressed in EBV-transformed lymphocytes, stomach and visceral adipose tissue⁷⁶.

HIP1R (huntingtin interacting protein 1 related). *HIP1R* is a multi-domain protein that promotes actin binding and cell survival and interacts with CLTB and HIP1 (GeneCards). *HIP1* and *HIP1R* appear to play central roles in clathrin-coated vesicle formation and intracellular membrane trafficking by promoting transient interaction between actin filaments and the endocytic machinery^{79,80}. *HIP1R* is most expressed in the stomach tissue, brain (substantia nigra, spinal cord, hippocampus), and sun-exposed skin⁷⁶.

KSR2 (kinase suppressor of ras 2). *KSR2* is an intracellular protein that functions as a molecular scaffold to regulate MAP kinases ERK1/2 and determine cell fates. *KSR2* also regulates AMPK activity controlling cellular thermogenesis, fat oxidation, and glucose metabolism^{18,61,62}. Knockout mouse models and human

mutations have been linked to obesity risk⁶². KSR2 is almost exclusively expressed in the brain. It has fewer missense variants than expected and is highly intolerant to LoF mutations⁵².

MC4R (melanocortin 4 receptor). MC4R is a seven-transmembrane G-protein coupled receptor, predominantly expressed in the brain⁷⁶. MC4R has been known to play a key role in body weight regulation for more than 20 years. Activation of MC4R by α -MSH, a POMC-derived peptide, suppresses food intake, MC4R antagonists increase food intake and *MC4R* deficiency in human and rodent models results in hyperphagia and severe and early-onset obesity⁸¹. More than 150 *MC4R* mutations have been identified in individuals with severe, early-onset obesity⁸¹, many of which lead to a complete or partial loss of function^{82,83}. Up to 6% of individuals with severe, early-onset obesity carry pathogenic mutations in *MC4R*, making *MC4R* deficiency the most common form of monogenic obesity^{82,84}.

PRKAG1 (protein kinase AMP-activated non-catalytic subunit gamma 1). The protein encoded by *PRKAG1* is one of the gamma regulatory subunits of the AMP-activated protein kinase (AMPK), which is an important energy-sensing enzyme that monitors cellular energy status³⁴. AMPK and PRKAG1 are ubiquitously expressed⁷⁶. In the hypothalamus, AMPK influences food intake, energy expenditure and glucose homeostasis³⁶. Muscle-specific overexpression of AMPK γ 1 subunit in mice results in increased food intake, but does not affect body weight, presumably through a compensatory increased energy expenditure⁸⁵.

RAB21 (member RAS oncogene family). RAB21 belongs to the Rab family of monomeric GTPases involved in the control of cellular membrane traffic. The encoded protein is widely expressed⁷⁶ and plays a role in the targeted trafficking of integrins, and is involved in the regulation of cell adhesion and migration⁸⁶. *RAB21* is thought to be intolerant to LoF mutations⁵².

RAPGEF3 (rap guanine nucleotide exchange factor 3, also EPAC1). *RAPGEF3* encodes the exchange protein directly activated by cAMP isoform 1 (EPAC1), one of two cAMP sensors that are involved in numerous intracellular cAMP-mediated functions⁸⁷. EPAC1 is ubiquitously expressed⁷⁶, and insights from mouse knockout models suggest a role in energy homeostasis and the development of obesity and diabetes

through the regulation of leptin and insulin signaling^{31,87}.

ZFR2 (zinc finger RNA binding protein 2). The biological function of the gene product is as yet undetermined. GO annotations related to this gene include *nucleic acid binding*. It may have a role in dendritic branching and axon guidance^{88,89}. ZFR2 is predominantly expressed in the brain⁷⁶.

ZBTB7B (zinc finger and BTB domain containing 7B, also ThPOK). ZBTB7B is a transcription factor regulating T-cell fate in the thymus, particularly as the master regulator of CD4⁺ lineage commitment⁹⁰. It is a repressor of type 1 collagen gene expression⁹¹. This gene is mainly expressed in T-cell lineages, skin and gastrointestinal tissues. ZBTB7B is thought to be intolerant to LoF mutations⁵².

ZFHX3 (zinc finger homeobox 3). ZFHX3 encodes a transcription factor with multiple homeodomains and zinc finger motifs and plays a role in cell-cycle, myogenic and neuronal differentiation. This gene is a tumor suppressor⁹² that influences circadian rhythms^{93,94} and sleep⁹⁴. It may also contribute to the genesis of atrial fibrillation⁹⁵. ZFHX3 is highly expressed in arterial tissue and also other tissues⁷⁶. The ZFHX3 gene is highly intolerant to LoF mutations⁵².

ZNF169 (zinc finger protein 169). The biological function of the gene product is as yet unclear. GO annotations suggest that ZNF169 is involved in *nucleic acid binding and transcriptional regulation*. This gene is ubiquitously expressed⁷⁶.

More details and references in Supplementary Table 24.

ONLINE METHODS

Study design & participants

The discovery cohort consisted of 123 studies (163 datasets) comprising 526,508 adult (≥ 18 yrs) individuals of the following ancestries (**Supplementary Figure 1**): 1) European (N = 449,889), 2) South Asian (N = 29,398), 3) African (N = 27,610), 4) East Asian (N = 8,839), and 5) Hispanic (N = 10,772). All participating institutions and coordinating centers approved this project and informed consent was obtained from all study participants. Discovery meta-analyses were carried out in each ancestry separately and in the All-ancestries combined group, for both sex-specific and sex-combined analyses. SNVs for which associations reach suggestive significance ($P < 2.0 \times 10^{-6}$) in the discovery analyses, were taken forward for follow-up in 192,226 individuals of European ancestry from the UK BioBank and deCODE. Conditional analyses were conducted in the All-ancestries and European descent groups. Study-specific design, sample quality control and descriptive statistics are provided in **Supplementary Tables 1-3**.

Phenotype

Body mass index (BMI: weight [in kilograms] / height [in meters]²) was corrected for age, age² and genomic principal components (PC, derived from GWAS data, the variants with MAF > 1% on ExomeChip, or ancestry informative markers available on the ExomeChip), as well as any additional study-specific covariates (e.g. recruiting center), in a linear regression model. For studies with non-related individuals, residuals were calculated separately by sex, whereas for family-based studies sex was included as a covariate in the model. Additionally, residuals for case/control studies were calculated separately. Finally, residuals were subject to inverse normal transformation⁹⁶.

Genotype calling

The majority of studies followed a standardized protocol and performed genotype calling using the designated manufacturer software, which was then followed by zCall⁹⁷. For 10 studies, participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the raw intensity data for the samples from seven genotyping centers were assembled into a single project for joint

calling⁹⁸. Study-specific quality control (QC) measures of the genotyped variants were implemented before association analysis (**Supplementary Table 2**).

Statistical analyses

Study-level association analyses. Individual cohorts were analyzed separately for each ancestry, in sex-combined and sex-specific groups, with either RAREMETALWORKER (see URL links at the end of the **Online Methods**) or RVTEST⁹⁹ (**Supplementary Table 2**), to associate inverse normal transformed BMI with genotype accounting for potential cryptic relatedness (kinship matrix) in a linear mixed model. These software tools are designed to perform score-statistics based rare-variant association analyses, can accommodate both unrelated and related individuals, and provide single-variant results and variance-covariance matrices. The covariance matrix captures linkage disequilibrium (LD) relationships between markers within 1 Mb, which is used for gene-level meta-analyses and conditional analyses¹⁰⁰. Single-variant analyses were performed for both additive and recessive models.

Centralized quality-control. A centralized quality-control procedure, implemented in EasyQC¹⁰¹, was applied to individual cohort association summary statistics to identify cohort-specific problems: (1) assessment of possible problems in BMI transformation, (2) comparison of allele frequency alignment against 1000 Genomes Project phase 1 reference data to pinpoint any potential strand issues, and (3) examination of quantile-quantile (QQ) plots per study to identify any problems arising from population stratification, cryptic relatedness and genotype biases.

Meta-analyses. Meta-analyses were carried out by two different analysts at two sites in parallel. We excluded variants with a call rate < 95%, Hardy-Weinberg equilibrium P -value < 1×10^{-7} , or large allele frequency deviations from reference populations (> 0.6 for all-ancestry analyses and > 0.3 for ancestry-specific population analyses). Significance for single-variant analyses was defined at the array-wide level (a Bonferroni-corrected threshold of $P < 2 \times 10^{-7}$ for ~250,000 SNVs). To test for sex-differences of the significant variants ($P < 2 \times 10^{-7}$), we calculated the P -diff for each SNP, which tests for differences between women-specific and men-specific beta estimates using EasyStrata¹⁰². For gene-based analyses, we applied

the sequence kernel association test (SKAT)¹⁰³ and the Variable Threshold (VT)¹⁰⁴ gene-based methods using two different sets of criteria (broad and strict) to select predicted damaging R/LF variants with MAF < 5%, based on coding variant annotation from five prediction algorithms (PolyPhen2 HumDiv and HumVar, LRT, MutationTaster and SIFT)²⁰. Our *broad* gene-based tests included nonsense, stop-loss, splice site, and missense variants that are annotated as damaging by at least one algorithm mentioned above. Our *strict* gene-based tests included only nonsense, stop-loss, splice site, and missense variants annotated as damaging by all five algorithms. Statistical significance for gene-based tests was set at a Bonferroni-corrected threshold of $P < 2.5 \times 10^{-6}$ for about 20,000 genes^{16,105}. Single-variant and gene-based meta-analyses were both performed using RareMETALS R-package¹⁰⁶. As our secondary analyses are nested and/or highly correlated with our primary analysis, we chose the same, already stringent, Bonferroni-corrected significance threshold for both analyses.

Genomic inflation. Although the overall λ_{GC} value is in the normal range for all coding variants ($\lambda_{GC} = 1.1$, **Supplementary Table 23**), we observed a marked genomic inflation of the test statistics even after adequate control for population stratification (linear mixed model) arising from common markers ($\lambda_{GC} = 1.99$, **Supplementary Figure 2a** and **Supplementary Table 23**). Such inflation is expected for a highly polygenic trait like BMI, as was previously confirmed for height¹⁵, and is consistent with our very large sample size^{5,107}. Furthermore, some of the inflation may be due to the design of the ExomeChip, which besides R/LF coding SNVs also contains (common and non-coding) SNVs that include previously identified GWAS loci for all traits, including for BMI and BMI-related traits, reported in the GWAS catalogue at the time of its design.

After removing established loci (+/- 1Mb), the excess of significant associations is markedly reduced and inflation reduced (**Supplementary Figures 2c and 2d**).

Furthermore, to exclude the possibility that some of the observed associations between BMI and R/LF SNVs could be due to allele calling problems in the smaller studies, we performed a sensitivity meta-analysis with primarily European ancestry studies totaling >5,000 participants. We found very concordant

effect sizes, suggesting that smaller studies do not bias our results (**Supplementary Figure 12**).

Follow-up Analysis. We sought additional evidence for association of the top signals ($P < 2.0 \times 10^{-6}$) identified in the discovery meta-analysis using two independent studies from the UK (UK Biobank, interim release, $N = 119,613$) and Iceland (deCODE, $N = 72,613$), respectively (**Supplementary Tables 1-3**). We used the same QC and analytical methodology as described above. We used the inverse-variance weighted fixed effects meta-analysis in METAL¹⁰⁸, to combine the discovery and follow-up association results. Significant associations were defined at $P < 2 \times 10^{-7}$ in the combined meta-analysis of discovery, UK Biobank and deCODE results.

Effect of study design. To investigate the potential effect of study design of the participating studies, we tested for heterogeneity between population-based, all case-control studies, T2D case-control studies (**Supplementary Table 26**). None of these comparisons showed significant evidence of heterogeneity ($P < 7.4 \times 10^{-5}$, correcting for multiple testing).

Conditional analyses. The RareMETALS R-package¹⁰⁶ was used to identify independent BMI associated signals across the all-ancestry meta-analysis results in the discovery phase. RareMETALS performs conditional analyses by using covariance matrices from each individual cohort to distinguish true signals from the shadows of adjacent significant variants in LD. The conditional associations of all the variants within 1Mb of each R/LF coding variant were analyzed to identify [1] nearby secondary signals and [2] to determine independence from nearby non-coding variants or previously identified GWAS loci (previously defined as a window of 1Mb surrounding the lead SNP). Gene-based conditional analyses were also performed in RareMETALS.

Due to the selective coverage of variants on the ExomeChip, we also conducted the respective conditional analyses in the UK Biobank dataset that included 847,441 genome-wide genotyped markers, and 72,355,667 variants imputed against UK10k haplotype reference panel, merged with the 1000 Genomes Phase 3 reference panel. Where available, directly genotyped variants were used for conditional analyses. Otherwise, imputed variants with good imputation quality (IMPUTE2 info score > 0.6) were used. We used

QCTOOL to extract variants of interest from the original imputed data set. Subsequently, GTOOL was used to convert to PLINK format (genotype calling threshold 0.99) and merged with the directly genotyped variants for conditional analyses in PLINK v1.90b3.35 64-bit (25 Mar 2016).

Conversions of effect size and explained variants. We assumed that 1 SD = 4.5 kg/m² BMI-units, based on population based data, and 1.7m as the average height of a person to convert effects sizes in SD-units into body weight. The variance explained by each variant was calculated using the effect allele frequency (f) and beta (β) from the meta analyses using the formula¹⁰⁹ of explained variance = $2f(1-f)\beta^2$.

Penetrance analysis. We examined the penetrance for the four rare SNVs, p.Arg525Gln (rs56214831) in *KSR2*, p.Tyr35Ter (rs13447324) in *MC4R*, and p.Arg190Gln (rs139215588) and p.Glu288Gly (rs143430880) in *GIPR* in European ancestry data from the UKBiobank (N up to 120,000). For each variant, we compared the prevalence of underweight (BMI < 18.5 kg/m²), normal weight (18.5 kg/m² ≤ BMI < 25 kg/m²), overweight (25 kg/m² ≤ BMI < 30 kg/m²) and obesity (BMI ≥ 30 kg/m²) of non-carriers with non-carriers. We used a Pearson χ^2 test to test for difference between distributions, and a χ^2 for linear trend to test whether distributions of carriers were shifted compared to non-carriers. For p.Arg525Gln in *KSR2* and p.Tyr35Ter in *MC4R*, we hypothesized that obesity prevalence was higher in carriers than in non-carriers, whereas for the two *GIPR* variants, we hypothesized that the prevalence of normal weight was higher in carriers than non-carriers.

Associations with obesity for the coding rare and low-frequency loci in children. For each of the 14 R/LF SNVs, we tested for association with childhood obesity in the CHOP cohort (Childhood Obesity: Early Programming by Infant Nutrition), the Severe Childhood Onset Obesity Project (SCOOP), the UK Household Longitudinal Study (UKHLS) and INTERVAL Study (INTERVAL). Summary statistics across the studies were combined using a fixed effects inverse-variance meta-analysis with METAL¹⁰⁸.

In the CHOP study, cases (1,358 boys, 1,060 girls) were defined as having a BMI > 95th percentile

at any point in their childhood. Controls (1,412 boys, 1,143 girls) were defined as having < 50th percentile consistently through throughout childhood. The BMI percentiles are based on the CDC 2000 Growth Charts. All children were classified based on their BMI measurements between the ages of 2 and 18. All individuals are of European ancestry and were collected at the Children's Hospital of Philadelphia. Informed consent was obtained from all study participants and study protocols were approved by the local ethics committees. Genotypes were obtained using the HumanHap550v1, HumanHap550v3, and Human610-Quad high-density SNP arrays from Illumina. The intersection of all SNPs on the arrays was used in all subsequent pre-imputation analyses. Before imputation, we excluded SNPs with a Hardy-Weinberg equilibrium P -value < 1.0×10^{-6} , call rate of < 95% or MAF of < 1%. The genotypes were then pre-phased using Shapeit2 and imputed using the 1000 Genomes Phase 1 integrated variant set with Impute2. After imputation, SNPs were excluded if the INFO score was < 0.4. Boys and girls were analyzed separately using a logistic regression of case and control status, adjusting for three eigenvectors, and summary statistics were combined using a fixed effects inverse-variance meta-analysis with METAL¹⁰⁸.

SCOOP is a sub-cohort of the Genetics Of Obesity Study (GOOS) cohort. It includes >1,500 UK European ancestry individuals with severe, early onset obesity (BMI Standard Deviation Score > 3 and obesity onset before the age of 10 years), in whom known monogenic causes of obesity have been excluded (cases with *MC4R* mutations were excluded). Two case-control analyses with SCOOP cases were performed: 1) SCOOP vs. UKHLS for which array (Illumina HumanCoreExome) data was available, and 2) SCOOP vs. INTERVAL, for whom whole-exome sequencing data was available.

For the array based analyses, UKHLS controls were genotyped on the Illumina HumanCoreExome-12v1-0 Beadchip. SCOOP cases and 48 UKHLS controls were genotyped on the Illumina HumanCoreExome-12v1-1 Beadchip. The 48 overlapping UKHLS samples were used for quality control to ensure there were no systematic differences and bias between the two versions of the chip. SCOOP and UKHLS samples were phased with SHAPEITv2, and imputed with IMPUTE2 using the combined UK10K-1000G Phase III reference panel. For the WES analyses, SCOOP vs. INTERVAL controls were WES within the UK10K-EXOME project (Agilent v3) and the INTERVAL project (Agilent v5) respectively and

were then jointly called and QC-ed on the union of the sequencing baits. Individuals overlapping or related between the array based and WES studies were removed.

After QC, 1,456 SCOOP and 6,460 UKHLS (BMI range 19-30), and 521 SCOOP and 4,057 INTERVAL individuals were available for the two analyses, all were unrelated, of high quality, and of European ancestry. For both analyses (i.e. SCOOP vs. UKHLS and SCOOP vs. INTERVAL), a maximum likelihood frequentist association test with the additive genetic model was implemented in SNPTEST v2.5. In the SCOOP vs. UKHLS analysis, sex and the first six PCs were included as covariates and variants with a SNPTEST INFO score <0.4 and HWE $p < 10^{-6}$ were removed. For the SCOOP vs INTERVAL analysis, we performed an unadjusted analysis (adjustment for PCs did not change sufficiently the results) and variants were limited to those covered at $\geq 7x$ in at least 80% of each sequencing cohort, meeting the VQSR threshold of -2.52 , missingness $<80\%$, HWE $P\text{-value} < 10^{-8}$, and GQ ≥ 30 .

Cross-trait analyses. We evaluated each of the 14 R/LF SNVs for their association with other relevant obesity-related traits and conditions. We performed lookups in ExomeChip meta-analysis results from other consortia, including, our own GIANT consortium (height¹⁵, WHR adjusted for BMI²⁴), MAGIC (HbA1c, Fasting Insulin, Fasting Glucose, 2-hour glucose), GLGC (HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), triglycerides and total cholesterol)), IBPC⁴⁰ (systolic and diastolic blood pressure), REPROGEN²³ (age at menarche and menopause) and GoT2D/T2D-GENES¹⁶ (type 2 Diabetes). Associations were considered significant at $P < 2.0 \times 10^{-5}$, accounting for multiple testing.

Phenome-wide association analysis (PheWAS). To evaluate the potential for pleiotropic effects for SNPs discovered from primary analyses, we performed phenome-wide association studies (PheWASs) using genotype and phenotype data from two independent sources of electronic health records (EHR): Vanderbilt University Medical Center Biorepository (BioVU) and the United Kingdom BioBank (UKBB). Phenotype selection and analysis strategy were synchronized across sites. A total of 1502 hierarchical phenotype codes from EHRs were curated by grouping International Classification of Disease, Ninth Revision (ICD-9) clinical/billing codes as previously described¹¹⁰. Phenotype codes with 20 or more cases and with minor

allele count of 5 or greater in cases and controls were eligible for analysis. Series of logistic regression analyses were then performed in individuals of European ancestry for each eligible phenotype-genotype combination while adjusting for 5 genetic ancestry PCs. Odds ratios from genotype-phenotype combinations present in both BioVU and UKBB were then aggregated using inverse-variance weighted fixed-effects meta-analysis. Associations with p-values corresponding to false discovery rate (FDR) cut off of less than 10% were considered statistically significant.

Gene set enrichment analysis. We adapted DEPICT, a gene set enrichment analysis method for GWAS data, for use with the ExomeChip ('EC-DEPICT'). DEPICT's primary innovation is the use of "reconstituted" gene sets, where many different types of gene sets (e.g. canonical pathways, protein-protein interaction networks, and mouse phenotypes) were extended through the use of large-scale microarray data (see¹¹¹ for details). EC-DEPICT computes *P*-values based on Swedish ExomeChip data (Malmö Diet and Cancer [MDC], All New Diabetics in Scania [ANDIS], and Scania Diabetes Registry [SDR] cohorts, N=11,899) and, unlike DEPICT, takes as input only coding variants and only the genes directly containing those variants, rather than all genes within a specified amount of linkage disequilibrium (**Supplementary Note**).

Four analyses were performed for the BMI EC variants: [1] all coding variants with $P < 5 \times 10^{-4}$, [2] all coding variants with $P < 5 \times 10^{-4}$ independent of known GWAS variants⁵, [3] all coding R/LF variants with $P < 5 \times 10^{-4}$, and [4] all coding R/LF variants with $P < 5 \times 10^{-4}$ independent of known GWAS variants. Affinity propagation clustering³ was used to group highly correlated gene sets into "meta-gene sets". For each meta-gene set, the member gene set with the best *P*-value was used as representative for purposes of visualization (**Supplementary Note**). DEPICT for ExomeChip was written using the Python programming language (See URLs).

Drosophila RNAi knockdown experiments. For each of the 13 genes in which R/LF coding variants were associated with BMI, we searched for its corresponding orthologues in *Drosophila* in the ENSEMBL orthologue database. Orthologues were available for nine genes, but missing for *ZBTB7B*, *MC4R*, *GIPR*,

and *ZNF169*. For each of the nine genes, we generated adipose-tissue (cg-Gal4) and neuronal (elav-Gal4) specific RNAi-knockdown crosses, leveraging upstream activation sequence (UAS)-inducible short-hairpin knockdown lines, available through the Vienna Drosophila Resource Center (VDRC). We crossed male UAS-RNAi flies and elav-GAL4 or CG-GAL4 virgin female flies. All fly experiments were carried out at 25 °C. Five-to-seven-day-old males were sorted into groups of 20, weighed and homogenated in PBS with 0,05% Tween with Lysing Matrix D in a beadshaker. The homogenate was heat-inactivated for 10 min in a thermocycler at 70 °C. 10µl of the homogenate was subsequently used in triglyceride assay (Sigma, Serum Triglyceride Determination Kit) which was carried out in duplicates according to protocol, with one alteration: the samples were cleared of residual particulate debris by centrifugation before absorbance reading. Resulting triglyceride values were normalized to fly weight and larval/population density. We used the non-parametric Kruskal-Wallis test to compare wild type with knockdown lines.

Enrichment analysis in monogenic genes of obesity. We identified 39 genes with strong evidence that disruption causes monogenic or syndromic forms of obesity (**Supplementary Table 21**). To test whether these genes are enriched for R/LF coding variant associations with BMI, we conducted simulations by matching each of the 39 genes with other genes based on gene length and number of variants tested, to create a matched set of genes. We generated 1,000 matched gene sets from our data and assessed how often the number of R/LF coding variants that exceeded given significance thresholds was greater in our monogenic/syndromic obesity gene set compared to the matched gene sets.

DATA AVAILABILITY

Summary statistics can be downloaded from http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium

REFERENCES

96. Auer, P.L., Reiner, A.P. & Leal, S.M. The effect of phenotypic outliers and non-normality on rare-variant association testing. *Eur J Hum Genet* **24**, 1188-94 (2016).
97. Goldstein, J.I. *et al.* zCall: a rare variant caller for array-based genotyping: genetics and population analysis. *Bioinformatics* **28**, 2543-5 (2012).

98. Grove, M.L. *et al.* Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. *PLoS One* **8**, e68095 (2013).
99. Zhan, X., Hu, Y., Li, B., Abecasis, G.R. & Liu, D.J. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. *Bioinformatics* **32**, 1423-6 (2016).
100. Liu, D.J. *et al.* Meta-analysis of gene-level tests for rare variant association. *Nat Genet* **46**, 200-4 (2014).
101. Winkler, T.W. *et al.* Quality control and conduct of genome-wide association meta-analyses. *Nat Protoc* **9**, 1192-212 (2014).
102. Winkler, T.W. *et al.* EasyStrata: evaluation and visualization of stratified genome-wide association meta-analysis data. *Bioinformatics* **31**, 259-61 (2015).
103. Wu, M.C. *et al.* Rare-variant association testing for sequencing data with the sequence kernel association test. *Am J Hum Genet* **89**, 82-93 (2011).
104. Price, A.L. *et al.* Pooled association tests for rare variants in exon-resequencing studies. *Am J Hum Genet* **86**, 832-8 (2010).
105. Kiezun, A. *et al.* Exome sequencing and the genetic basis of complex traits. *Nat Genet* **44**, 623-30 (2012).
106. Feng, S., Liu, D., Zhan, X., Wing, M.K. & Abecasis, G.R. RAREMETAL: fast and powerful meta-analysis for rare variants. *Bioinformatics* **30**, 2828-9 (2014).
107. Yang, J. *et al.* Genomic inflation factors under polygenic inheritance. *Eur J Hum Genet* **19**, 807-12 (2011).
108. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).
109. Thorleifsson, G. *et al.* Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat Genet* **41**, 18-24 (2009).
110. Denny, J.C. *et al.* PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. *Bioinformatics* **26**, 1205-10 (2010).
111. Pers, T.H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat Commun* **6**, 5890 (2015).

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure underpinning obesity

Valérie Turcot, Yingchang Lu, Heather M Highland, Claudia Schurmann *et al.*

SUPPLEMENTARY NOTE

1. COMMON CODING VARIANTS ASSOCIATED WITH BMI	P. 2
2. COMPARISON OF NOVEL COMMON, LOW FREQUENCY AND RARE VARIANTS ACROSS ANCESTRIES	P. 3
3. GENE SET ENRICHMENT ANALYSIS (EC-DEPICT)	P. 5
4. SUPPLEMENTARY FIGURES	P. 11
5. AUTHOR CONTRIBUTIONS	P. 47
6. ACKNOWLEDGMENTS	P. 53
7. CONSORTIA MEMBERS	P. 73

1. COMMON CODING VARIANTS ASSOCIATED WITH BMI

The main focus of our study was the analysis of the 215,917 rare and low frequency (R/LF) coding variants, which are more likely to disrupt protein function^{1,2}. However, besides R/LF coding variants, the ExomeChip also carries 13,786 common coding SNVs, which were also tested for association with BMI as part of the study.

We identified 41 novel loci that showed association with BMI (AWS: $P < 2.0 \times 10^{-7}$), independent from any previously identified loci (**Supplementary Table 4, Supplementary Figure 4**). The reasons why these 41 novel loci has not been reported by previous large-scale GWAS before are; the sample size of the current study is more than twice as large as the most recent GWAS³, thus providing greater statistical power for discovery, and/or SNPs may not have been tested in previous GWAS efforts because they were not available in HapMap, and thus not imputed, SNPs did not pass quality control, or are located on the X-chromosome, which has so far not been considered in GWAS.

We also identified common variants that clustered in 51 loci that had been identified before (< 1 Mb previous GWAS lead SNP) in large-scale GWAS efforts of adiposity traits (**Supplementary Table 4, Supplementary Figure 4**). Using conditional analyses (**Online Methods**), we were able to show that 38 of these 51 loci represent the same locus as the one identified before and one represents an independent secondary signal in the previously established locus. For the remaining 12 loci, we were not able to confirm whether the association represented secondary or the same signal within the established locus because the original SNP (or proxy) was not available on the ExomeChip to perform conditional analyses (**Supplementary Table 4, Supplementary Figure 4**).

Effect sizes of the 41 novel loci are smaller (on average 0.014 SD/allele, [range: 0.010 – 0.024 SD/allele]) than those of the 37 previously established loci (average 0.021 SD/allele, [range: 0.010 – 0.050 SD/allele]) (**Supplementary Figure 5**). This difference is likely due to the increased sample size ($N > 700,000$), and thus power, of our meta-analyses, compared to sample size of

previous GWAS efforts (N up to 340,000), allowing the identification of loci with smaller effects. Signals in established loci, for which conditional analyses could not convincingly determine whether it was a secondary observation, have effect sizes in between the novel and established loci (average 0.016 SD/allele, [range: 0.010 – 0.030 SD/allele]). The explained variance of the 41 novel loci ranges between 0.004% and 0.02%, and add up to a combined explained variance of 0.394%, as compared to the 2.7% of the variance explained by the 97 loci reported in our latest GWAS BMI effort³.

The novel common coding loci have features similar to those of previously established GWAS loci; i.e. they represent a cluster of variants in high LD with each other that require further fine-mapping efforts to identify the causal genes/variants in the locus. The common coding variants, including those that reached $P < 5 \times 10^{-4}$, were included in the EC-DEPICT analyses and results are described in the **Main text**.

2. COMPARISON OF NOVEL COMMON, LOW FREQUENCY AND RARE VARIANTS ACROSS ANCESTRIES

2.1. Low-frequency and rare coding SNVs

We observed no significant heterogeneity in effect sizes across ancestries, accounting for multiple testing across novel SNVs ($P_{\text{threshold}} = 9 \times 10^{-4} = 0.05/(14+41)$), which may in part be due to low statistical power in non-European ancestry populations (**Supplementary Table 7, Supplementary Figure 6**). Minor allele frequencies are general consistent across ancestries, with two exceptions. The minor allele of rs7636 (p.Pro477Pro) in *ACHE* is of low frequency in European ancestry populations (4.2%), but much more common in African (24.4%) and Hispanic (9.9%) ancestry populations and, similarly, that of rs12236219 in *ZNF169* is of low frequency in European ancestry populations, but common in all other ancestries studied.

Of interest are the two SNVs (p.His353Asn, p.Pro477Pro) in *ACHE*, which track together nearly perfectly in European ancestry populations ($r^2=0.98$; $D'=0.99$, MAFs=4.2%), whereas in African ancestry populations they are not correlated ($r^2=0.01$; $D'=0.95$). In the African ancestry

data, the non-synonymous SNV p.His353Asn is rare (0.60%) and has a similar estimated effect size (0.057 SD/allele, 95% CI [-0.050-0.164], $P=0.29$) to the effect seen in European ancestry individuals (0.034 SD/allele, 95% CI [0.023-0.044]), whereas the synonymous p.Pro477Pro is common (24.4%) and has no detectable effect on BMI (-0.006 SD/allele, $P=0.56$). Even though our sample size was relatively small, an effect of 0.023-0.044 SD/allele, as observed in European ancestry individuals, would have been detectable in our African-ancestry population (MAF=24.4%, $N \sim 24,000$, power $\sim 80\%$, at $\alpha=0.01$). The absence of such association suggests that p.Pro477Pro may not be driving the association at this locus and that p.His353Asn (or potentially a variant correlated with p.His353Asn, but not with p.Pro477Pro, in African-ancestry populations) is more likely to be the causal variant. This is consistent with functional role of many non-synonymous, as compared to synonymous variants.

2.2. Novel common SNVs

None of the 41 novel common SNVs showed evidence of heterogeneity across ancestries ($P_{\text{threshold}} = 9 \times 10^{-4}$). Generally, allele frequencies of the BMI-increasing allele in European ancestry populations were consistent with those of South Asian ($r^2 = 0.82$) and Hispanic ($r^2 = 0.86$) ancestry populations, and somewhat lower with African ($r^2 = 0.52$) and East Asian ($r^2 = 0.48$) ancestries (**Supplementary Table 7, Supplementary Figure 6**). Because of the relatively small sample sizes of non-European ancestry populations, statistical power for replication of associations observed in the total sample or European ancestry only meta-analyses was low. Nevertheless, of the 41 SNVs, associations were directionally consistent for 32 SNVs (78%), of which 7 reached nominal significance, in the African ancestry meta-analysis (**Supplementary Table 7, Supplementary Figure 6**). The directional consistency between European ancestry associations was similar for South Asian (34 SNVs (83%) of which 5 nominally significant) and Hispanic (34 SNVs (83%) of which 3 nominally significant) ancestry populations, and lower for East Asian ancestry populations (61 SNVs (61%) of which 6 nominally significant).

3. GENE SET ENRICHMENT ANALYSIS (EC-DEPICT)

DEPICT is a method for gene set enrichment analysis and gene prioritization of GWAS data⁴. Briefly, 14,462 gene sets from KEGG⁵, REACTOME⁶, Gene Ontology⁷, InWeb⁸ (protein-protein networks) and Mouse Phenotype⁹ databases were obtained and “reconstituted” using large-scale microarray data, based on the logic of guilt-by-association (genes with similar patterns of expression are more likely to be members of the same gene sets). We have adapted the gene set enrichment functionality of DEPICT for the ExomeChip (EC-DEPICT), with a few alterations: (1) instead of including all genes within a specified amount of linkage disequilibrium to each index SNP, we include only the gene containing the index SNV, (2) we include only nonsynonymous and splicing (coding) SNVs, discarding noncoding associations and (3) we use null ExomeChip data for p-value calculation (rather than null GWAS data). In this supplement, we provide a brief overview of the method and more detailed explanations of each analysis.

3.1. Method

The EC-DEPICT method has been described elsewhere¹⁰. We generated null ExomeChip data from the Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS), and Scania Diabetes Registry (SDR) cohorts (a total of 11,899 samples with Swedish ancestry). After generating simulated normally-distributed phenotypes, we conducted 2,200 null ExomeChip association studies, filtering out all variants not present in the BMI association study. The variants in each null study were then sorted by ascending *P*-value and clumped (+/- 1 Mb on each side). Annotations from the CHARGE consortium were used to assign variants to genes (see URLs). For analyses of rare/low-frequency variants, a separate set of backgrounds was created that retained only loci where the index SNV had a minor allele frequency of <5%.

The method for gene set enrichment is as follows. A list of significant input variants from the ExomeChip is obtained (index SNVs for each locus, coding variants only) and filtered to remove variants not present in the null backgrounds or that are not marked as nonsynonymous/splice-site in the CHARGE consortium annotations. Then, we map the variants

to genes. For each gene set, we then calculate a test statistic: the sum of gene set membership z-scores from the reconstituted gene sets¹ for the input genes. We then take 2000 nulls and compute the average (null) test statistic and standard deviation for the given gene set (where the number of top genes we take from each null as “input genes” is matched to the observed number of input genes). A z-score for the gene set is then computed as the observed test statistic minus the null test statistic divided by the null standard deviation, which is converted to a p-value based on the normal distribution. False discovery rates (FDRs) were calculated using an additional 50 null permutations to generate a distribution of null p-values. The FDR was calculated as the average number of null p-values less than a given threshold divided by the number of observed p-values less than that threshold.

Our null data (MDC, ANDIS, and SDR cohorts) was also used for the ExomeChip analysis of height¹⁰. As in the height analysis, before gene set enrichment analysis of BMI-associated variants, we removed variants absent in this null ExomeChip data. This resulted in exclusion of about 30% of the BMI-associated variants at suggestive of array-wide significance. Most of the excluded variants were in the very rarest allele frequency bins, and mostly reached suggestive rather than array-wide significance. The exclusion of the rarest variants is expected due to the much smaller sample size of the null cohorts relative to the BMI data. To try to include more variants in the analysis, we also generated null ExomeChip data based on the UK Biobank, which resulted in the exclusion of fewer BMI-associated variants (due to the much larger sample size of the UK Biobank data). However, we observed that use of these null data, despite including more of the rarest BMI-associated variants in the gene set enrichment analysis, dampened the signal and resulted in fewer significantly enriched gene sets. This result suggests that 1) the rarest variants are more likely to have a lower true positive rate and/or 2) the heterogeneity of the underlying biology increases with the inclusion of very rare variants.

Although some variants were excluded from the EC-DEPICT analysis, we have included them in the heatmap figures (Figure 2, Supplementary Figure 10). This is because we assume

that if the genes containing those variants have strong predicted membership in gene sets found to be significantly enriched, they are still good candidates for prioritization (and one of the main purposes of the heatmap strategy is to visually prioritize the best candidate genes). In fact, this is arguably even stronger evidence for prioritization of these genes, because they had no opportunity to influence the gene sets that are identified as enriched and, as such, independently support the biology implicated by these gene sets.

We have observed that extreme non-normality of gene set membership z-scores can, in certain situations, cause minor inflation of Type I error. To address this issue, we repeated the original EC-DEPICT analysis with an inverse-normal-transformed version of the reconstituted gene sets, in which every gene set is forced to have a normal z-score distribution for pathway membership. We then compared the rank of each significant gene set in the original results with the rank in the inverse normal transform and flagged “outliers” with respect to the change in rank ($> 1.5 \times$ the interquartile range). In visualizing the results with heat maps and in supplementary tables, outlier gene sets were excluded.

3.2. Analyses

We performed four different analyses of the BMI-associated variants. In each case, for each locus, we included the best coding variant, including secondary signals if present. “GWAS-independent” analyses were performed by excluding EC loci conditionally dependent on or <1 Mb away from a known GWAS locus (see below for details). For this purpose, “known loci” consisted of a list of all variants used as input in the original DEPICT analysis in Locke et al.³ ($P < 5 \times 10^{-4}$). This was necessary to confirm true independence from the original DEPICT findings (i.e. gene set enrichment results for EC that come from a completely non-overlapping set of genes relative to the original DEPICT analysis).

The breakdown of included variants is as follows. Array-wide significant variants ($P < 2 \times 10^{-7}$) came from the final meta-analysis of Discovery, deCODE, and UK Biobank results across all analysis strata. For these variants (“stringent”), independence from genome-wide significant

GWAS loci was determined by conditional analysis. Additional variants with p-values between 5×10^{-4} and 2×10^{-7} (“relaxed”) were based on Discovery in the all-ancestries sex-combined additive model. For these variants, independence from genome-wide significant GWAS loci was based on a distance of >1 Mb. For both stringent and relaxed variants, independence from marginally significant GWAS loci was also based on a distance of > 1 Mb. All loci were clumped ± 1 Mb.

For the first analysis, we included all EC loci with $p < 5 \times 10^{-4}$. After filtering, this left 244 variants in 242 genes; we discovered 67 gene sets (24 meta-gene sets) at FDR < 0.05 . After removing inverse normal transform outliers (see description above), that left 62 gene sets (still in 24 meta-gene sets). The second analysis included EC loci with 5×10^{-4} “independent” of a known GWAS locus³ (110 variants in 110 genes after filtering). We found no significant gene sets in this analysis.

The third and fourth analyses included rare and low-frequency (RLF; $< 5\%$ MAF) variants only. The third analyses included all RLF variants with $P < 5 \times 10^{-4}$, representing a total of 50 variants in 50 genes after filtering. We found 512 significant gene sets at FDR < 0.05 (107 meta-gene sets). After applying the inverse normal transform filter, this was reduced to 471 significant gene sets in 106 meta-gene sets. Finally, the last analysis included RLF variants with $P < 5 \times 10^{-4}$ “independent” of a known GWAS locus³ (after filtering, 30 variants in 30 genes). This recovered 31 significant gene sets in 12 meta-gene sets at FDR < 0.05 . After the inverse normal transform, we retained 29 significant gene sets, still in 12 meta-gene sets.

3.3. Affinity propagation clustering

To collapse the most highly correlated gene sets, affinity propagation clustering was performed as described in Marouli et al. (2017)¹⁰. Briefly, “meta-gene sets” were generated by affinity propagation clustering³ of all pairs of 14,462 gene sets, using SciKit-Learn.clustering.AffinityPropagation version 0.17¹¹, with a maximum iteration of 10,000 and a convergence iteration of 1,000. For each meta-gene set, P -values were assigned based on the most significant member gene set (considered the “best representative gene set”). In heat maps,

z-scores for meta-gene set membership represent the z-score of the best representative gene set. Heat maps were generated with the ComplexHeatmap package in R¹². For Online Mendelian Inheritance in Man (OMIM) annotations, a manual curation of obesity-related terms in the OMIM database was performed.

3.4. URLs

CHARGE Consortium ExomeChip annotation file:

<http://www.chargeconsortium.com/main/exomechip/>

EC-DEPICT: <https://github.com/RebeccaFine/obesity-ec-depict>

EC-DEPICT meta-gene sets: https://github.com/RebeccaFine/obesity-ec-depict/blob/master/data/metacluster_labels.txt


References

1. Kryukov, G.V., Pennacchio, L.A. & Sunyaev, S.R. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. *Am J Hum Genet* **80**, 727-39 (2007).
2. Tennessen, J.A. *et al.* Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science* **337**, 64-9 (2012).
3. Locke, A.E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206 (2015).
4. Pers, T.H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat Commun* **6**, 5890 (2015).
5. Ogata, H. *et al.* KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res* **27**, 29-34 (1999).
6. Croft, D. *et al.* Reactome: a database of reactions, pathways and biological processes. *Nucleic Acids Res* **39**, D691-7 (2011).
7. Ashburner, M. *et al.* Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* **25**, 25-9 (2000).
8. Lage, K. *et al.* A human phenome-interactome network of protein complexes implicated in genetic disorders. *Nat Biotechnol* **25**, 309-16 (2007).
9. Blake, J.A. *et al.* The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse. *Nucleic Acids Res* **42**, D810-7 (2014).
10. Marouli, E. *et al.* Rare and low-frequency coding variants alter human adult height. *Nature* (2017).
11. Pedregosa, F., Grisel, O., Weiss, R., Passos, A. & Brucher, M. in *Scikit-learn: Machine Learning in Python* 2825-2830 (2011).
12. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847-9 (2016).
13. Mistry, V., Barroso, I. & I. Sadaf, F. Metabolic Research Laboratories, University of Cambridge, Cambridge, CB2 0QQ, UK.

14. Mistry, V., Barroso, I. & I. Sadaf, F. NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
15. Boehnke, M. *et al.* Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, 48109, USA.
16. Sim, X. Saw Swee Hock School of Public Health, National University Health System, National University of Singapore, Singapore 117549, Singapore.


4. SUPPLEMENTARY FIGURES

Supplementary Figure 1 | Flowchart of the GIANT ExomeChip BMI study design.




Supplementary Figure 2 | Quantile-quantile plots of BMI associations for coding SNVs tested in the Discovery GIANT meta-analyses. A-B. Quantile-quantile plots of BMI associations tested in all-ancestries (**A**) and European ancestry (**B**) strata for all coding (exonic and splicing) SNVs in black, and stratified by minor allele frequency (MAF) cut-offs; common variants ($MAF \geq 5\%$) in green, rare and low-frequency variants ($MAF < 5\%$) in dark blue, and rare variants ($MAF < 1\%$) in light blue. **C-D.** Quantile-quantile plots of BMI associations tested in all-ancestries (C) and European ancestry (D) strata for all coding (exonic and splicing) SNVs in black, and after excluding ($\pm 1\text{Mb}$) known and novel loci identified in previous BMI GWAS and in the ExomeChip meta-analysis (pink).


A




B



C






D



Supplementary Figure 3 | Manhattan plots of coding rare and low-frequency SNV associations in the Discovery GIANT dataset appended with the significant SNVs from the final combined meta-analysis. Manhattan plot of associations in all-ancestries sex-combined additive (A), all-ancestries women additive (B) and European ancestry sex-combined additive (C) strata. Each locus was defined using a 1Mb window on each side of the lead coding variant. Dots correspond to the Discovery GIANT meta-analysis results, while the final combined meta-analysis results were appended to the plots using triangles. Only significant loci in the final combined meta-analysis were colored; novel loci, secondary signals (in known GWAS loci, but independent from GWAS hit/proxy) and known loci were highlighted in red, light blue and dark blue, respectively.

A



B**C**


Supplementary Figure 4 | Manhattan plots of coding common SNV associations obtained in the Discovery GIANT dataset appended with the significant SNVs from the final combined meta-analysis See also Supplementary Table 4 for detailed results.

Each locus was defined using a 1Mb window on each side of the lead coding variant. Dots correspond to the Discovery GIANT meta-analysis results, while the final combined meta-analysis results were appended to the plots using triangles.


Panels A, B & C: Results from novel loci and novel secondary signals. Manhattan plot of associations in all-ancestries sex-combined additive (A), all-ancestries sex-combined recessive (B) and European ancestry sex-combined additive (C) strata. Only novel loci (in red) and novel secondary signals in known loci (in cyan) are shown in panels A, B & C.

Panels D & E: Results from known loci, some of which with potential secondary signals. Manhattan plot of associations in all-ancestries sex-combined additive (D) and all-ancestries women additive (E) strata. Loci that were previously established (in blue), and signals in previously known loci, but for which conditional analyses could not convincingly determine whether the signal was secondary or the same locus (in grey) are shown in panels D & E.


A




B




C



D




E


Supplementary Figure 5 | Regional association plots for the significant rare and low-frequency coding loci identified in the final combined meta-analysis among all analysis strata. The association results shown in these plots are from the Discovery GIANT meta-analysis in the specified analysis strata for all ExomeChip SNVs (dots) and appended with the previous BMI GWAS results (European ancestry) from Locke et al. (crosses; Locke et al. Nature 518, 197-206). The size of the dots and crosses are weighted on the minor allele frequency. We have used the UK Biobank dataset (European ancestry; N=136,727) to calculate the linkage disequilibrium between the SNVs in the window and the reference coding SNV shown in turquoise. Only GWAS traits related with body weight are shown in the plots. (A) Regional plots for loci with only one significant coding SNV in the region (only unconditioned results shown). (B) Regional plots for loci with more than one significant coding SNVs or with a GWAS hit or proxy ($r^2 > 0.80$ in EUR 1000G phase 3) in the region ($< \pm 1\text{MB}$). Both unconditioned and conditioned results are shown.

A


ZBTB7B - All-ancestries sex-combined additive




RAPGEF3 - All-ancestries sex-combined additive




RAB21 - All-ancestries sex-combined additive




KSR2 - All-ancestries sex-combined additive



ZFR2 - All-ancestries women additive




ZNF169 - Europeans sex-combined additive




B


ACHE - All-ancestries sex-combined additive




PRKAG1 - All-ancestries sex-combined additive




HIP1R - All-ancestries sex-combined additive




ZFH3 - All-ancestries sex-combined additive




MC4R - All-ancestries sex-combined additive



GIPR - All-ancestries sex-combined additive



ENTPD6 - All-ancestries sex-combined additive



Supplementary Figure 6 | Relationship of allele frequencies and effect sizes of novel SNVs between European-ancestry and other ancestry populations (see also Supplementary Table 7). Panel A shows the data for the minor alleles of 14 low-frequency and rare SNVs. Panel B shows the data for the BMI-increasing allele of the 41 common SNVs.

A


European vs African

European vs South Asian


European vs Hispanic

European vs East Asian

Allele frequencies



Effect sizes



B


European vs African

European vs South Asian


European vs Hispanic

European vs East Asian


Allele frequencies




Effect sizes




Supplementary Figure 7 | Effect sizes (y-axis) of the 92 common coding variants by their BMI-increasing allele frequency. Effect sizes are expressed in SD per allele (**Supplementary Table 4**). Blue dots represent the 42 novel loci, orange dots represent loci that have been identified before in GWAS for obesity traits, and green dots represent association signals in previously established loci, but for which conditional analyses was not able to convincingly determine the signal as secondary or not (i.e. the previously established lead SNP was not available on the chip).



Supplementary Figure 8 | Effects of the two rare SNVs (p.Arg190Gln, p.Glu288Gly) in *GIPR* on BMI in the UK Biobank (N = 115,611, Interim release). Y-axis shows the difference from mean BMI in the UKBiobank, after adjusting for age and sex.




Supplementary Figure 9 | Heatmaps of cross-trait associations for the novel R/LF independent loci identified in the final combined meta-analysis. Heatmap squares are $-\log_{10}(P\text{-values})$ with red-to-blue shading based on beta effect direction for the BMI-increasing allele in the final combined meta-analysis (blue). Green-to-blue shading hits correspond to positive beta effects with P -values between 0.05 and $<2E-5$, orange-to-red shading hits correspond to negative beta effects with P -values between 0.05 to $<2E-5$, yellow squares are not significant ($P>0.05$), and white squares are missing values. Clustering was done using the complete linkage method with Euclidean distance measure for the loci. SNVs clustering together are more significantly associated with the same set of traits.




Supplementary Figure 10 | Heatmaps showing full DEPICT gene set enrichment results A) of rare and low frequency nonsynonymous SNVs (from main text figure 2), B) of novel rare and low frequency nonsynonymous SNVs, and C) nonsynonymous SNVs of all allele frequencies. For any given square, the color indicates how strongly the corresponding gene (shown on the x-axis) is predicted to belong to the reconstituted gene set (y-axis). This value is based on the gene's z-score for gene set inclusion in DEPICT's reconstituted gene sets, where red indicates a higher and blue a lower z-score. To visually reduce redundancy and increase clarity, we chose one representative "meta-gene set" for each group of highly correlated gene sets based on affinity propagation clustering (**Online Methods, Supplementary Information**). Heatmap intensity and DEPICT *P*-values (see *P*-values in **Supplementary Tables 17-19**) correspond to the most significantly enriched gene set within the meta-gene set. Annotations for the genes indicate (1) whether the gene has an OMIM annotation as underlying a monogenic obesity disorder (black and grey), (2) the minor allele frequency of the significant ExomeChip (EC) variant (shades of blue; if multiple variants, the lowest-frequency variant was kept), (3) whether the variant's *P*-value reached array-wide significance ($<2 \times 10^{-7}$) or suggestive significance ($<5 \times 10^{-4}$) (shades of purple), (4) whether the variant was novel, overlapping "relaxed" GWAS signals from Locke et al.³ (GWAS $P < 5 \times 10^{-4}$), or overlapping "stringent" GWAS signals (GWAS $P < 5 \times 10^{-8}$) (shades of pink), and (5) whether the gene was included in the gene set enrichment analysis or excluded by filters (shades of brown/orange) (**Online Methods and Supplementary Information**). Annotations for the gene sets indicate if the meta-gene set was found significant (shades of green; FDR < 0.01 , < 0.05 , or not significant) in the DEPICT analysis of GWAS results from Locke et al.³


B



C




Supplementary Figure 11 | Quantile-quantile plot for BMI associations for rare and low-frequency coding SNVs located in monogenic and syndromic genes of obesity. Single variant association results obtained in the final combined meta-analysis are enriched for coding SNVs located in monogenic and syndromic genes of obesity (see gene list and results in **Supplementary Table 21**).



Supplementary Figure 12 | Scatter plot comparison of the effect sizes for all variants that reached significance in the European-ancestry-discovery results ($n = 526,508$) and results including only studies with sample sizes of more than 5,000 individuals ($n = 317,511$).

5.



5. AUTHOR CONTRIBUTIONS

Writing Group (wrote and edited manuscript)

Panos Deloukas, Mary F. Feitosa, Timothy M. Frayling, Mariaelisa Graff, Heather M. Highland, Joel N. Hirschhorn, Anne E. Justice, Guillaume Lettre, Cecilia M. Lindgren, Adam E. Locke, Ruth J.F. Loos, Yingchang Lu, Kari E. North, Claudia Schurmann, Valérie Turcot, Kristin L. Young

Data preparation group (program development and quality control of data from contributing cohorts for meta-analyses)

Tamuno Alfred, Ingrid B. Borecki, Tonu Esko, Shuang Feng, Mariaelisa Graff, Heather M. Highland, Anne Justice, Tugce Karaderi, Daijiang J. Liu, Ken Sin Lo, Adam E. Locke, Ruth J.F. Loos, Yingchang Lu, Eirini Marouli, Nicholas G.D. Masca, Carolina Medina-Gomez, Poorva Mudgal, Maggie C.Y. Ng, Manuel A. Rivas, Suthesh Sivapalaratnam, Claudia Schurmann, Kathy Stirrups, Valérie Turcot, Sailaja Vedantam, Sara M. Willems, Thomas W. Winkler, Kristin L. Young, Xiaowei Zhan

BMI meta-analyses (*discovery and follow-up, single-variant and gene-based*)

Ingrid B. Borecki, Timothy M. Frayling, Heather M. Highland, Anne E. Justice, Joel N. Hirschhorn, Ching-Ti Liu, Daijiang J. Liu, Yingchang Lu, Ruth J.F. Loos, Claudia Schurmann, Valérie Turcot, Kristin L. Young

Childhood data (analyses and interpretation)

Inês Barroso, Jonathan P Bradfield, I. Sadaf Farooqi, Struan FA Grant, Hakon Hakonarson, Vanisha Mistry, Audrey E Hendricks, Gaëlle Marenne

Pleiotropy working group

Gonçalo Abecasis, Michael Boehnke, James P. Cook, Panos Deloukas, Fotios Drenos, Jose C. Florez, Heather M. Highland, Sekar Kathiresan, Hidetoshi Kitajima, Cecilia M. Lindgren, Daijiang J. Liu, Ruth J.F. Loos, Anubha Mahajan, Eirini Marouli, Gaëlle Marenne, Mark I. McCarthy, Patricia B. Munroe, Gina M. Peloso, John R.B. Perry, Katherine S. Ruth, Xueling Sim, Shuai Wang, Jennifer Wessel, Sara M. Willems, Cristen J. Willer^{15,1615,1613,144,5}

Phenome-wide association studies

Lisa Bastarache, Josh C. Denny, Todd L. Edwards, Ayush Giri, Anubha Mahajan, Mark I. McCarthy

Gene-set enrichment analyses analyses

Rebecca S. Fine, Joel N. Hirschhorn, Tune H. Pers

Monogenic and syndromic gene enrichment analyses

Heather M. Highland, Alisa K. Manning

Fly Obesity Screen

Adelheid M. Lempradl, John A. Pospisilik

Overseeing of contributing studies

(1958 Birth Cohort) Panos Deloukas; (Add Health) Penny Gordon-Larsen, Kathleen Mullan Harris; (ADDITION-DK) Daniel R. Witte, Marit E. Jørgensen; (AGES) Vilmundur Gudnason, Tamara B. Harris; (Airwave) Paul Elliott; (AMC PAS) G. Kees Hovingh; (Amish) Jeffrey R. O'Connel; (ARIC) Eric Boerwinkle; (ARIC, Add Health) Kari E. North; (ASCOT-UK, ASCOT-UK) Helen R. Warren; Patricia B. Munroe; (ATBC) Satu Männistö; (Athero-Express Biobank Study) Hester M den Ruijter,

Gerard Pasterkamp; (ATVB, Ottawa) Sekar Kathiresan; (BioVU) Todd L Edwards; (BRAVE) Emanuele Di Angelantonio, Rajiv Chowdhury; (BRIGHT) Patricia B Munroe; (CARDIA) Myriam Fornage, Pamela J. Schreiner; (CCHS) Gorm B. Jensen; (Cebu Longitudinal Health and Nutrition Survey) Karen L. Mohlke; (CGPS) Børge G. Nordestgaard; (CHD Exome + Consortium) Adam S. Butterworth, Joanna MM Howson, Dermot F. Reilly, John Danesh; (CHES) Rohit Varma; (CHOP) Struan F.A. Grant, Hakon Hakonarson; (Clear/eMERGE (Seattle)) Gail P. Jarvik; (CROATIA_Korcula) Veronique Vitart, Ozren Polasek, Igor Rudan; (deCODE) Kari Stefansson, Unnur Thorsteinsdottir; (DHS) Donald W. Bowden; (DIABNORD) Paul W. Franks; (DIACORE) Carsten A. Böger; (DPS) Jaakko Tuomilehto, Matti Uusitupa; (Duke) Sekar Kathiresan, Svati Shah; (EFSOCH) Andrew T. Hattersley, Timothy M. Frayling; (EGCUT) Tõnu Esko; (eMERGE (Seattle)) Eric B. Larson; (ENDO) Andrew P. Morris, Krina T. Zondervan; (EPIC-Potsdam) Matthias B. Schulze, Heiner Boeing; (EpiHealth) Erik Ingelsson, Paul W. Franks; (EUGENDA) Anneke I. den Hollander, Sascha Fauser; (EXTEND) Andrew T. Hattersley, Timothy M. Frayling; (Family Heart Study) Ingrid B. Borecki; (Fenland, EPIC) Robert A. Scott; (Fenland, EPIC, InterAct) Nicholas J. Wareham, Claudia Langenberg; (EPIC-CVD) John Danesh; (FIA3) Paul W. Franks; (FINCAVAS) Mika Kähönen, Kjell Nikus; (Finnish Twin Cohort) Jaakko Kaprio; (FINRISK) Veikko Salomaa; (FVG) Paolo Gasparini; (GECCO) Peter T. Campbell, Robert E. Schoen; (GeMEP) Gerard Tromp, David J. Carey, Helena Kuivaniemi; (GENDEP) Gerome Breen; (Generation Scotland) Caroline Hayward, Sandosh Padmanabhan; (Genetic Epidemiology Network of Arteriopathy (GENOA)) Sharon LR Kardia, Patricia A. Peyser; (GLACIER) Paul W. Franks, Frida Renström; (GoDARTS) Colin NA Palmer, Andrew D. Morris; (GRAPHIC) Nilesh J. Samani; (GSK-STABILITY) Dawn M. Waterworth, Lars Wallentin, Harvey D. White; (Health) Allan Linneberg; (Health ABC) Tamara B. Harris, Yongmei Liu; (HELIC MANOLIS) Eleftheria Zeggini, George Dedoussis; (HELIC Pomak) Eleftheria Zeggini, George Dedoussis; (HUNT-MI) Cristen J Willer; (Inter99) Torben Hansen, Torben Jørgensen; (INTERVAL Study) John Danesh; (IRASFS) Nicholette D. Palmer, Elizabeth K. Speliotes; (Jackson Heart Study (JHS)) James G. Wilson; (KORA S4) Konstantin Strauch, Annette Peters, Iris M. Heid; (LASA (BBMRI-NL)) Martin den Heijer; (LBC1921) John M. Starr; (LBC1921/LBC1936) Ian J. Deary; (Leipzig-Adults) Matthias Blüher, Peter Kovacs; (LOLIPOP-Exome) John C. Chambers, Jaspal S. Kooner; (LOLIPOP-OmniEE) John C. Chambers, Jaspal S. Kooner; (Marshfield Clinic Personalized Medicine Research Project) Murray H. Brilliant, Peggy L. Peissig; (Massachusetts General Hospital Cardiology and Metabolic Patient Cohort (CAMP)) Paul L. Huang; (MESA) Jerome I. Rotter, Xiuqing Guo; (Montreal Heart Institute Biobank (MHIBB)) Marie-Pierre Dubé, Guillaume Lettre, John D. Rioux, Jean-Claude Tardif; (MORGAM Central Laboratory) Markus Perola; (MORGAM Data Centre) Kari Kuulasmaa; (OBB) Fredrik Karpe; (Ophthalmic Western Australia Biobank & Blue Mountains Eye Study) Alex W. Hewitt; (PCOS) Andrew P. Morris, Cecilia M. Lindgren; (PIVUS) Cecilia M. Lindgren, Lars Lind; (PRIME - Belfast) Frank Kee; (PRIME - Lille) Philippe Amouyel; (PRIME - Strasbourg) Mary Moitry; (PRIME - Toulouse) Jean Ferrieres; (PROMIS) Danish Saleheen; (PROSPER) Naveed Sattar; (QC) Manuel A. Rivas; (QIMR) Grant W. Montgomery, Dale R. Nyholt, Andrew C. Heath, Sarah E. Medland; (Raine) Alex W. Hewitt; (RISC) Beverley Balkau, Ele Ferrannini, Mark Walker; (Rotterdam Study I) André G. Uitterlinden, Oscar H. Franco, M. Arfan Ikram; (SCOOP) Inês Barroso, I. Sadaf Farooqi; (SEARCH) Alison M. Dunning; (SHIP/SHIP-Trend) Hans-Jörgen Grabe; (SIBS) Douglas F. Easton; (SOLID TIMI-52) Dawn M. Waterworth; (SORBS) Andrew P. Morris, Michael Stumvoll, Anke Tönjes; (Southampton) Andrew J. Lotery; (The Hoorn Diabetes Care System Cohort study (BBMRI-NL)) Nienke van Leeuwen; (The Mother Child Cohort of Norway) Pål R. Njølstad, Stefan Johansson; (The Mount Sinai BioMe Biobank) Erwin P. Bottinger, Ruth JF Loos; (The NEO Study) Dennis O. Mook-Kanamori; (The NHAPC study, The GBTDS study) Xu Lin; (The Western Australian Pregnancy Cohort (Raine) Study) Craig E. Pennell, Trevor A. Mori; (TUDR) Wayne H-H Sheu; (TwinsUK) Timothy D. Spector; (UCLA-Utrecht) Roel A. Ophoff; (UCP (BBMRI-NL)) Mark CH de Groot; (ULSAM) Andrew P. Morris; (Utrecht Health Project) Folkert W. Asselbergs; (Vejle

Biobank) Ivan Brandslund, Cramer Christensen, Oluf Pedersen; (WGHS) Daniel I. Chasman, Paul M. Ridker; (Women's Health Initiative) Paul L. Auer; (WOSCOPS) Ian Ford; (WTCCC-UKT2D) Mark I. McCarthy, Katharine R. Owen; (YFS) Terho Lehtimäki, Olli T. Raitakari

Genotyping of contributing studies

(1958 Birth Cohort) Kathleen E. Stirrups, Stavroula Kanoni; (Add Health) Penny Gordon-Larsen, Ethan M. Lange, Leslie A. Lange, Angela L. Mazul; (ADDITION-DK) Anette P. Gjesing; (Airwave) Evangelos Evangelou, Marcelo P. Segura-Lepe; (AMC PAS) Suthesh Sivapalaratnam; (Amish) Laura M. Yerges-Armstrong, James A. Perry; (ARIC) Ellen W. Demerath, Megan Grove; (ASCOT-UK, ASCOT-SC) Patricia B. Munroe; (Athero-Express Biobank Study) Sander W van der Laan; (BBMRI-NL) Sita H. Vermeulen Linda Broer, Cornelia M. van Duijn, Paul I.W. de Bakker; (BRAVE) Emanuele Di Angelantonio; (Cambridge Cancer Studies) Joe G. Dennis; (CARDIA) Myriam Fornage; (CCHS) Anne Tybjaerg-Hansen, Anette Varbo; (CGPS) Børge G. Nordestgaard, Sune F. Nielsen; (CHD Exome + Consortium) Adam S. Butterworth, Joanna MM Howson, Dermot F. Reilly, John Danesh, Robin Young; (CHOP) Struan F.A. Grant, Hakon Hakonarson; (CIHDS) Marianne Benn, Ruth Frikke-Schmidt; (Clear/eMERGE (Seattle)) Gail P. Jarvik; (CROATIA_Korcula) Veronique Vitart; (DIABNORD) Paul W. Franks; (DIACORE) Carsten A. Böger, Mathias Gorski; (DPS) Jaakko Tuomilehto; (DR's EXTRA) Timo A. Lakka, Rainer Rauramaa; (Duke) Sekar Kathiresan; (EGCUT) Tõnu Esko, Lili Milani; (ENDO) Andrew P. Morris; (EPIC-Potsdam) Matthias B. Schulze, Karina Meidtner; (EpiHealth) Erik Ingelsson, Paul W. Franks; (EUGENDA) Anneke I den Hollander; (Family Heart Study) Kent D. Taylor; (Fenland, EPIC) Robert A. Scott; (Fenland, EPIC, InterAct) Nicholas J. Wareham, Claudia Langenberg; (FINCAVAS) Mika Kähönen; (Finnish Twin Cohort) Anu Loukola; (FUSION) Michael Boehnke, Francis S. Collins; (FVG) Ilaria Gandin; (GECCO) Peter T. Campbell, Robert E. Schoen; (GeMEP) Gerard Tromp, David J. Carey, Helena Kuivaniemi; (Generation Scotland) Caroline Hayward; (Genetic Epidemiology Network of Arteriopathy (GENOA)) Sharon LR Kardia; (GLACIER) Paul W. Franks; (GoDARTS) Colin NA Palmer; (GRAPHIC) Nilesh J. Samani; (GSK-STABILITY) Dawn M. Waterworth; (Health) Jette Bork-Jensen; (Health ABC) Tamara B. Harris, Yongmei Liu; (Health and Retirement Study (HRS)) Jessica D. Faul, Wei Zhao; (HELIC MANOLIS) Lorraine Southam; (HELIC Pomak) Lorraine Southam; (ID1000/Spinoza (BBMRI-NL)) Anke Hammerschlag; (Inter99) Torben Hansen, Niels Grarup; (INTERVAL Study) Carmel Moore, David Roberts, Adam Butterworth; (IRASFS) Nicholette D. Palmer; (KORA) Martina Müller-Nurasyid; (KORA S4) Konstantin Strauch; (LBC1921/LBC1936) Gail Davies; (Leipzig-Adults) Anubha Mahajan; (LOLIPOP-Exome) John C. Chambers, Jaspal S. Kooner; (LOLIPOP-OmniEE) John C. Chambers, Jaspal S. Kooner; (Marshfield Clinic Personalized Medicine Research Project) Murray H. Brilliant; (MESA) Jerome I. Rotter, Yii-Der Ida Chen, Kent D. Taylor; (METSIM) Johanna Kuusisto, Markku Laakso; (Montreal Heart Institute Biobank (MHIBB)) Marie-Pierre Dubé; (OBB) Fredrik Karpe; (Ophthalmic Western Australia Biobank & Blue Mountains Eye Study) Alex W. Hewitt; (PCOS) Andrew P. Morris; (PIVUS) Cecilia M. Lindgren; (QIMR) Grant W. Montgomery, Dale R. Nyholt; (Raine) Alex W. Hewitt; (Rotterdam Study I) André G. Uitterlinden, Carolina Medina-Gomez, Fernando Rivadeneira; (SDC) Henrik Vestergaard; (SEARCH) Alison M. Dunning; (SHIP/SHIP-Trend) Uwe Völker; (SOLID TIMI-52) Dawn M. Waterworth; (SORBS) Andrew P. Morris; (Southampton) Andrew J. Lotery, Helen L. Griffiths; (SR) Stefania Cappellani, Angela D'Eustacchio; (The Hoorn Diabetes Care System Cohort study (BBMRI-NL)) Nienke van Leeuwen; (The Mother Child Cohort of Norway) Øyvind Helgeland; (The Mount Sinai BioMe Biobank) Erwin P. Bottinger, Ruth JF Loos, Yingchang Lu, Claudia Schurmann; (The NEO Study) Ruifang Li-Gao; (The NHAPC study, The GBTDS study) Xu Lin, Huaixing Li, Yao Hu; (The Western Australian Pregnancy Cohort (Raine) Study) Craig E. Pennell; (TUDR) Eric Kim; (TwinsUK) Andrew P. Morris; (UCLA-Utrecht) Roel A. Ophoff; (UCP (BBMRI-NL)) Mark CH de Groot; (ULSAM) Andrew P. Morris; (Utrecht Health Project) Michiel L. Bots; (WGHS) Daniel I. Chasman, Audrey Y. Chu; (Women's Health Initiative) Charles L. Kooperberg; (WOSCOPS) Chris

J. Packard; (WTCCC-UKT2D) Mark I. McCarthy; (YFS) Terho Lehtimäki, Leo-Pekka Lyytikäinen

Phenotyping of contributing studies

(Add Health) Penny Gordon-Larsen, Kathleen Mullan Harris; (ADDITION-DK) Daniel R. Witte; (Airwave) Evangelos Evangelou; (AMC PAS) Suthesh Sivapalaratnam; (Amish) Laura M. Yerges-Armstrong; (ARIC) Ellen W. Demerath; (ARIC, Add Health) Kari E. North; (ASCOT-SC) Mark J. Caulfield; (ATBC) Satu Männistö; (BBMRI-NL) Sita H. Vermeulen; (BioVU) Todd L. Edwards, Digna R. Velez Edwards; (Blue Mountains Eye Study) Paul Mitchell; (BRAVE) Emanuele Di Angelantonio; (BRIGHT) Mark J Caulfield; (CARL) Antonietta Robino; (CCHS) Gorm B Jensen, Anne Tybjaerg-Hansen, Anette Varbo; (Cebu Longitudinal Health and Nutrition Survey) Nanette R. Lee; (CGPS) Børge G. Nordestgaard, Pia R. Kamstrup; (CHD Exome + Consortium) Adam S. Butterworth, Joanna MM Howson, Dermot F. Reilly, John Danesh, Robin Young; (CHES) Rohit Varma, Roberta McKean-Cowdin; (CHOP) Struan F.A. Grant, Hakon Hakonarson, Jonathan P. Bradfield; (CIHDS) Ruth Frikke-Schmidt, Lia E. Bang; (Clear/eMERGE (Seattle)) Gail P. Jarvik, Amber A. Burt; (CROATIA_Korcula) Ozren Polasek, Igor Rudan; (DIABNORD) Olov Rolandsson; (DIACORE) Carsten A. Böger, Myriam Rheinberger; (DPS) Anne U Jackson, Jaana Lindström; (DR's EXTRA) Pirjo Komulainen, Timo A. Lakka, Rainer Rauramaa; (Duke) Svati Shah; (EFSOCH) Andrew T. Hattersley; (EGCUT) Evelin Mihailov; (ENDO) Krina T. Zondervan; (EPIC-Potsdam) Heiner Boeing; (EPIC-CVD) Adam Butterworth; (EpiHealth) Erik Ingelsson; (EUGENDA) Sascha Fauser; (EXTEND) Andrew T. Hattersley; (Family Heart Study) Mary F. Feitosa; (Fenland, EPIC, InterAct) Nicholas J. Wareham; (FIA3) Jan-Håkan Jansson; (FINCAVAS) Mika Kähönen, Kjell Nikus; (Finnish Twin Cohort) Jaakko Kaprio; (FINRISK) Veikko Salomaa; (FUSION) Amy J. Swift; (FVG) Eulalia Catamo; (GECCO) Peter T. Campbell, Robert E Schoen; (GeMEP) Gerard Tromp; (Generation Scotland) Caroline Hayward; (Genetic Epidemiology Network of Arteriopathy (GENOA)) Sharon LR Kardia; (GLACIER) Frida Renström; (GoDARTS) Colin NA Palmer, Andrew D Morris; (GRAPHIC) Nilesh J. Samani; (GSK-STABILITY) Lars Wallentin, Harvey D. White; (Health) Allan Linneberg, Betina H Thuesen; (Health ABC) Tamara B. Harris, Yongmei Liu; (Health and Retirement Study (HRS)) Jessica D. Faul; (HELIC MANOLIS) Lorraine Southam, Aliki-Eleni Farmaki, Emmanouil Tsafantakis; (HELIC Pomak) Lorraine Southam, Aliki-Eleni Farmaki, Maria Karaleftheri; (HUNT-MI) Oddgeir L. Holmen; (BBMRI-NL)) Anke Hammerschlag; (Inter99) Torben Jørgensen, Niels Grarup; (INTERVAL Study) Carmel Moore, David Roberts; (IRASFS) Nicholette D. Palmer, Bratati Kahali; (KORA) Martina Müller-Nurasyid; (KORA S4) Annette Peters; (LBC1921) John M Starr, Alison Pattie; (LBC1921/LBC1936) Ian J. Deary; (LBC1936) Janie Corley; (Leipzig-Adults) Matthias Blüher, Peter Kovacs; (LOLIPOP-Exome) John C. Chambers, Jaspal S. Kooner; (LOLIPOP-OmniEE) John C. Chambers, Jaspal S Kooner; (Marshfield Clinic Personalized Medicine Research Project) Peggy L. Peissig, Thomas N. Person; (Massachusetts General Hospital Cardiology and Metabolic Patient Cohort (CAMP)) Steven A. Lubitz, Patrick T. Ellinor; (MESA) Matthew Allison; (METSIM) Xueling Sim; (Montreal Heart Institute Biobank (MHIBB)) Guillaume Lettre, Ken Sin Lo, Valérie Turcot; (MORGAM Data Centre) Kari Kuulasmaa; (NESCOG (BBMRI-NL)) Tinca J. Polderman; (OBB) Fredrik Karpe, Matt Neville; (Ophthalmic Western Australia Biobank & Blue Mountains Eye Study) Alex W. Hewitt; (PCOS) Cecilia M. Lindgren; (PIVUS) Lars Lind; (PRIME - Belfast) Frank Kee; (PRIME - Lille) Philippe Amouyel; (PRIME - Strasbourg) Mary Moitry; (PRIME - Toulouse) Jean Ferrieres; (PROSPER) Stella Trompet; (QIMR) Grant W. Montgomery, Dale R. Nyholt, Andrew C. Heath, Sarah E. Medland; (Raine) Alex W. Hewitt; (RISC) Beverley Balkau, Ele Ferrannini; (Rotterdam Study I) Oscar H. Franco, M. Arfan Ikram, Carolina Medina-Gomez, Fernando Rivadeneira; (SDC) Eva RB Petersen; (SORBS) Michael Stumvoll, Anke Tönjes; (Southampton) Andrew J Lotery, Helen L Griffiths; (SR) Marco Brumat; (The Mother Child Cohort of Norway) Pål R. Njølstad, Øyvind Helgeland; (The Mount Sinai BioMe Biobank) Erwin P. Bottinger, Yingchang Lu, Claudia Schurmann; (The NEO Study) Renée de Mutsert; (The NHAPC study, The GBTDS study) Xu Lin, Huaixing Li, Liang Sun; (The Western Australian Pregnancy

Cohort (Raine) Study) Craig E. Pennell, Trevor A. Mori; (TUDR) Wayne H-H Sheu, Keng-Hung Lin; (TwinsUK) Timothy D. Spector, Kerrin S. Small; (UCLA-Utrecht) René S. Kahn; (UCP (BBMRI-NL)) Mark CH de Groot; (UKGPCS) Artitaya Lophatananon; (ULSAM) Vilmantas Giedraitis; (Utrecht Health Project) Michiel L. Bots; (WGHS) Daniel I. Chasman, Paul M. Ridker; (Women's Health Initiative) Charles L. Kooperberg; (WOSCOPS) Chris J. Packard; (WTCCC-UKT2D) Mark I. McCarthy, Katharine R. Owen; (YFS) Terho Lehtimäki, Olli T Raitakari

Data analysis of contributing studies

(1958 Birth Cohort) Kathleen E. Stirrups, Sameer Alharthi; (AGES) Albert Vernon Smith; (Airwave) Evangelos Evangelou, Marcelo P. Segura-Lepe; (AMC PAS) Suthesh Sivapalaratnam; (Amish) Jeffrey R. O'Connell, Laura M. Yerges-Armstrong, James A. Perry; (ARIC, Add Health) Kari E. North; (ARIC/Add Health) Kristin L. Young, Mariaelisa Graff; (ASCOT-UK, ASCOT-SC) Helen R. Warren; Hanieh Yaghootkar; (Athero-Express Biobank Study) Sander W. van der Laan; (ATVB, Ottawa) Hayato Tada; (BBMRI-NL) Linda Broer; (BioVU) Todd L. Edwards, Ayush Giri; (BRAVE) Rajiv Chowdhury, Dewan S. Alam; (BRIGHT) Helen R. Warren; (Cambridge Cancer Studies) Joe G. Dennis, Ailith Pirie, Deborah J. Thompson; (CARDIA) Myriam Fornage, Li-An Lin; (CARL) Antonietta Robino, Massimiliano Cocca, Dragana Vuckovic; (Cebu Longitudinal Health and Nutrition Survey) Ying Wu; (CHD Exome + Consortium) Adam S. Butterworth, Joanna MM Howson, Dermot F. Reilly, Robin Young, Praveen Surendran; (CHES) Yucheng Jia; (CHOP) Jonathan P. Bradfield; (CROATIA_Korcula) Veronique Vitart; (deCODE) Valgerdur Steinthorsdottir, Gudmar Thorleifsson; (DHS) Amanda J Cox, Poorva Mudgal, Maggie CY Ng; (DIABNORD) Tibor V. Varga; (DIACORE) Carsten A. Böger, Mathias Gorski, Myriam Rheinberger; (Duke) Aniruddh P. Patel; (EFSOCH) Hanieh Yaghootkar; (EGCUT) Tõnu Esko; (eMERGE (Seattle)) David S. Crosslin; (ENDO) Anubha Mahajan, Tugce Karaderi, Neil Robertson; (EPIC) Jing Hua Zhao; (EPIC-Potsdam) Karina Meidtner; (EPIC-CVD) Adam S. Butterworth, Joanna MM Howson, Dermot F. Reilly, Robin Young, Praveen Surendran; (EpiHealth) Stefan Gustafsson; (EUGENDA) Jordi Corominas Galbany; (EXTEND) Hanieh Yaghootkar; (Family Heart Study) Mary F Feitosa; (Fenland) Jian'an Luan; (Fenland, EPIC) Robert A. Scott; (Fenland, InterAct) Sara M. Willems; (FIA3) Tibor V. Varga; (FINCAVAS) Jussi Hernesniemi; (FIN-D2D 2007) Hannu Puolijoki, Matti Uusitupa; (Finnish Twin Cohort) Liang He; (FINRISK 2007 (T2D)) Tellervo Korhonen, Satu Männistö, Heather Stringham; (Finrisk Extremes and QC) Sailaja Vedantam; (Framingham Heart Study) Ching-Ti Liu, Nancy L. Heard-Costa; (FVG) Ilaria Gandin; (GECCO) Mengmeng Du; (GeMEP) Gerard Tromp; (GENDEP) Katherine E. Tansey, Rudolf Uher; (Generation Scotland) Caroline Hayward, Jennifer E. Huffman; (Genetic Epidemiology Network of Arteriopathy (GENOA)) Lawrence F. Bielak; (GIANT-Analyst) Anne E. Justice; (GLACIER) Tibor V. Varga; (GoDARTS) Anubha Mahajan; (GRAPHIC) Nilesh J. Samani, Nicholas GD Masca, Christopher P. Nelson; (GSK-STABILITY) Dawn M. Waterworth, Andrew J. Slater; (Health) Jette Bork-Jensen; (Health ABC) Mike A. Nalls; (Health and Retirement Study (HRS)) Wei Zhao, Erin B. Ware; (HELIC MANOLIS) Lorraine Southam; (HELIC Pomak) Lorraine Southam; (HUNT-MI) Wei Zhou; (Inter99) Niels Grarup; (INTERVAL Study) Adam Butterworth; (IRASFS) Nicholette D. Palmer, Bratati Kahali; (Jackson Heart Study (JHS)) Leslie A. Lange, Jin Li; (KORA S4) Thomas W Winkler; (LBC1921/LBC1936) Gail Davies; (Leipzig-Adults) Anubha Mahajan; (LOLIPOP-Exome) John C. Chambers, Jaspal S. Kooner, Weihua Zhang; (LOLIPOP-OmniEE) John C. Chambers, Jaspal S. Kooner, Weihua Zhang; (Massachusetts General Hospital Cardiology and Metabolic Patient Cohort (CAMP)) Steven A. Lubitz, Honghuang Lin; (MESA)

Jerome I. Rotter, Xiuqing Guo, Jie Yao; (METSIM) Johanna Kuusisto, Markku Laakso, Xueling Sim; (MONICA-Brianza) Giovanni Veronesi; (Montreal Heart Institute Biobank (MHIBB)) Guillaume Lettre, Ken Sin Lo, Valérie Turcot; (OBB) Anubha Mahajan; (Ophthalmic Western Australia Biobank & Blue Mountains Eye Study) Gabriel Cuellar-Partida; (PCOS) Anubha Mahajan, Tugce Karaderi, Neil Robertson; (PIVUS) Anubha Mahajan, Tugce Karaderi, Neil Robertson; (PROMIS) Asif Rasheed, Wei Zhao; (PROSPER) J Wouter Jukema; (QC GoT2D/T2D-GENES (FUSION, METSIM, etc)) Adam E Locke; (QIMR) Yadav Sapkota; (RISC) Hanieh Yaghootkar; (Rotterdam Study I) Carolina Medina-Gomez, Fernando Rivadeneira; (SCOOP) Vanisha Mistry, Audrey E. Hendricks, Gaëlle Marenne; (SDC) Christian T Have; (SHIP/SHIP-Trend) Alexander Teumer; (SOLID TIMI-52) Dawn M. Waterworth, Andrew Slater; (SORBS) Andrew P. Morris; (Southampton) Jane Gibson; (The Hoorn Diabetes Care System Cohort study (BBMRI-NL)) Nienke van Leeuwen; (The Mother Child Cohort of Norway) Stefan Johansson, Øyvind Helgeland; (The Mount Sinai BioMe Biobank) Yingchang Lu, Claudia Schurmann; (The NEO Study) Ruifang Li-Gao; (The NHAPC study, The GBTDS study) Xu Lin, Huaixing Li, Yao Hu; (The Western Australian Pregnancy Cohort (Raine) Study) Carol A. Wang; (UCLA-Utrecht) Loes M Olde Loohuis; (UCP (BBMRI-NL)) Mark CH de Groot; (UK Biobank) Andrew R. Wood, Timothy M. Frayling; (UKGPCS) Artitaya Lophatananon; (UKOPS) Jonathan P. Tyrer; (ULSAM) Anubha Mahajan, Tugce Karaderi, Neil Robertson; (Utrecht Health Project) Jessica van Setten; (WGHS) Daniel I Chasman, Audrey Y Chu; (Women's Health Initiative) Paul L. Auer, Jeff Haessler; (WOSCOPS) Ian Ford, Sandosh Padmanabhan; (WTCCC-UKT2D) Wei Gan; (YFS) Leo-Pekka Lyytikäinen

6. ACKNOWLEDGMENTS

Cohort or individual	Acknowledgements (funding, personal, groups, ...), include funding identification numbers/codes
1958 Birth Cohort	We are grateful for being able to use the British 1958 Birth Cohort DNA collection. Sample collection funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. Genotyping was funded by the Wellcome Trust.
1958 Birth Cohort	Deloukas work forms part of the research themes contributing to the translational research portfolio of Barts Cardiovascular Biomedical Research Unit which is supported and funded by the National Institute for Health Research. Analysis was supported by BHF grant (Deloukas) RG/14/5/30893
Add Health	The analysis grant funded by National Institutes of Health Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development R01HD057194 supported genotyping, phenotyping, and analysis using data from National Longitudinal Study of Adolescent to Adult Health (Add Health), a program project directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 23 other federal agencies and foundations. Special acknowledgment is due Ronald R. Rindfuss and Barbara Entwisle for assistance in the original design. Information on how to obtain the Add Health data files is available on the Add Health website (http://www.cpc.unc.edu/addhealth). No direct support was received from grant P01-HD31921 for this analysis. We thank Amy Perou of the BioSpecimen Processing facility and Amanda Floyd Beaty and Michael Andre of the Mammalian Genotyping Core at University of North Carolina at Chapel Hill. We are grateful to the Carolina Population Center (P2C HD050924) for general support.
ADDITION-DK	We would like to thank the ADDITION-DK participants and the participating general practitioners for their contribution to the study. We acknowledge the very important contributions of Dr. Knut Borch-Johnsen, Professor Anneli Sandbæk, and Professor Torsten Lauritzen in setting up the ADDITION-DK study. The ADDITION-DK study received funding from: the Danish Center for Evaluation and Health Technology Assessment; the Danish Research Foundation for General Practice; the counties of Aarhus, Copenhagen, Ringkøbing, Ribe, and South Jutland; the National Board of Health; the Danish Medical Research Council (22-04-0390); the Danish Diabetes Association; the Danish Diabetes Academy; the Danish Council for Strategic Research; the Novo Nordisk Foundation; the Diabetes Fund of the National Board of Health; the A.P. Møller Foundation; and the Aarhus University Research Foundation. ADDITION-DK has been given unrestricted grants from Novo Nordisk A/S, Novo Nordisk Scandinavia AB, Novo Nordisk UK, ASTRA Denmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark, Servier Denmark A/S, and HemoCue Denmark A/S. The ADDITION-PRO study was funded by an unrestricted grant from the European Foundation for the Study of Diabetes/Pfizer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes (74550801), by the Danish Council for Strategic Research and by internal research and equipment funds from Steno Diabetes Center A/S.

AGES-Reykjavik	This study has been funded by NIH contracts N01-AG-1-2100 and 271201200022C, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00-063. The researchers are indebted to the participants for their willingness to participate in the study.
Airwave	Funding: The Airwave Study is funded by the Home Office (grant number 780-TETRA) with additional support from the National Institute for Health Research (NIHR) Imperial College Healthcare NHS Trust (ICHNT) and Imperial College Biomedical Research Centre (BRC). Paul Elliott is an NIHR Senior Investigator and is supported by the ICHNT and Imperial College BRC, the MRC-PHE Centre for Environment and Health and the NIHR Health Protection Research Unit on Health Impact of Environmental Hazards. This work used computing resources of the UK MEDical BIOinformatics partnership - aggregation, integration, visualisation and analysis of large, complex data (UK MED-BIO) which is supported by the Medical Research Council [grant number MR/L01632X/1]. Acknowledgements: We thank all participants in the Airwave Health Monitoring Study. We also thank Louisa Cavaliero who assisted in data collection and management as well as Peter McFarlane and the Glasgow CARE, Patricia Munroe at Queen Mary University of London, Joanna Sarnecka and Ania Zawodniak at Northwick Park for their contributions to the study.
Alex P. Reiner	Alex P. Reiners was supported by R01 DK089256-05.
Alex W Hewitt	AWH is supported by an NHMRC Practitioner Fellowship (APP1103329).
Alisa K. Manning	Dr. Alisa K. Manning received funding from NIH/NIDDK K01 DK107836
Amish	We gratefully acknowledge our Amish liaisons, field workers and clinic staff and the extraordinary cooperation and support of the Amish community without which these studies would not have been possible. The Amish studies are supported by grants and contracts from the NIH, including K01HL116770, U01 HL072515-06, U01 HL84756, U01HL105198, U01 GM074518, . We thank our Amish research volunteers for their long-standing partnership in research, and the research staff at the Amish Research Clinic for their hard work and dedication.
Andrew Hattersley	Andrew T Hattersley is a Wellcome Trust Senior Investigator (WT098395); and a National Institute of Health Research Senior Investigator.
Andrew Morris	Andrew P Morris is a Wellcome Trust Senior Fellow in Basic Biomedical Science (grant number WT098017).
Andrew R Wood	Andrew R Wood is supported by the European Research Council (grant 323195: SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC)
Anne Justice	American Heart Association (13POST16500011); NIH (R01-DK089256, 1R01DK101855-01, 1K99HL130580-01A1)
Anneke den Hollander (EUGENDA)	The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013) / ERC Grant Agreement n. 310644 (MACULA).
ARIC	The Atherosclerosis Risk in Communities (ARIC) study is carried out as a collaborative study supported by the National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The authors thank the staff and participants of the ARIC study for their important contributions. Funding support for "Building on GWAS for NHLBI-diseases: the U.S. CHARGE consortium" was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419).

ASCOT-UK and ASCOT-SC	This work was supported by Pfizer, New York, NY, USA, for the ASCOT study and the collection of the ASCOT DNA repository; by Servier Research Group, Paris, France; and by Leo Laboratories, Copenhagen, Denmark. We thank all ASCOT trial participants, physicians, nurses, and practices in the participating countries for their important contribution to the study. In particular we thank Clare Muckian and David Toomey for their help in DNA extraction, storage, and handling. Genotyping of ASCOT-SC and the Exome chip in ASCOT-UK was funded by the National Institutes of Health Research.
ATBC	The ATBC Study was supported by contracts HHSN261201000006C and HHSN261201500005C
Athero-Express Biobank Study	We also acknowledge the support from the Netherlands CardioVascular Research Initiative from the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences.
Athero-Express Biobank Study	Sander W. van der Laan is funded through grants from the Netherlands CardioVascular Research Initiative ("GENIUS", CVON2011-19), the Interuniversity Cardiology Institute of the Netherlands (ICIN, 09.001), and through the FP7 EU project CVgenes@target (HEALTH-F2-2013-601456). Claudia Tersteeg, Krista den Ouden, Mirjam B. Smeets, and Loes B. Collé are graciously acknowledged for their work on the DNA extraction. Saskia Haitjema, Ian D. van Koeveerden, Evelyn Velema, Sara van Laar, Sander M. van de Weg, Arjan H. Schoneveld, Petra H. Homoeed-van der Kraak, and Aryan Vink are graciously acknowledged for their continuing work on the Athero-Express Biobank Study. We would also like to thank all the (former) employees involved in the Athero-Express Biobank Study of the Departments of Surgery of the St. Antonius Hospital Nieuwegein and University Medical Center Utrecht for their continuing work. Jessica van Setten is graciously acknowledged for her help in the quality assurance and quality control of the genotype data. Lastly, we would like to thank all participants of the Athero-Express Biobank Study; without you these kinds of studies would not be possible.
BBMRI-NL	The BBMRI-NL embodies the Dutch Biobanking and Biomolecular Research Infrastructure project, including large population cohorts and clinical collections. All studies were financially supported by a Research Infrastructure financed by the Dutch government (NWO 184.021.007). The Hoorn Diabetes Care System Cohort study likes to acknowledge the Netherlands Organisation for Health Research and Development (ZonMW) for funding (grant number 113102006) and is supported by the Diabetes Care System West-Friesland. Contributing members of the DCS study are: G Nijpels, J Beulens, AMW van der Heijden, F Rutters, S Rauh, JM Dekker, all VU University Medical Center Amsterdam and LM 't Hart, N van Leeuwen, Leiden University Medical Center, Leiden, The Netherlands. NESCOG received funding from NWO/MaGW VIDI-016-065-318; NWO VICI 453-14-005, and this research was part of Science Live, the innovative research program of science center NEMO that enables scientists to carry out real, publishable, peer-reviewed research using NEMO visitors as volunteers. The Longitudinal Aging Study Amsterdam is supported by a grant from the Netherlands Ministry of Health Welfare and Sports, Directorate of Long-Term Care. The authors would like to acknowledge DJH Deeg, M den Heijer, MA Huisman, NM van Schoor, and KMA Swart*. UCP would like to acknowledge Prof.Dr. Olaf H. Klungel and Dr. Anke-Hilse Maitland-Van der Zee for granting access to the UCP study data.

BioVU	The BioVU dataset used in the analyses described were obtained from Vanderbilt University Medical Centers BioVU which is supported by institutional funding and by the Vanderbilt CTSA grant ULTR000445 from NCATS/NIH. Genotyping was funded by NIH grants RC2GM092618 from NIGMS/OD and U01HG004603 from NHGRI/NIGMS. Funding for TLE and DRVE was provided by 1R21HL12142902 from NHLBI/NIH.
Blue Mountains Eye Study	The Westmead/Sydney samples were collected in three studies that were supported by the National Health and Medical Research Council (NHMRC), Australia: Grant IDs 974159, 211069, 457349 and 512423 supported the Blue Mountains Eye Study that provided population-based controls; Grant ID 302010 supported the Cataract Surgery and Risk of Age-related Macular Degeneration study that provided clinic-based early and late AMD cases and controls; and Grant ID 571013 supported the Genes and Environment in late AMD study that provided clinic-based late AMD cases. The NHMRC had no role in the design or conduct of these studies.
Bratati Kahali and Elizabeth K. Speliotes	BK and EKS were supported by the Doris Duke Medical Foundation, NIH grant R01DK106621-01, the University of Michigan Internal Medicine Department, Division of Gastroenterology, the University of Michigan Biological Sciences Scholars Program and The Central Society for Clinical Research
BRAVE	The BRAVE study genetic epidemiology working group is a collaboration between the Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK, the Centre for Control of Chronic Diseases, icddr,b, Dhaka, Bangladesh and the National Institute of Cardiovascular Diseases, Dhaka, Bangladesh. UK Medical Research Council (G0800270)
BRIGHT	This work was funded by the Medical Research Council of Great Britain (grant number: G9521010D) and the Wellcome Trust Strategic Award (grant number: 083948). The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT nursing team. The funders had no role in study design, data collection and analysis. The BRIGHT study genotyping of the Exome chip was funded by Wellcome Trust Strategic Awards 083948 and 085475.
CARDIA	The CARDIA Study is conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the University of Alabama at Birmingham (HHSN268201300025C & HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging. Exome Chip genotyping was supported from grants R01-HL093029 and U01- HG004729 to MF. This manuscript has been reviewed and approved by CARDIA for scientific content.
CCHS/CGPS/CIHDS	We thank participants and staff of the Copenhagen City Heart Study, Copenhagen Ischemic Heart Disease Study, and the Copenhagen General Population Study for their important contributions.
Cebu Longitudinal Health and Nutrition Survey	The Cebu Longitudinal Health and Nutrition Survey (CLHNS) was supported by National Institutes of Health grants DK078150, TW005596, HL085144 and TW008288 and pilot funds from RR020649, ES010126, and DK056350. We thank the USC-Office of Population Studies Foundation research and data collection teams and the study participants who generously provided their time for this study.
CHD Exome+ Consortium	This work was funded by the UK Medical Research Council (G0800270), British Heart Foundation (SP/09/002), UK National Institute for Health Research Cambridge Biomedical Research Centre, European Research Council (268834), European Commission Framework Programme 7 (HEALTH-F2-2012-279233), Merck, Sharp & Dohme and Pfizer.

CHES	This paper was supported in part by The Chinese-American Eye Study (CHES) grant EY017337. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.
CHES	This paper was supported in part by The Chinese-American Eye Study (CHES) grant EY017337. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.
CHOP	This research was financially supported by an Institute Development Award from the Children's Hospital of Philadelphia, a Research Development Award from the Cotswold Foundation, the Daniel B. Burke Endowed Chair for Diabetes Research and NIH grant R01 HD056465. The authors thank the network of primary care clinicians and the patients and families for their contribution to this project and to clinical research facilitated by the Pediatric Research Consortium (PeRC) at The Children's Hospital of Philadelphia. R. Chiavacci, E. Dabaghyan, A. (Hope) Thomas, K. Harden, A. Hill, C. Johnson-Honesty, C. Drummond, S. Harrison, F. Salley, C. Gibbons, K. Lilliston, C. Kim, E. Frackelton, F. Mentch, G. Otieno, K. Thomas, C. Hou, K. Thomas and M.L. Garris provided expert assistance with genotyping and/or data collection and management. The authors would also like to thank S. Kristinsson, L.A. Hermannsson and A. Krisbjörnsson of Raförnninn ehf for extensive software design and contributions.
CLEAR	NIH RO1 HL67406
Cristen J. Willer	C.J.W. is supported by HL094535 and HL109946 from the National Heart, Lung and Blood Institute.
CROATIA_Korcula	The CROATIA-Korcula study was funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947), European Commission Framework 7 project BBMR-LPC (grant 313010), Republic of Croatia Ministry of Science, Education and Sports research grant (216-1080315-0302) and Croatian Science Foundation (grant 8875). We would like to acknowledge the invaluable contributions of the recruitment team in Korcula, the administrative teams in Croatia and Edinburgh and the people of Korcula. The SNP genotyping for the CROATIA-Korcula cohort was performed in Helmholtz Zentrum München, Neuherberg, Germany
Dajiang J. Liu	DJL is supported by 1R01HG008983-01 and 1R21DA040177-01
Daniel R. Witte	Daniel R. Witte is supported by the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation.
deCODE	We thank participants in deCODE cardiovascular- and obesity studies and collaborators for their cooperation. The research performed at deCODE Genetics was part funded through the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-2007- 201413.
Diabetes Heart Study	This study was supported in part by R01 HL67348, R01 HL092301, R01 NS058700 (to DWB) and the General Clinical Research Centre of the Wake Forest School of Medicine (M01 RR07122, F32 HL085989). The authors thank the other investigators, the staff, and the participants of the DHS study for their valuable contributions.
DIABNORD	We are grateful to the study participants who dedicated their time and samples to these studies. We also thank the Västerbotten Health Survey (VHS), the Swedish Diabetes Registry and Umeå Medical Biobank staff for the biomedical data and DNA extraction. We also thank M Sterner, G Gramsperger and P Storm for their expert technical assistance with genotyping and genotype data preparation. The current study was funded by Novo Nordisk, the

	Swedish Research Council, Pahlssons Foundation, the Swedish Heart Lung Foundation, and the Skåne Regional Health Authority (all to PWF).
DIACORE	We thank all participating patients of the DIACORE study. The DIACORE study is funded by the KfH Stiftung Präventivmedizin e.V. . Genotyping was funded by the Else Kröner-Fresenius-Stiftung to CAB (2012_A147) and the University Hospital Regensburg. CAB has received funding from the KfH Stiftung Präventivmedizin e.V., the Else Kröner-Fresenius-Stiftung and the Dr Robert Pfleger Stiftung. We thank the physicians and health insurance companies supporting the DIACORE study: Axel Andreae, Gerhard Haas, Sabine Haas, Jochen Manz, Johann Nusser, Günther Kreisel, Gerhard Bawidamann, Frederik Mader, Susanne Kißkalt, Johann Hartl, Thomas Segiet, Christiane Gleixner, Christian Scholz, Monika Schober (Chief of Supply Management, Allgemeine Ortskrankenkasse Bayern), Cornelia Heinrich (Communication Manager, Allgemeine Ortskrankenkasse Bayern), Thomas Bohnhoff (Disease Management, Techniker Krankenkasse), Thomas Heilmann (Head of Disease Management, Techniker Krankenkasse), Stefan Stern (Consulting Physician, Allgemeine Ortskrankenkasse Bayern), Andreas Utz (Head of Department, Allgemeine Ortskrankenkasse Bayern), Georg Zellner (Chief of Supply Management, Deutsche Angestellten Krankenkasse), Werner Ettl (Barmer-GEK), Thomas Buck (Barmer-GEK), Rainer Bleek (IKK classic), Ulrich Blaudzun (IKK classic). We further thank the study nurses for their expert work in performing the study visits: Simone Neumeier, Sarah Hufnagel, Petra Jackermeier, Sabrina Obermüller, Christiane Ried, Ulrike Hanauer, Bärbel Sendtner, Natalia Riewe-Kerow.
DPS	The DPS has been financially supported by grants from the Academy of Finland (117844 and 40758, 211497, and 118590 (MU); The EVO funding of the Kuopio University Hospital from Ministry of Health and Social Affairs (5254), Finnish Funding Agency for Technology and Innovation (40058/07), Nordic Centre of Excellence on ÖSystems biology in controlled dietary interventions and cohort studies, SYSDIET (070014), The Finnish Diabetes Research Foundation, Yrjö Jahnsson Foundation (56358), Sigrid Juselius Foundation and TEKES grants 70103/06 and 40058/07.
DR'S EXTRA	The DR's EXTRA Study was supported by grants to Rainer Rauramaa by the Ministry of Education and Culture of Finland (627;2004-2011), Academy of Finland (102318; 123885), Kuopio University Hospital, Finnish Diabetes Association, Finnish Heart Association, Päivikki and Sakari Sohlberg Foundation and by grants from European Commission FP6 Integrated Project (EXGENESIS); LSHM-CT-2004-005272, City of Kuopio and Social Insurance Institution of Finland (4/26/2010).
EGCUT	EGCUT work was supported by IUT20-60 from the Estonian Research Council; by the European Regional Development Fund to the Centre of Excellence in Genomics and Translational Medicine (GenTransMed); EGCUT were further supported by the US National Institute of Health [R01DK075787].
eMERGE-Seattle	NIH U01HG008657 and a State of Washington Life Sciences Discovery Award (265508) to the Northwest Institute of Genetic Medicine and U01 AG 06781 grant. U01 HG 06375 with additional support for the original cohort assembly being U01 AG006781.
ENDO and PCOS	Genotyping was funded by the Wellcome Trust under awards WT064890 and WT086596. Analysis of genetic data was funded by the Wellcome Trust under awards WT098017, WT086596 and WT090532.

EPIC-CVD Consortium	CHD case ascertainment and validation and genotyping in EPIC-CVD were principally supported by grants awarded to the University of Cambridge from the EU Framework Programme 7 (HEALTH-F2-2012-279233), the UK Medical Research Council (G0800270) and British Heart Foundation (SP/09/002), and the European Research Council (268834). We thank all EPIC participants and staff for their contribution to the study, the laboratory teams at the Medical Research Council Epidemiology Unit for sample management and Cambridge Genomic Services for genotyping, Sarah Spackman for data management, and the team at the EPIC-CVD Coordinating Centre for study coordination and administration.
EPIC-InterAct	We thank all EPIC participants and staff for their contribution to the EPIC-InterAct study. Funding for the EPIC-InterAct project was provided by the EU FP6 programme (LSHM_CT_2006_037197).
EPIC-Norfolk	EPIC-Norfolk is supported by programme grants from the Medical Research Council UK (G1000143) and Cancer Research UK (C864/A14136) and with additional support from the European Union, Stroke Association, British Heart Foundation, Research into Ageing, Department of Health, The Wellcome Trust and the Food Standards Agency. NJW, CL and RAS also acknowledge support from the Medical Research Council, UK (MC_UU_12015/1; MC_PC_13048). We thank all EPIC participants and staff for their contribution to the study, and the laboratory teams at the MRC Epidemiology Unit for sample management.
EPIC-Potsdam	The study was supported in part by a grant from the German Federal Ministry of Education and Research (BMBF) and the State of Brandenburg to the German Center for Diabetes Research (DZD e.V.). The recruitment phase of the EPIC-Potsdam study was supported by the Federal Ministry of Science, Germany (01 EA 9401) and the European Union (SOC 95201408 05 F02). The follow-up of the EPIC-Potsdam study was supported by German Cancer Aid (70-2488-Ha I) and the European Community (SOC 98200769 05 F02). Exome chip genotyping of EPIC-Potsdam samples was carried out under supervision of Per Hoffmann and Stefan Herms at Life & Brain GmbH, Bonn. We thank all EPIC-Potsdam participants for their invaluable contribution to the study.
EpiHealth	EpiHealth was supported by the Swedish Research Council strategic research network Epidemiology for Health, Uppsala University and Lund University. Genotyping in EpiHealth was supported by Swedish Heart-Lung Foundation (grant no. 20120197 and 20140422), Knut och Alice Wallenberg Foundation (grant no. 2013.0126), and Swedish Research Council (grant no. 2012-1397). Genotyping was performed by the SNP&SEQ Technology Platform in Uppsala. We thank the EpiHealth participants for their dedication and commitment.
EXTEND	EXTEND data were provided by the Peninsula Research Bank, part of the NIHR Exeter Clinical Research Facility
Family Heart Study	The Family Heart Study (FamHS) research was supported by NIH grants: R01-HL-117078 from NHLBI, and R01-DK-089256 from NIDDK.
Fenland	We thank the Fenland Study volunteers for their time and help, the General Practitioners and practice staff for assistance with recruitment, the Investigators, Co-ordination team and the Epidemiology Field, Data and Laboratory teams. The Fenland Study is funded by the MRC (MC_U106179471) and Wellcome Trust. NJW, CL and RAS also acknowledge support from the Medical Research Council, UK (MC_UU_12015/1; MC_PC_13046).
FIN-D2D 2007	The FIN-D2D 2007 study was supported by funds from the hospital districts of Pirkanmaa; Southern Ostrobothnia; North Ostrobothnia; Central Finland and Northern Savo; the Finnish National Public Health Institute; the Finnish Diabetes Association; the Ministry of Social Affairs and Health in Finland; Finland's Slottery Machine Association; the Academy of Finland [grant number 129293] and Commission of the European Communities, Directorate C-Public Health [grant agreement no. 2004310]. The Broad Genomics Platform performed the genotyping.

FINCAVAS	The Finnish Cardiovascular Study (FINCAVAS) has been financially supported by the Competitive Research Funding of the Tampere University Hospital (Grant 9M048 and 9N035), the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, Finland, and the Tampere Tuberculosis Foundation. The authors thank the staff of the Department of Clinical Physiology for collecting the exercise test data.
Finnish Twin Cohort	Phenotyping and genotyping of the Finnish Twin Cohort (FTC) has been supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (grants 213506, 129680), the Academy of Finland (grants 100499, 205585, 118555, 141054, 265240, 263278 and 264146 to J. Kaprio), National Institute for Health (grant DA12854 to P.A.F. Madden), National Institute of Alcohol Abuse and Alcoholism (grants AA-12502, AA-00145, and AA-09203 to R. J. Rose and AA15416 and K02AA018755 to D. M. Dick), Sigrid Juselius Foundation (to J. Kaprio), Global Research Award for Nicotine Dependence, Pfizer Inc. (to J. Kaprio), and the Wellcome Trust Sanger Institute, UK. Genotyping was done at the Wellcome Trust Sanger Institute, Hinxton, UK. Antti-Pekka Sarin and Samuli Ripatti are acknowledged for genotype data quality controls and imputation. Association analyses were run at the ELIXIR Finland node hosted at CSC – IT Center for Science for ICT resources.
FINRISK 2007 (T2D)	VS was supported by the Academy of Finland, grant #139635, and the Finnish Foundation for Cardiovascular Research. The Broad Genomics Platform performed the genotyping.
FINRISK/Veikko Salomaa	Dr. Salomaa has been supported by the Finnish Foundation for Cardiovascular Research
Folkert W. Asselbergs	Folkert W. Asselbergs is supported by a Dekker scholarship-Junior Staff Member 2014T001 – Netherlands Heart Foundation and UCL Hospitals NIHR Biomedical Research Centre.
Fotios Drenos	FD is supported by the UK Medical Research Council (MC_UU_12013/1-9)
Framingham Heart Study	This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). This research was partially supported by grant NIDDK 1R01DK8925601. A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center.
FUSION	The FUSION study was supported by DK093757, DK072193, DK062370, and ZIA-HG000024. The Center for Inherited Disease Research (CIDR) and the Broad Genomics Platform performed the genotyping.
Gabriel Cuellar-Partida	G.C.P received scholarship support from the University of Queensland and QIMR Berghofer

GECCO and individual studies

GECCO: National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (U01 CA137088; R01 CA059045). ASTERISK: Supported by the local Hospital Program of Clinical Research PHRC-BRD09/C from the University Hospital Center of Nantes (CHU de Nantes), the Regional Council of Pays de la Loire, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne Génétique and the Ligue Régionale Contre le Cancer (LRCC). CPS-II: The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II (CPS-II) cohort. This study was conducted with Institutional Review Board approval. HPFS is supported by the National Institutes of Health (P01 CA 055075, UM1 CA167552, R01 137178, R01 CA151993 and P50 CA127003) and NHS by the National Institutes of Health (UM1 CA186107, R01 CA137178, P01 CA87969, R01 CA151993 and P50 CA127003). NFCCR: This work was supported by an Interdisciplinary Health Research Team award from the Canadian Institutes of Health Research (CRT 43821); the National Institutes of Health, U.S. Department of Health and Human Services (U01 CA74783); and National Cancer Institute of Canada grants (18223 and 18226). The authors wish to acknowledge the contribution of Alexandre Belisle and the genotyping team of the McGill University and Génome Québec Innovation Centre, Montréal, Canada, for genotyping the Sequenom panel in the NFCCR samples. PLCO: Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. PMH: National Institutes of Health (R01 CA076366). GECCO: The authors would like to thank all those at the GECCO Coordinating Center for helping bring together the data and people that made this project possible. ASTERISK: We are very grateful to Dr. Bruno Buecher without whom this project would not have existed. We also thank all those who agreed to participate in this study, including the patients and the healthy control persons, as well as all the physicians, technicians and students. CPS-II: The authors thank the CPS-II participants and Study Management Group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program. HPFS and NHS: We would like to acknowledge Patrice Soule and Hardeep Ranu of the Dana Farber Harvard Cancer Center High-Throughput Polymorphism Core who assisted in the genotyping for NHS and HPFS under the supervision of Dr. Immaculata Devivo and Dr. David Hunter, and Qin (Carolyn) Guo and Lixue Zhu who assisted in programming for NHS and HPFS. We would like to thank the participants and staff of the Nurses' Health Study and the Health Professionals Follow-Up Study, for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. PLCO: The authors thank Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff, Information Management Services, Inc., Ms. Barbara O'Brien and staff, Westat, Inc., and Drs. Bill Kopp and staff, SAIC-Frederick. Most importantly, we acknowledge the study participants for their contributions to making this study possible. The statements contained herein are solely those of the authors and do not represent or imply concurrence or endorsement by NCI. PMH: The authors would like to thank the study participants and staff of the Hormones and Colon Cancer study.

GeMEP (Geisinger Genomic Medicine Exome Project)	The biobanking and genotyping at Geisinger Health System was funded by Pennsylvania Commonwealth Universal Research Enhancement Program, the Ben Franklin Technology Development Fund of PA, Grants from the NIH (P30DK072488, R01DK088231 and R01DK091601), and the Geisinger Clinical Research Fund.
Generation Scotland	Generation Scotland received core funding from the Chief Scientist Office of the Scottish Government Health Directorate CZD/16/6 and the Scottish Funding Council HR03006. Genotyping of the GS:SFHS samples was carried out by staff at the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the UK's Medical Research Council. We are grateful to the families who took part in GS:SFHS, the GPs and Scottish School of Primary Care for their help in recruiting them, and the whole GS team, which includes academic researchers, clinic staff, laboratory technicians, clerical workers, statisticians and research managers. We are grateful to the families who took part in GS:SFHS, the GPs and Scottish School of Primary Care for their help in recruiting them, and the whole GS team, which includes academic researchers, clinic staff, laboratory technicians, clerical workers, statisticians and research managers
Genetic Epidemiology Network of Arteriopathy (GENOA)	Support for GENOA was provided by the National Heart, Lung and Blood Institute (HL119443, HL054464, HL054457, HL054481, HL87660, and HL086694) of the National Institutes of Health. Genotyping was performed at the Mayo Clinic (Stephen T. Turner, MD, Mariza de Andrade PhD, Julie Cunningham, PhD). Genotyping for GENOA whites was performed by Eric Boerwinkle, PhD and Megan L. Grove from the Human Genetics Center and Institute of Molecular Medicine and Division of Epidemiology, University of Texas Health Science Center, Houston, Texas, USA. Genotyping for GENOA African Americans was performed at the Center for Inherited Disease Research (CIDR) at Johns Hopkins University. We would also like to thank the families that participated in the GENOA study.
GLACIER	We are indebted to the study participants who dedicated their time and samples to these studies. We thank J Hutiainen and Å Ågren (Umeå Medical Biobank) for data organization and K Enquist and T Johansson (Västerbottens County Council) for technical assistance with DNA extraction. We also thank M Sterner, G Gramsperger and P Storm for their expert technical assistance with genotyping and genotype data preparation. The current study was funded by Novo Nordisk, the Swedish Research Council, Pålssons Foundation, the Swedish Heart Lung Foundation, and the Skåne Regional Health Authority (all to PWF).
GoDARTS	GoDARTS study was funded by The Wellcome Trust Study Cohort Wellcome Trust Functional Genomics Grant (2004-2008) (Grant No: 072960/2/03/2) and The Wellcome Trust Scottish Health Informatics Programme (SHIP) (2009-2012). (Grant No: 086113/Z/08/Z).
GRAPHIC	The GRAPHIC Study was funded by the British Heart Foundation (BHF) (RG/200004). Exome array genotyping was funded by the NIHR and the Wellcome Trust (083948/B/07/Z). NM is funded by the NIHR Leicester Cardiovascular Biomedical Research Unit. CPN is funded by the BHF (CH/03/001). NJS holds a Chair funded by the BHF (CH/03/001) and is a NIHR Senior Investigator.
Guillaume Lettre	GL is funded by the Montreal Heart Institute Foundation and the Canada Research Chair program.
Hanieh Yaghootkar	H.Y. is supported by the European Research Council grant: 323195; SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC.
Hanieh Yaghootkar & Tim Frayling	H.Y. and T.M.F. are supported by the European Research Council grant: 323195; SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC.

Health	Establishment of the Health2006 cohort was financially supported by The Velux Foundation; The Danish Medical Research Council, Danish Agency for Science, Technology and Innovation; The Aase and Ejner Danielsens Foundation; ALK-Abelló A/S (Hørsholm, Denmark), Timber Merchant Vilhelm Bangs Foundation, MEKOS Laboratories (Denmark), and Research Centre for Prevention and Health, the Capital Region of Denmark.
Health ABC	HABC funding/acknowledgement: The Health ABC Study was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106 and, in part, by the NIA Intramural Research Program. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, Md. (http://biowulf.nih.gov).
Health and Retirement Study (HRS)	HRS is supported by the National Institute on Aging (NIA U01AG009740). The genotyping was funded separately by the National Institute on Aging (RC2 AG036495, RC4 AG039029) and was conducted by the NIH Center for Inherited Disease Research (CIDR) at Johns Hopkins University. Genotyping quality control and final preparation of the data were performed by the University of Michigan School of Public Health. A portion of this work was also supported by R03 AG046398.
HELIC MANOLIS, HELIC Pomak	This work was funded by the Wellcome Trust (098051) and the European Research Council (ERC-2011-StG 280559-SEPI). The MANOLIS cohort is named in honour of Manolis Giannakakis, 1978-2010. We thank the residents of the Mylopotamos villages, and of the Pomak villages, for taking part. The HELIC study has been supported by many individuals who have contributed to sample collection (including A. Athanasiadis, O. Balafouti, C. Batzaki, G. Daskalakis, E. Emmanouil, C. Giannakaki, M. Giannakopoulou, A. Kaparou, V. Kariakli, S. Koinaki, D. Kokori, M. Konidari, H. Koundouraki, D. Koutoukidis, V. Mamakou, E. Mamalaki, E. Mpamiaki, G. Papanikolaou, M. Tsoukana, D. Tzakou, K. Vosdogianni, N. Xenaki, E. Zengini), data entry (T. Antonos, D. Papagrigoriou, B. Spiliopoulou), sample logistics (S. Ekins, E. Gray), genotyping (R. Andrews, H. Blackburn, D. Simpkin, S. Whitehead), research administration (A. Kolb-Kokocinski, S. Smee, D. Walker) and informatics (M. Pollard, J. Randall).
HUNT-MI	The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between the HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), the Nord-Trøndelag County Council, the Central Norway Health Authority and the Norwegian Institute of Public Health. The HUNT-MI study is a collaboration between investigators from the HUNT study and the University of Michigan. Genotyping services for 3992 samples were provided by the Northwest Genomics Center at the University of Washington, Department of Genome Sciences, under US Federal Government contract number HHSN268201100037C from the National Heart, Lung, and Blood Institute. We thank the HUNT study participants for their contributions to scientific research.
IAMDGC	We would like to acknowledge the contribution of the International AMD Genomics Consortium (IAMDGC) that is supported by a grant from NIH (R01 EY022310).

I. Sadaf Farooqi	This work was supported by the Wellcome Trust (098497/Z/12/Z), Medical Research Council, NIHR Cambridge Biomedical Research Centre, Bernard Wolfe Health Neuroscience Endowment, European Research Council and NIH grant DK064265 (GLM), the European Community's Seventh Framework Programme (FP7/2007-2013) project Beta-JUDO n°279153 (ISF, AK).
Inês Barroso	This work was supported by the Wellcome Trust (WT098051), NIHR Cambridge Biomedical Research Centre.
INGI-FVG	This study was partially supported by Regione FVG (L.26.2008) and Italian Ministry of Health (GR-2011-02349604).
Inter99	Data collection in the Inter99 study was supported economically by The Danish Medical Research Council, The Danish Centre for Evaluation and Health Technology Assessment, Novo Nordisk, Copenhagen County, The Danish Heart Foundation, The Danish Pharmaceutical Association, Augustinus foundation, Ib Henriksen foundation and Becket foundation. LLNH was supported by the Health Insurance Foundation (grant No. 2010 B 131).
INTERVAL Study	<p>Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported field work and other elements of the trial. DNA extraction and genotyping was funded by the National Institute of Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk/) and the NIHR Cambridge Biomedical Research Centre (www.cambridge-brc.org.uk). The academic coordinating centre for INTERVAL was supported by core funding from: NIHR Blood and Transplant Research Unit in Donor Health and Genomics, UK Medical Research Council (G0800270), British Heart Foundation (SP/09/002), and NIHR Research Cambridge Biomedical Research Centre. A complete list of the investigators and contributors to the INTERVAL trial is provided in reference [**].</p> <p>** Moore C, Sambrook J, Walker M, Tolkien Z, Kaptoge S, Allen D, et al. The INTERVAL trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply: study protocol for a randomised controlled trial. <i>Trials</i>. 2014;15:363.</p>
IRASFS	This research was supported by funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): DK097524, DK085175, and DK087914; the National Institute for Heart, Lung, and Blood Disorders (NHLBI): HL060944, HL061019, HL060919, HL060944, HL061019, and the National Human Genome Research Institute (NHGRI): HG007112. The provision of genotyping data was supported in part by funds from the Department of Internal Medicine at the University of Michigan.
Iris M Heid	BMBF 01ER1206 and BMBF 01ER1507
J. Andrew Pospisilik	NIH and the Max Planck Society
Jeff Haessler	Jeff Haessler was supported by NHLBI R21 HL121422-02.
JHS	We thank the Jackson Heart Study (JHS) participants and staff for their contributions to this work. The JHS is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities.
Joel N. Hirschhorn	NIH R01DK075787
Kari North	KEN was supported by R01-DK089256 ; 2R01HD057194; U01HG007416; R01DK101855, and AHA grant 13GRNT16490017

KORA	The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ.
KORA S4	The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. I.M.H. received funding from the Bundesministerium für Bildung und Forschung (BMBF 01ER1206, 01ER1507) and from the National Institutes of Health (NIH R01DK075787).
Leipzig-adults	This work was supported by the Kompetenznetz Adipositas (Competence network for Obesity) funded by the Federal Ministry of Education and Research (German Obesity Biomaterial Bank; FKZ 01GI1128), and by grants from the Collaborative Research Center funded by the German Research Foundation (CRC 1052 "Obesity mechanisms"; C01, B01, B03).
LOLIPOP-Exome, LOLIPOP-OmniEE	The LOLIPOP study is supported by the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre Imperial College Healthcare NHS Trust, the British Heart Foundation (SP/04/002), the Medical Research Council (G0601966, G0700931), the Wellcome Trust (084723/Z/08/Z), the NIHR (RP-PG-0407-10371), European Union FP7 (EpiMigrant, 279143), and Action on Hearing Loss (G51). We thank the participants and research staff who made the study possible. The work was carried out in part at the NIHR/Wellcome Trust Imperial Clinical Research Facility.
Lothian Birth Cohort 1921 and Lothian Birth Cohort 1936	We thank the cohort participants and team members who contributed to these studies. Phenotype collection in the Lothian Birth Cohort 1921 was supported by the UK's Biotechnology and Biological Sciences Research Council (BBSRC), The Royal Society and The Chief Scientist Office of the Scottish Government. Phenotype collection in the Lothian Birth Cohort 1936 was supported by Age UK (The Disconnected Mind project). Genotyping was supported by Centre for Cognitive Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, and the Royal Society of Edinburgh. The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the BBSRC and Medical Research Council (MRC) is gratefully acknowledged.
Manuel A. Rivas	Nuffield Department of Clinical Medicine Award, Clarendon Scholarship
Mark I McCarthy	Mark I McCarthy is a Wellcome Trust Senior Investigator (WT098381); and a National Institute of Health Research Senior Investigator.
Markus Perola	We wish to thank THL DNA laboratory for its skillful work. Funding: Finnish Academy grants no. 255935 and 269517; The EU FP7 under grant agreements nr. 313010 (BBMRI-LPC), nr. 305280 (MIMOmics), and HZ2020 633589 (Ageing with Elegans), The Yrjö Jahnsson Foundation, The Juho Vainio Foundation
Marshfield Clinic Personalized Medicine Research Project	funded by NIH U01HG8701 and UL1TR000427
Mengmeng Du	M.D. is supported by the National Cancer Institute, National Institutes of Health (R25 CA94880, P30 CA008748).

MESA	This research was supported by the Multi-Ethnic Study of Atherosclerosis (MESA) contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and by grants UL1-TR-000040 and UL1-RR-025005 from NCRR . Funding for MESA Family was provided by grants R01-HL-071205, R01-HL-071051, R01-HL-071250, R01-HL-071251, R01-HL-071252, R01-HL-071258, R01-HL-071259, and UL1-RR-025005. Funding for MESA SHARe genotyping was provided by NHLBI Contract N02-HL-6-4278. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.
METSIM	Academy of Finland (137,544 and 272,741), the Finnish Cardiovascular Research Foundation. Genotyping was conducted at the Genetic Resources Core Facility (GRCF) at the Johns Hopkins Institute of Genetic Medicine.
MONICA-Brianza	Key personnel for the MONICA-Brianza cohorts: Research Center on Epidemiology and Preventive Medicine, Department of Clinical and Experimental Medicine, University of Insubria, Varese: MM Ferrario (principal investigator), F Gianfagna, G Veronesi. Research Centre on Public Health, University of Milano-Bicocca, Monza, Italy: Giancarlo Cesana. Prof. Paolo Brambilla and dr. Stefano Signorini from Laboratory Medicine, Desio Hospital are acknowledged for lab analysis and biobanking. Recent research activities of the Brianza cohort study have been supported by the Health Administration of Regione Lombardia [grant numbers 17155/2004 and 10800/2009] and by the Italian Ministry of Health in collaboration with the Istituto Superiore di Sanità [grant 2012/597].
Montreal Heart Institute Biobank (MHIBB)	We thank all participants and staff of the André and France Desmarais Montreal Heart Institute's (MHI) Biobank. The genotyping of the MHI Biobank was done at the MHI Pharmacogenomic Centre and funded by the MHI Foundation.
MORGAM Data Centre	The MORGAM Project received funding during the work from European Union FP 7 projects CHANCES (HEALTH-F3-2010-242244) and BiomarCaRE (278913). This has supported central coordination and part of the activities of the The MORGAM Data Centre, at THL in Helsinki, Finland. MORGAM Participating Centres are funded by regional and national governments, research councils, charities, and other local sources
Mother Child Cohort of Norway	The Norwegian Ministry of Health and the Ministry of Education and Research, NIH/NIEHS (contract no. N01-ES-75558), and NIH/NINDS (grant no. 1 U01 NS 047537-01 and grant no. 2 U01 NS 047537-06A1)
Mount Sinai BioMe Biobank	The Mount Sinai IPM Biobank Program is supported by The Andrea and Charles Bronfman Philanthropies.

NEO Study	The authors of the NEO study thank all individuals who participated in the Netherlands Epidemiology in Obesity study, all participating general practitioners for inviting eligible participants and all research nurses for collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for the coordination, lab and data management of the NEO study. The genotyping in the NEO study was supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023).
NHAPC study & GBTDS study	The NHPAC study and the GBTDS study are supported by the National Basic Research Program of China (973 Program 2012CB524900), and the National Natural Science Foundation of China (30930081, 81170734, 81321062, and 81471013). We are grateful to all participants of the NHAPC and the GBTDS studies, and also thank our colleagues at the laboratory and local CDC staffs of Beijing and Shanghai, as well as local staffs of the Bijie People's Hospital for their assistance with data collection.
Niels Grarup, Torben Hansen, Oluf Pedersen, Henrik Vestergaard, Jette Bork-Jensen, Christian T. Have, Anette P. Gjesing	The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk).
Nijmegen	The Nijmegen Biomedical Study is a population-based survey conducted at the Department for Health Evidence and the Department of Laboratory Medicine of the Radboud university medical center. Principal investigators of the Nijmegen Biomedical Study are L.A.L.M. Kiemeney, A.L.M. Verbeek, D.W. Swinkels en B. Franke. The NBS exome chip data were generated in a research project that was financially supported by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007). The Nijmegen Bladder Cancer Study, NBCS exome chip data were generated in a research project that was financially supported by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007).
OBB	The Oxford Biobank is supported by the Oxford Biomedical Research Centre and part of the National NIHR Bioresource.
Ophthalmic Western Australia Biobank	The OWAB acknowledges financial support for participant recruitment and sample processing provided by the National Health and Medical Research Council (NHMRC) of Australia (#1023911), the Ophthalmic Research Institute of Australia, the BrightFocus Foundation and a Ramaciotti Establishment Grant. CERA receives Operational Infrastructure Support from the Victorian Government.
Pal R. Njolstad	European Research Council (AdG; 293574), Research Council of Norway, University of Bergen, KG Jebsen Foundation, Helse Vest, Norwegian Diabetes Association
Patrick T. Ellinor	This work was supported by grants from the National Institutes of Health to Dr. Ellinor (1R01HL092577, R01HL128914, K24HL105780). Dr. Ellinor is also supported by an Established Investigator Award from the American Heart Association (13EIA14220013) and by the Fondation Leducq (14CVD01).
Paul L. Auer	Paul L. Auer was supported by NHLBI R21 HL121422-02 and R01 DK089256-05.

Paul L. Huang	NIH grants NS33335 and HL57818
PIVUS and ULSAM	These projects were supported by Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellow), European Research Council (ERC Starting Grant), Swedish Diabetes Foundation (2013-024), Swedish Research Council (2012-1397, 2012-1727, and 2012-2215), Marianne and Marcus Wallenberg Foundation, County Council of Dalarna, Dalarna University, and Swedish Heart-Lung Foundation (20120197). The computations were performed on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project b2011036. Genotyping was funded by the Wellcome Trust under awards WT064890 and WT086596. Analysis of genetic data was funded by the Wellcome Trust under awards WT098017 and WT090532. We thank the SNP&SEQ Technology Platform in Uppsala (www.genotyping.se) for excellent genotyping.
PRIME Study	We thank the PRIME Study participants and staff for their contribution to the study. The recruitment of the PRIME Study was organized under an agreement between the French National Institute for Medical Research (Inserm) and the Merck, Sharp and Dohme-Chibret Laboratory, with the following participating Laboratories : The Strasbourg MONICA Project, Department of Epidemiology and Public Health, University of Strasbourg, Strasbourg, F-67085, France (D. Arveiler, B. Haas, M. Moitry); The Toulouse MONICA Project, INSERM, UMR 1027; and Department of Epidemiology, Université Paul Sabatier - Toulouse Purpan, Toulouse, France (J. Ferrieres, JB. Ruidavets); The Lille MONICA project; INSERM, U744; Institut Pasteur de Lille; Univ Lille Nord de France; UDSL, Lille, France (P. Amouyel, M. Montaye); The Department of Epidemiology and Public Health, Queen's University, Belfast, Northern Ireland (A. Evans, J. Yarnell, F. Kee); The Department of Atherosclerosis, INSERM, U545, Lille; Institut Pasteur de Lille, Lille; and Faculté de Médecine, and Université Lille Nord de France, Lille, France (G. Luc, JM. Bard); The Laboratory of Haematology, INSERM, U626, Marseille, Hôpital La Timone, Marseille, France (I. Juhan-Vague, Pierre Morange); Laboratory of Endocrinology, INSERM, U563, Toulouse, France (B. Perret); The Vitamin Research Unit, The University of Bern, Bern, Switzerland (F. Gey); The Nutrition and Metabolism Group, Centre for Public Health, Queen's University Belfast, Northern Ireland (Jayne Woodside, Ian Young); The DNA Bank, INSERM/UPMC, Paris Universitatis UMRS 937, Paris, F-75013 (F. Cambien); The Coordinating Center, INSERM, Université Paris-Sud, Villejuif, France (P. Ducimetiere, A. Bingham).
PROMIS	We are thankful to all the study participants in Pakistan. Recruitment in PROMIS was funded through grants available to investigators at the Center for Non-Communicable Diseases, Pakistan (Danish Saleheen and Philippe Frossard) and investigators at the University of Cambridge, UK (Danish Saleheen and John Danesh). Field-work, genotyping, and standard clinical chemistry assays in PROMIS were principally supported by grants awarded to the University of Cambridge from the British Heart Foundation, UK Medical Research Council, Wellcome Trust, EU Framework 6-funded Bloodomics Integrated Project, Pfizer, Novartis, and Merck, Sharp & Dohme.
PROSPER/WOSCOPS	The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F2-2009-223004.
QIMR	We are grateful to the twins and their families for their generous participation in these studies. We would like to thank staff at the Queensland Institute of Medical Research: Dixie Statham, Ann Eldridge and Marlene Grace for sample collection, Lisa Bowdler, Steven Crooks and staff of the Molecular Epidemiology Laboratory for sample processing and preparation, Scott Gordon, Brian McEvoy, Belinda Cornes and Beben Benyamin for data QC and preparation, and David Smyth and Harry Beeby for IT support. We acknowledge funding from the Australian National Health and Medical Research Council (NHMRC grants 241944, 339446, 389875, 389891, 389892, 389938, 442915,

	442981, 496739, 496688, 552485, 572613, 613672, 613674, 619667, 1049472, 1050208, 1075175, 1078399), the U.S. National Institute of Health (grants AA07535, AA10248, AA014041, AA13320, AA13321, AA13326, AA011998 and DA12854) and the Australian Research Council (ARC grant DP0770096).
Rebecca S. Fine	NIH T32 GM096911-05
RISC	The RISC study was supported by European Union grant QLGI-CT-2001-01252 and AstraZeneca. The initial genotyping of the RISC samples was funded by Merck, Sharp & Dohme.
RSI	The generation and management of the Illumina exome chip v1.0 array data for the Rotterdam Study (RS-I) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The Exome chip array data set was funded by the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, from the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO)-sponsored Netherlands Consortium for Healthy Aging (NCHA; project nr. 050-060-810); the Netherlands Organization for Scientific Research (NWO; project number 184021007) and by the Rainbow Project (RP10; Netherlands Exome Chip Project) of the Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL; www.bbMRI.nl). We thank Ms. Mila Jhamai, Ms. Sarah Higgins, and Mr. Marijn Verkerk for their help in creating the exome chip database, and Carolina Medina-Gomez, MSc, Lennard Karsten, MSc, and Linda Broer PhD for QC and variant calling. Variants were called using the best practice protocol developed by Grove et al. as part of the CHARGE consortium exome chip central calling effort. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.
Ruth Loos	Ruth loos is funded by R01DK110113, U01HG007417, R01DK101855, R01DK107786
SCOOP	We are indebted to the patients and their families for their participation and to the physicians involved in the Genetics of Obesity Study (GOOS). A portion of this study comprises one arm of the UK10K Consortium (WT091310).
SEARCH	CRUK ref: A490/A10124
SEARCH/SIBS genotyping	CRUK ref: C8197/A16565
SHIP/SHIP-Trend	SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald Approach to Individualized Medicine (GANI_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). ExomeChip data have been supported by the Federal Ministry of Education and Research (grant no. 03Z1CN22) and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH.
SIBS	CRUK ref: C1287/A8459
Silk Road	The study was funded by the sponsors of the scientific expedition Marcopolo 2010, and by Ministry of Health RC 35/09

SORBS	<p>This work was supported by the Federal Ministry of Education and Research (BMBF), Germany, FKZ: 01EO1501 (AD2-060E).</p> <p>This project was further supported by grants from the Collaborative Research Center funded by the German Research Foundation (CRC 1052; C01, B01, B03), from the German Diabetes Association, from the DHFD (Diabetes Hilfs- und Forschungsfonds Deutschland) and from Boehringer Ingelheim Foundation. We thank all those who participated in the study. Sincere thanks are given to Knut Krohn (Microarray Core Facility of the Interdisciplinary Centre for Clinical Research, University of Leipzig) for the genotyping support.</p>
Southampton	The Southampton study acknowledges Southampton Wellcome Trust Clinical Research Facility for research nurse support in collecting DNA samples. Jenny Scott is acknowledged for technical assistance. AJL supported at the University of Southampton by funding from The Wellcome Trust (076169/A), American Health Assistance Foundation (M2007110), Macula Vision Research Foundation, TFC Frost Charitable Trust, Brian Mercer Charitable Trust, Macular Society, Hobart Trust, NIHR Senior Investigator Award (NF-SI-0515-10020) and the Gift of Sight appeal.
Steven A. Lubitz	NIH grants K23HL114724 and Doris Duke Charitable Foundation Clinical Scientist Development Award 2014105
Thomas F. Vogt	Thomas F. Vogt current affiliation: CHDI Management/CHDI Foundation, Princeton, New Jersey, USA
Timothy D Spector	Timothy D Spector is holder of an ERC Advanced Principal Investigator award.
Trevor Mori	Trevor A Mori is supported by an Australian National Health and Medical Research Fellowship (APP 1042255).
TUDR	This study was supported by the National Eye Institute of the National Institutes of Health (EY014684 to J.I.R. and Y.-D.I.C.) and ARRA Supplement (EY014684-03S1, -04S1), the National Institute of Diabetes and Digestive and Kidney Disease grant DK063491 to the Southern California Diabetes Endocrinology Research Center, the Eye Birth Defects Foundation Inc., the National Science Council, Taiwan (NSC 98-2314-B-075A-002-MY3 to W.H.S.) and the Taichung Veterans General Hospital, Taichung, Taiwan (TCVGH-1003001C to W.H.S.), the Ministry of Science and Technology, Taiwan (MOST 104-2314-B-075A-006 -MY3 to W.H.S.) and the Taichung Veterans General Hospital, Taichung, Taiwan (TCVGH-1030101C to W.H.S.).
Tune H. Pers	Lundbeck Foundation and Benzon Foundation for support
TwinsUK	TwinsUK study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). The study also receives support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London.
UCLA-Utrecht	Funding provided by NIMH R01 MH090553 and R01 MH078075 (to RAO)
UCP	We acknowledge Prof. Dr. Olaf H. Klungel and Dr. Anke-Hilse Maitland-Van der Zee for granting access to the UCP study data. The exome chip data were generated in a research project that was financially supported by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007)

UKGPCS	UKGPCS would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. UKGPCS should also like to acknowledge the NCRN nurses, data managers and Consultants for their work in the UKGPCS study. A list of UKGPCS collaborators can be found at: http://www.icr.ac.uk/our-research/research-divisions/division-of-genetics-and-epidemiology/oncogenetics/research-projects/ukgpcs/ukgpcs-collaborators
UKHLS	The UK Household Longitudinal Study is led by the Institute for Social and Economic Research at the University of Essex and funded by the Economic and Social Research Council. The survey was conducted by NatCen and the genome-wide scan data were analysed and deposited by the Wellcome Trust Sanger Institute. Information on how to access the data can be found on the Understanding Society website https://www.understandingsociety.ac.uk/ . Understanding Society Scientific Group Michaela Benzeval ¹ , Jonathan Burton ¹ , Nicholas Buck ¹ , Annette Jäckle ¹ , Meena Kumari ¹ , Heather Laurie ¹ , Peter Lynn ¹ , Stephen Pudney ¹ , Birgitta Rabe ¹ , Dieter Wolke ² . 1) Institute for Social and Economic Research; 2) University of Warwick
UKOPS	The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre (to U. Menon and S.A. Gayther).
Utrecht Health Project (UHP)	The Utrecht Health Project received grants from the Ministry of Health, Welfare and Sports (VWS), the University of Utrecht, the Province of Utrecht, the Dutch Organisation of Care Research, the University Medical Centre of Utrecht, and the Dutch College of Healthcare Insurance Companies.
Utrecht Health Project (UHP)	The exome chip data were generated in a research project that was financially supported by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007).
Valerie Turcot	Valerie Turcot is supported by a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR)
Vejle Biobank	The Vejle Diabetes Biobank was supported by The Danish Research Council for Independent Research
Warren, Munroe and Caulfield	This work forms part of the research themes contributing to the translational research portfolio for the NIHR Barts Cardiovascular Biomedical Research Unit. Caulfield is a NIHR Senior Investigator.
Western Australian Pregnancy Cohort (Raine) Study	This study was supported by the National Health and Medical Research Council of Australia [grant numbers 403981, 1021105 and 003209] and the Canadian Institutes of Health Research [grant number MOP-82893]. The authors are grateful to the Raine Study participants and their families, and to the Raine Study research staff for cohort co-ordination and data collection. The authors gratefully acknowledge the following institutes for providing funding for Core Management of the Raine Study: The University of Western Australia (UWA) , Curtin University, the Raine Medical Research Foundation, the UWA Faculty of Medicine, Dentistry and Health Sciences, the Telethon Kids Institute, the Women and Infants Research Foundation (King Edward Memorial Hospital) and Edith Cowan University). The authors gratefully acknowledge the assistance of the Western Australian DNA Bank (National Health And Medical Reserach Council of Australia National Enabling Facility). This work was supported by resources provided by the Pawsey Supercomputing Centre with funding from the Australian Government and Government of Western Australia.

WGHS	The WGHS is supported by the National Heart, Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913), with collaborative scientific support and funding for genotyping provided by Amgen.
WHI	The WHI program is funded by the National Heart, Lung, and Blood Institute, the US National Institutes of Health and the US Department of Health and Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C). Exome chip data and analysis were supported through the Exome Sequencing Project (NHLBI RC2 HL-102924, RC2 HL-102925 and RC2 HL-102926), the Genetics and Epidemiology of Colorectal Cancer Consortium (NCI CA137088), and the Genomics and Randomized Trials Network (NHGRI U01-HG005152). The authors thank the WHI investigators and staff for their dedication and the study participants for making the program possible.
YFS	The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Kuopio, Tampere and Turku University Hospital Medical Funds (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of Cardiovascular Research ; Finnish Cultural Foundation; Tampere Tuberculosis Foundation ; Emil Aaltonen Foundation ; and Yrjö Jahnsson Foundation. The expert technical assistance in the statistical analyses by Ville Aalto and Irina Lisinen is gratefully acknowledged.
Zoltan Kutalik	Leenaards Foundation(http://www.leenaards.ch/), Swiss National Science Foundation (31003A-143914) and SystemsX.ch (51RTP0_151019).

7. CONSORTIA MEMBERS

CHD Exome+ Consortium

Praveen Surendran¹, Robin Young¹, Daniel R. Barnes¹, James R. Staley¹, Daniel F. Freitag¹, Sune Fallgaard Nielsen², Asif Rasheed³, Maria Samuel³, Wei Zhao⁴, Jukka Kontto⁵, Markus Perola^{5,6,7}, Muriel Caslake⁸, Anton JM. de Craen⁹, Stella Trompet^{9,10}, Maria Uria-Nickelsen¹¹, Anders Malarstig¹², Dermot F. Reilly¹³, Maarten Hoek¹⁴, Thomas Vogt^{14,15}, J Wouter. Jukema^{11,16}, Naveed Sattar¹⁷, Ian Ford⁸, Chris J. Packard⁸, Dewan S. Alam¹⁸, Abdulla al Shafi. Majumder¹⁹, Emanuele Di Angelantonio^{1,20}, Rajiv Chowdhury¹, Philippe Amouyel^{21,22,23,24}, Dominique Arveiler²⁵, Stefan Blankenberg^{26,27}, Jean Ferrières²⁸, Frank Kee²⁹, Kari Kuulasmaa⁵, Martina Müller-Nurasyid^{30,31,32}, Giovanni Veronesi³³, Jarmo Virtamo⁵, Philippe Frossard³, Børge Grønne Nordestgaard², Danish Saleheen^{4,3,1}, John Danesh^{1,35,20}, Adam S. Butterworth^{1,20}, Joanna MM. Howson¹

1. Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
2. Department of Clinical Biochemistry Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
3. Centre for Non-Communicable Diseases, Karachi, Pakistan
4. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
5. Department of Health, National Institute for Health and Welfare, Helsinki, Finland
6. Institute of Molecular Medicine FIMM, University of Helsinki, Finland
7. Estonian Genome Center, University of Tartu, Tartu, Estonia
8. University of Glasgow, Glasgow, UK
9. Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
10. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
11. Development Management and Planning, Pfizer Worldwide Research and Development
12. Pfizer Worldwide Research and Development, Stockholm, Sweden
13. Genetics and Pharmacogenomics, Merck Research Laboratories, Boston, Massachusetts, USA.
14. Merck Research Laboratories, Kenilworth, New Jersey, USA
15. CHDI Management/CHDI Foundation, Princeton, New Jersey, USA
16. The Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands
17. Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
18. ICDDR, B; Mohakhali, Dhaka, Bangladesh
19. National Institute of Cardiovascular Diseases, Sher-e-Bangla Nagar, Dhaka, Bangladesh
20. The National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
21. University of Lille, Risk Factors and Molecular Determinants of aging-related diseases, Lille, France
22. Inserm, Lille, France
23. Centre Hospitalier Universitaire Lille, Public Health, Lille, France
24. Institute Pasteur de Lille, Lille, France
25. Department of Epidemiology and Public Health, EA 3430, University of Strasbourg, Strasbourg, France
26. Department of General and Interventional Cardiology, University Heart Center Hamburg, Germany
27. University Medical Center Hamburg-Eppendorf, Hamburg, Germany
28. Department of Epidemiology, UMR 1027- INSERM, Toulouse University-CHU Toulouse, Toulouse, France
29. Director, UKCRC Centre of Excellence for Public Health, Queens University, Belfast, Northern Ireland
30. Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
31. Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany
32. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
33. Research Center in Epidemiology and Preventive Medicine, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

34. A full list of members and affiliations appears in the Supplementary Note
35. Wellcome Trust Sanger Institute, Hinxton, UK

The EPIC-CVD Consortium

Kim Overvad^{1,2}, Anne Tjønneland³, Francoise Clavel-Chapelon⁴, Rudolf Kaaks⁵, Heiner Boeing⁶, Antonia Trichopoulou^{7,8}, Pietro Ferrari⁹, Domenico Palli¹⁰, Vittorio Krogh¹¹, Salvatore Panico¹², Rosario Tumino¹³, Giuseppe Matullo^{14,15}, Jolanda Boer¹⁶, Yvonne van der Schouw¹⁷, Elisabete Weiderpass^{18,19,20,21}, J. Ramon Quiros²², María-José Sánchez^{23,24}, Carmen Navarro²⁵, Conchi Moreno-Iribas²⁶, Larraitz Arriola²⁷, Olle Melander²⁸, Patrik Wennberg²⁹, Nicholas J. Wareham³⁰, Timothy J. Key³¹, Elio Riboli³², Adam S. Butterworth^{33,34}, John Danesh^{33,34,35}

1. Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark
2. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
3. Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
4. INSERM, Centre for Research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones, and Women's Health Team, Institut Gustave Roussy, Villejuif, France
5. Division of Cancer Genetic Epidemiology, German Cancer Research Centre (DKFZ), im Neuenheimer Feld 581, 69120 Heidelberg, Germany
6. Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Germany
7. WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
8. Hellenic Health Foundation, Athens, Greece
9. International Agency for Research on Cancer, Lyon, France
10. Molecular and Nutritional Epidemiology Unit, Centro per lo Studio e la Prevenzione Oncologica-Scientific Institute of Tuscany, Florence, Italy
11. Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
12. Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy
13. Cancer Registry and Histopathology Unit, Civic- M.P.Arezzo Hospital, ASP Ragusa, Italy
14. Human Genetics Foundation, Turin, Italy
15. Department of Medical Sciences, University of Turin, Italy
16. Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
17. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
18. Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
19. Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
20. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
21. Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland
22. Public Health Directorate, Asturias, Spain
23. Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria IBS.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
24. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
25. Epidemiology Department, Murcia Health Authority, Murcia, Spain
26. Public Health Institute of Navarra, Pamplona, Spain
27. Public Health Division of Gipuzkoa, Instituto Bio-Donostia, Basque Government, CIBERESP, Spain
28. Department of Clinical Sciences, Hypertension & Cardiovascular Disease, Clinical Research Centre, Malmö University Hospital, Malmö, Sweden
29. Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden
30. Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK
31. Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK
32. School of Public Health, Imperial College London, UK

33. Cardiovascular Epidemiology Unit, Department of Public Health & Primary Care, University of Cambridge, UK
34. The National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge, UK
35. Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK

ExomeBP Consortium

Kraja AT, Cook JP, Warren HR, Surendran P, Liu C, Evangelou E, Manning AK, Grarup N, Drenos F, Sim X, Smith AV, Amin N, Blakemore AIF, Bork-Jensen J, Brandslund I, Farmaki AE, Fava C, Ferreira T, Herzig KH, Giri A, Giulianini F, Grove ML, Guo X, Harris SE, Have CT, Havulinna AS, Zhang H, Jørgensen ME, Käräjämäki A, Kooperberg C, Linneberg A, Little L, Liu Y, Bonnycastle LL, Lu Y, Mägi R, Mahajan A, Malerba G, Marioni RE, Mei H, Menni C, Morrison AC, Padmanabhan S, Palmas W, Poveda A, Rauramaa R, Rayner NW, Riaz M, Rice K, Richard MA, Smith JA, Southam L, Stančáková A, Stirrups KE, Tragante V, Tuomi T, Tzoulaki I, Varga TV, Weiss S, Yiorkas AM, Young R, Zhang W, Barnes MR, Cabrera CP, Gao H, Boehnke M, Boerwinkle E, Chambers JC, Connell JM, Christensen CK, de Boer RA, Deary IJ, Dedoussis G, Deloukas P, Dominiczak AF, Dörr M, Joehanes R, Edwards TL, Esko T, Fornage M, Franceschini N, Franks PW, Gambaro G, Groop L, Hallmans G, Hansen T, Hayward C, Heikki O, Ingelsson E, Tuomilehto J, Jarvelin MR, Kardia SLR, Karpe F, Kooner JS, Lakka TA, Langenberg C, Lind L, Loos RJF, Laakso M, McCarthy MI, Melander O, Mohlke KL, Morris AP, Palmer CNA, Pedersen O, Polasek O, Poulter NR, Province MA, Psaty BM, Ridker PM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sever PJ, Skaaby T, Stafford JM, Starr JM, van der Harst P, van der Meer P, van Duijn CM, Vergnaud AC, Gudnason V, Wareham NJ, Wilson JG, Willer CJ, Witte DR, Zeggini E, Saleheen D, Butterworth AS, Danesh J, Asselbergs FW, Wain LV, Ehret GB, Chasman DI, Caulfield MJ, Elliott P, Lindgren CM, Levy D, Newton-Cheh C, Munroe PB, Howson JMM

From the Division of Statistical Genomics, Department of Genetics and Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO (A.T.K., M.A.P.); Department of Biostatistics, University of Liverpool, United Kingdom (J.P.C., A.P.M.); Department of Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom (H.R.W., L.L., K.E.S., C.P.C., M.R.B., P.D., M.J.C., P.B.M.); National Institute for Health Research Barts Cardiovascular Biomedical Research Unit, Queen Mary University of London, United Kingdom (H.R.W., M.R.B., C.P.C., P.D., M.J.C., P.B.M.); MRC/BHF Cardiovascular Epidemiology Centre, Department of Public Health and Primary Care (P.S., R.Y., A.S.B., J.D., J.M.M.H.), Department of Haematology (K.E.S.), Department of Public Health and Primary Care (D.S.), NIHR Blood and Transplant Research Unit in Donor Health and Genomics (J.D.) and British Heart Foundation, Cambridge Centre for Excellence, Department of Medicine (A.S.B., J.D.), University of Cambridge, United Kingdom; The Framingham Heart Study, MA (C.L., R.J., D.L.); The Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute (C.L., D.L.), Mathematical and Statistical Computing Laboratory, Center for Information Technology (R.J.), National Institutes of Health, Bethesda, MD; Department of Epidemiology and Biostatistics, School of Public Health (E.E., I.T., W.Z., H.G., J.C.C., M.-R.J., A.-C.V., P.E.), Section of Investigative Medicine, Department of Medicine (A.I.F.B., A.M.Y.), MRC-PHE Centre for Environment and Health (I.T., H.G., M.-R.J., P.E.), International Centre for Circulatory Health (N.R.P., P.J.S.), National Institute for Health Research Imperial College Healthcare NHS Trust Biomedical Research Unit (P.E.), Imperial College London, United Kingdom; Department of Hygiene and Epidemiology, University of Ioannina Medical School, Greece (E.E., I.T.); Center for Genomic Medicine (A.K.M., C.N.-C.), Cardiovascular Research Center, Massachusetts General Hospital (C.N.-C.); Department of Medicine (A.K.M., P.M.R., D.I.C.), Institute for Aging Research, Hebrew SeniorLife (R.J.), Harvard Medical School (P.M.R., D.I.C.), Boston, MA; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark (N.G., J.B.-J., C.T.H., T.H., O.P.); Medical Research Council Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, United Kingdom (F.D.); Centre for Cardiovascular Genetics, Institute of Cardiovascular Science (F.D.) and Faculty of Population Health Sciences (F.W.A.), University College London, United Kingdom; Department of Biostatistics and Center for Statistical Genetics (X.S., M.B.), Department of Internal Medicine, Division of Cardiovascular Medicine (H.Z., C.J.W.), Department of Epidemiology, School of Public Health (J.A.S., S.L.R.K.), Department of Computational Medicine and Bioinformatics (C.J.W.) and Department of Human Genetics (C.J.W.),

University of Michigan, Ann Arbor; Saw Swee Hock School of Public Health, National University of Singapore (X.S.); Icelandic Heart Association, Kopavogur (A.V.S., V.G.); Faculty of Medicine, University of Iceland, Reykjavik (A.V.S., V.G.); Genetic Epidemiology Unit, Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands (N.A., C.M.v.D.); Department of Life Sciences, Brunel University London, United Kingdom (A.I.F.B., A.M.Y.); Department of Clinical Biochemistry (I.B.), Medical Department (C.K.C.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Odense (I.B.); Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece (A.-E.F., G.D.); Department of Clinical Sciences, University of Lund, Malmö, Sweden (C.F., O.M.); Department of Medicine (C.F.) and Department of Neuroscience, Biomedicine and Movement, Section of Biology and Genetics (G.M.), University of Verona, Italy; Wellcome Trust Centre for Human Genetics (T.F., A.M., N.W.R., L.S., M.I.M., C.M.L.), Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine (N.W.R., F.K., M.I.M.), and Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, United Kingdom (C.M.L.); Research Unit of Biomedicine and Biocenter of Oulu, University of Oulu, Finland (K.-H.H.); Medical Research Center (MRC) & Oulu University Hospital, Finland (K.-H.H.); Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poland (K.-H.H.); Vanderbilt Epidemiology Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN (A.G., T.L.E.); Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA (F.G., P.M.R., D.I.C.); Human Genetics Center, School of Public Health (M.L.G., A.C.M., M.A.R., E.B.) and Brown Foundation Institute of Molecular Medicine, McGovern Medical School (M.A.R., M.F.), The University of Texas Health Science Center at Houston (M.L.G., A.C.M., E.B.); Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA (X.G., J.I.R.); Centre for Cognitive Ageing and Cognitive Epidemiology (S.E.H., R.E.M., I.J.D., J.M.S.), Centre for Genomic and Experimental Medicine (S.E.H., R.E.M.), Psychology (I.J.D.), Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine (C.H.), Usher Institute of Population Health Sciences and Informatics (I.R.), and Alzheimer Scotland Research Centre (J.M.S.), University of Edinburgh, United Kingdom; Department of Health (A.S.H., V.S.), Chronic Disease Prevention Unit, National Institute for Health and Welfare (J.T.), and Institute of Molecular Medicine Finland (A.S.H.), Helsinki, Finland; Dasman Diabetes Institute, Kuwait (J.T.); Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia (J.T.); Department of Neurosciences and Preventive Medicine, Danube University Krems, Austria (J.T.); Steno Diabetes Center, Copenhagen, Gentofte, Denmark (M.E.J.); Department of Primary Health Care, Vaasa Central Hospital, Finland (A.K.); Diabetes Center, Vaasa Health Care Center, Finland (A.K.); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (C.K.); Research Centre for Prevention and Health, The Capital Region of Denmark, Copenhagen (A.L., T.S.); Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark (A.L.); Epidemiology & Prevention Center for Genomics and Personalized Medicine Research, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC (Y.Liu); Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD (L.L.B.); Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, NY (Y.Lu, R.J.F.L.); Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN (Y.Lu); Estonian Genome Center, University of Tartu, Estonia (R.M., T.E.); Department of Data Science (H.M.) and Department of Physiology and Biophysics (J.G.W.), University of Mississippi Medical Center, Jackson; Department of Twin Research & Genetic Epidemiology, King's College London (C.M.); British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (S.P., A.F.D.); Department of Medicine, Columbia University Medical Center, New York, NY (W.P.); Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden (A.P., P.W.F.); Kuopio Research Institute of Exercise Medicine (R.R., T.V.V., T.A.L.), Department of Clinical Physiology and Nuclear Medicine (R.R., T.A.L.), University of Eastern Finland (A.S.), and Department of Medicine, University of Eastern Finland & Kuopio University Hospital (M.L.); Wellcome Trust Sanger Institute, Hinxton, United Kingdom (N.W.R., L.S., E.Z., J.D.); Department of Cardiovascular Sciences (M.R., N.J.S.) and Department of Health Sciences (L.V.W.), University of Leicester, United Kingdom; NIHR Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (M.R., N.J.S.); Department of Biostatistics (K.R.), Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle (B.M.P.); Department of Cardiology, University Medical

Center Utrecht, The Netherlands (V.T., F.W.A.); Folkhälsan Research Centre (T.T.) and Department of Endocrinology (T.T.), Helsinki University Central Hospital, Finland; Interfaculty Institute for Genetics and Functional Genomics, University Medicine and Ernst-Moritz-Arndt-University Greifswald, Germany (S.W., M.D.); DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, Germany (S.W.); Department of Cardiology, Ealing Hospital, London North West Healthcare NHS Trust, United Kingdom (W.Z., J.C.C., J.S.K.); Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX (E.B.); Imperial College Healthcare NHS Trust, London, United Kingdom (J.C.C., J.S.K.); University of Dundee, Ninewells Hospital & Medical School, United Kingdom (J.M.C.); Department of Cardiology (R.A.d.B., P.v.d.H., P.v.d.M.) and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, The Netherlands; Department of Internal Medicine B-Cardiology, Pneumology, Infectious Diseases, Intensive Care Medicine, University Medicine Greifswald, Germany (M.D.); Department of Epidemiology (N.F.) and Department of Genetics (K.L.M.), University of North Carolina, Chapel Hill; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA (P.W.F.); Department of Public Health & Clinical Medicine (P.W.F.) and Department of Biobank Research (T.T., G.H.), Umeå University, Sweden; Department of Nephrology and Dialysis, Università Cattolica del Sacro Cuore, Roma, Italy (G.G.); Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malmö, Sweden (L.G.); Finnish Institute for Molecular Medicine (FIMM) (T.T., L.G.), Helsinki University, Finland; Tampere University Hospital, Finland (O.H.); Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (E.I.); Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden (E.I., L.L.); Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Finland (M.-R.J.); Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, United Kingdom (F.K., M.I.M.); National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, United Kingdom (J.S.K.); Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio (T.A.L.); MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, United Kingdom (C.L., N.J.W.); Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Scotland, United Kingdom (C.N.A.P.); Faculty of Medicine, University of Split, Croatia (O.P.); Kaiser Permanente Washington Health Research Institute, Seattle, (B.M.P.); Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC (J.M.S.); Department of Public Health, Aarhus University, Denmark (D.R.W.); Danish Diabetes Academy, Odense, Denmark (D.R.W.); Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.S.); Centre for Non-Communicable Diseases, Karachi, Pakistan (D.S.); Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (G.B.E.); Cardiology, Department of Medicine, Geneva University Hospital, Switzerland (G.B.E.); and Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge (C.M.L., C.N.-C.).

Global Lipids Genetic Consortium

Liu DJ1, Peloso GM2,3, Yu H4, Butterworth AS5,6, Wang X7, Mahajan A8, Saleheen D5,9,10, Emdin C3,11, Alam D12, Alves AC13, Amouyel P14, Di Angelantonio E5,6, Arveiler D15, Assimes TL16,17, Auer PL18, Baber U19, Ballantyne CM20, Bang LE21, Benn M22,23, Bis JC24, Boehnke M25, Boerwinkle E26,27, Bork-Jensen J28, Bottinger EP29, Brandslund I30,31, Brown M32, Busonero F33, Caulfield MJ32,34,35, Chambers JC36,37,38, Chasman DI39,40, Chen YE41, Chen YI42, Chowdhury R5, Christensen C43, Chu AY39,44, Connell JM45, Cucca F33,46, Cupples LA2,44, Damrauer SM47,48, Davies G49,50, Deary IJ49,50, Dedoussis G51, Denny JC52,53, Dominiczak A54, Dubé MP55,56,57, Ebeling T58, Eiriksdottir G59, Esko T3,60, Farmaki AE51, Feitosa MF61, Ferrario M62, Ferrieres J63, Ford I64, Fornage M65, Franks PW66,67,68, Frayling TM69, Frikke-Schmidt R22,23, Fritsche LG25, Frossard P10, Fuster V19,70, Ganesh SK41,71, Gao W72, Garcia ME73, Gieger C74,75,76, Giulianini F39, Goodarzi MO77,78, Grallert H74,75,76, Grarup N28, Groop L79, Grove ML26, Gudnason V59,80, Hansen T28,81, Harris TB82, Hayward C83, Hirschhorn JN3,84, Holmen OL85,86, Huffman J83, Huo Y87, Hveem K88, Jabeen S10, Jackson AU25, Jakobsdottir J59,89, Jarvelin MR13, Jensen GB90, Jørgensen ME91,92, Jukema JW93,94, Justesen JM28, Kamstrup PR95, Kanoni S96, Karpe F97,98, Kee F99, Khera AV3,11, Klarin D3,11,100, Koistinen HA101,102,103, Kooner JS37,38,104, Kooperberg C105, Kuulasmaa K101, Kuusisto J106, Laakso M106, Lakka T107,108,109, Langenberg C110, Langsted A95,111, Launer LJ82, Lauritzen T112, Liewald DCM49,50, Lin LA65, Linneberg A113,114,115, Loos RJF29,116, Lu Y29, Lu

X41,117, Mägi R60, Malarstig A118,119, Manichaikul A120, Manning AK3,11,121, Mäntyselkä P122, Marouli E96, Masca NGD123,124, Maschio A33, Meigs JB3,121,125, Melander O126, Metspalu A60, Morris AP8,127, Morrison AC26, Mulas A33, Müller-Nurasyid M76,128,129, Munroe PB32,35, Neville MJ97, Nielsen JB41, Nielsen SF95,111, Nordestgaard BG95,111, Ordovas JM130,131,132, Mehran R19, O'Donnell CJ100,40, Orho-Melander M126, Molony CM133, Muntendam P134, Padmanabhan S54, Palmer CNA45, Pasko D69, Patel AP3,11,40,135, Pedersen O28, Perola M101,136, Peters A74,76,129, Pisinger C115, Pistis G33, Polasek O137,138, Poulter N139, Psaty BM24,140,141, Rader DJ142, Rasheed A10, Rauramaa R108,109, Reilly DF133, Reiner AP105,143, Renström F66,144, Rich SS120, Ridker PM39, Rioux JD55, Robertson NR8,97, Roden DM52,53, Rotter JI42, Rudan I138, Salomaa V101, Samani NJ123,124, Sanna S33, Sattar N54,97, Schmidt EM145, Scott RA110, Sever P139, Sevilla RS146, Shaffer CM53, Sim X25,147, Sivapalaratnam S148, Small KS149, Smith AV59,80, Smith BH150,151, Somayajula S152, Southam L8,153, Spector TD149, Speliotes EK145,154, Starr JM49,155, Stirrups KE96,156, Stitzel N157,158, Strauch K159,160, Stringham HM25, Surendran P5, Tada H161, Tall AR162, Tang H163, Tardif JC55,57, Taylor KD42, Trompet S93,164, Tsao PS16,17, Tuomilehto J165,166,167,168, Tybjaerg-Hansen A22,23, van Zuydam NR8,45, Varbo A95,111, Varga TV66, Virtamo J101, Waldenberger M75,76,129, Wang N162, Wareham NJ110, Warren HR32,35, Weeke PE53,169, Weinstock J25, Wessel J170,171, Wilson JG172, Wilson PWF173,174, Xu M175, Yaghootkar H69, Young R5, Zeggini E153, Zhang H41, Zheng NS176, Zhang W36, Zhang Y87, Zhou W145, Zhou Y2, Zoledziwska M33; Charge Diabetes Working Group; EPIC-InterAct Consortium; EPIC-CVD Consortium; GOLD Consortium; VA Million Veteran Program, Howson JMM5, Danesh J5,6,153, McCarthy MI8,97,98, Cowan CA4,177, Abecasis G25, Deloukas P96,178, Musunuru K7, Willer CJ41,71,145, Kathiresan S3,11,40,135.

1 Department of Public Health Sciences, Institute of Personalized Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA.

2 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.

3 Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.

4 Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.

5 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

6 The National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge, Cambridge, UK.

7 Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

8 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.

9 Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

10 Center for Non-Communicable Diseases, Karachi, Pakistan.

11 Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

12 ICDDR, B, Dhaka, Bangladesh.

13 Imperial College London, London, UK.

14 Université Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Risk Factors and Molecular Determinants of Aging-related Diseases, Lille, France.

15 Department of Epidemiology and Public Health, EA 3430, University of Strasbourg, Strasbourg, France.

16 VA Palo Alto Health Care System, Palo Alto, California, USA.

17 Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

18 Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.

19 Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

20 Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

21 Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

22 Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.

23 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

24 Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA.

25 Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public

Health, Ann Arbor, Michigan, USA.

26 Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

27 Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.

28 The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

29 The Charles Bronfman Institute for Personalized Medicine, Ichan School of Medicine at Mount Sinai, New York, New York, USA.

30 Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark.

31 Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

32 Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

33 Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche (CNR), Monserrato, Cagliari, Italy.

34 The Barts Heart Centre, William Harvey Research Institute, Queen Mary University of London, London, UK.

35 NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of London, London, UK.

36 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

37 Department of Cardiology, Ealing Hospital NHS Trust, Southall, UK.

38 Imperial College Healthcare NHS Trust, London, UK.

39 Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

40 Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

41 Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.

42 The Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Departments of Pediatrics and Medicine, Los Angeles, California, USA.

43 Medical Department, Lillebaelt Hospital, Vejle, Denmark.

44 NHLBI Framingham Heart Study, Framingham, Massachusetts, USA.

45 Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.

46 Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, Sassari, Italy.

47 Corporal Michael Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.

48 Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

49 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.

50 Department of Psychology, University of Edinburgh, Edinburgh, UK.

51 Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.

52 Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

53 Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

54 British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

55 Montreal Heart Institute, Montreal, Quebec, Canada.

56 Université de Montréal Beaulieu-Saucier Pharmacogenomics Center, Montreal, Quebec, Canada.

57 Université de Montréal, Montreal, Quebec, Canada.

58 Department of Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland.

59 The Icelandic Heart Association, Kopavogur, Iceland.

60 Estonian Genome Center, University of Tartu, Tartu, Estonia.

61 Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.

62 Research Centre in Epidemiology and Preventive Medicine-EPIMED, Department of Medicine and Surgery, University of Insubria, Varese, Italy.

63 Department of Epidemiology, UMR 1027-INSERM, Toulouse University-CHU Toulouse, Toulouse, France.

64 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.

- 65 Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
- 66 Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden.
- 67 Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden.
- 68 Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
- 69 Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK.
- 70 Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
- 71 Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.
- 72 Department of Cardiology, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Beijing, China.
- 73 National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
- 74 German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
- 75 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
- 76 Institute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
- 77 Departments of Medicine and of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- 78 Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- 79 Department of Clinical Sciences, Diabetes and Endocrinology, Clinical Research Centre, Lund University, Malmö, Sweden.
- 80 Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- 81 Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- 82 Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, Maryland, USA.
- 83 Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
- 84 Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, Massachusetts, USA.
- 85 Department of Public Health and General Practice, HUNT Research Centre, Norwegian University of Science and Technology, Levanger, Norway.
- 86 St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
- 87 Department of Cardiology, Peking University First Hospital, Beijing, China.
- 88 K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
- 89 Department of Health Sciences, University of Iceland, Reykjavik, Iceland.
- 90 The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark.
- 91 Steno Diabetes Center, Gentofte, Denmark.
- 92 National Institute of Public Health, Southern Denmark University, Copenhagen, Denmark.
- 93 Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
- 94 The Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands.
- 95 Department of Clinical Biochemistry and the Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
- 96 William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- 97 Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
- 98 Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, UK.
- 99 UKCRC Centre of Excellence for Public Health, Queens University, Belfast, UK.
- 100 Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA.
- 101 Department of Health, National Institute for Health and Welfare, Helsinki, Finland.
- 102 Department of Medicine and Abdominal Center: Endocrinology, University of Helsinki and Helsinki

University Central Hospital, Helsinki, Finland.

103 Minerva Foundation Institute for Medical Research, Helsinki, Finland.

104 National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.

105 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

106 Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.

107 Department of Physiology, Institute of Biomedicine, University of Eastern Finland, Kuopio Campus, Kuopio, Finland.

108 Kuopio Research Institute of Exercise Medicine, Kuopio, Finland.

109 Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland.

110 MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.

111 Faculty of Health and Medical Sciences, University of Denmark, Copenhagen, Denmark.

112 Department of Public Health, Section of General Practice, University of Aarhus, Aarhus, Denmark.

113 Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark.

114 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

115 Research Center for Prevention and Health, Copenhagen, Denmark.

116 The Mindich Child Health and Development Institute, Ichan School of Medicine at Mount Sinai, New York, New York, USA.

117 State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

118 Cardiovascular Genetics and Genomics Group, Cardiovascular Medicine Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

119 Pharmatherapeutics Clinical Research, Pfizer Worldwide R&D, Sollentuna, Sweden.

120 Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA.

121 Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

122 Unit of Primary Health Care, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.

123 Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.

124 NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.

125 Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

126 Department of Clinical Sciences, University Hospital Malmö Clinical Research Center, Lund University, Malmö, Sweden.

127 Department of Biostatistics, University of Liverpool, Liverpool, UK.

128 Department of Medicine I, Ludwig-Maximilians-University, Munich, Germany.

129 DZHK German Centre for Cardiovascular Research, Munich Heart Alliance, Munich, Germany.

130 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Investigation, Madrid, Spain.

131 IMDEA-Alimentación, Madrid, Spain.

132 Nutrition and Genomics Laboratory, Jean Mayer-USA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, USA.

133 Genetics, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, USA.

134 G3 Pharmaceuticals, Lexington, Massachusetts, USA.

135 Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

136 Institute of Molecular Medicine FIMM, University of Helsinki, Finland.

137 Faculty of Medicine, University of Split, Split, Croatia.

138 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.

139 International Centre for Circulatory Health, Imperial College London, London, UK.

140 Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.

141 Departments of Epidemiology and Health Services, University of Washington, Seattle, Washington, USA.

142 Departments of Genetics, Medicine, and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

143 Department of Epidemiology, University of Washington, Seattle, Washington, USA.

144 Department of Biobank Research, Umeå University, Umeå, Sweden.
 145 Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
 146 Imaging, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, USA.
 147 Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
 148 Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
 149 Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
 150 Division of Population Health Sciences, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
 151 Generation Scotland, Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK.
 152 Scientific Informatics, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, USA.
 153 Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK.
 154 Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA.
 155 Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK.
 156 Department of Haematology, University of Cambridge, Cambridge, UK.
 157 Cardiovascular Division, Departments of Medicine and Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.
 158 The McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri, USA.
 159 IBE, Faculty of Medicine, Ludwig-Maximilians-Universität Munich, Germany.
 160 Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
 161 Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
 162 Department of Medicine, Division of Molecular Medicine, Columbia University, New York, New York, USA.
 163 Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.
 164 Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.
 165 Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.
 166 Dasman Diabetes Institute, Dasman, Kuwait.
 167 Centre for Vascular Prevention, Danube-University Krems, Krems, Austria.
 168 Saudi Diabetes Research Group, King Abdulaziz University, Fahd Medical Research Center, Jeddah, Saudi Arabia.
 169 The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
 170 Department of Epidemiology, Indiana University Fairbanks School of Public Health, Indianapolis, Indiana, USA.
 171 Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
 172 Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA.
 173 Atlanta VA Medical Center, Decatur, Georgia, USA.
 174 Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia, USA.
 175 Department of Cardiology, Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China.
 176 Yale College, Yale University, New Haven, Connecticut, USA.
 177 Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
 178 Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia.

GoT2D Genes Consortium & T2D-Genes Consortium

Christian Fuchsberger^{1,2,3}, Jason Flannick^{4,5}, Tanya M Teslovich¹, Anubha Mahajan⁶, Vineeta Agarwala^{4,7}, Kyle J Gaulton⁶, Clement Ma¹, Pierre Fontanillas⁴, Loukas Moutsianas⁶, Davis J McCarthy^{6,8}, Manuel A Rivas⁶, John R B Perry^{6,9,10,11}, Xueling Sim¹, Thomas W Blackwell¹, Neil R Robertson^{6,12}, N William Rayner^{6,12,13}, Pablo Cingolani^{14,15}, Adam E Locke¹, Juan Fernandez Tajés⁶, Heather M Highland¹⁶, Josee Dupuis^{17,18}, Peter S

Chines¹⁹ Cecilia M Lindgren^{4,6} Christopher Hartl⁴ Anne U Jackson¹ Han Chen^{17,20} Jeroen R Huyghe¹ Martijn van de Bunt^{6,12} Richard D Pearson⁶ Ashish Kumar^{6,21} Martina Müller-Nurasyid^{22,23,24,25} Niels Grarup²⁶ Heather M Stringham¹ Eric R Gamazon²⁷ Jaehoon Lee²⁸ Yuhui Chen⁶ Robert A Scott¹⁰ Jennifer E Below²⁹ Peng Chen³⁰ Jinyan Huang³¹ Min Jin Go³² Michael L Stitzel³³ Dorota Pasko⁹ Stephen C J Parker³⁴ Tibor V Varga³⁵ Todd Green⁴ Nicola L Beer¹² Aaron G Day-Williams¹³ Teresa Ferreira⁶ Tasha Fingerlin³⁶ Momoko Horikoshi^{6,12} Cheng Hu³⁷ Iksoo Huh²⁸ Mohammad Kamran Ikram^{38,39,40} Bong-Jo Kim³² Yongkang Kim²⁸ Young Jin Kim³² Min-Seok Kwon⁴¹ Juyoung Lee³² Selyeong Lee²⁸ Keng-Han Lin¹ Taylor J Maxwell²⁹ Yoshihiko Nagai^{15,42,43} Xu Wang³⁰ Ryan P Welch¹ Joon Yoon⁴¹ Weihua Zhang^{44,45} Nir Barzilai⁴⁶ Benjamin F Voight^{47,48} Bok-Ghee Han³² Christopher P Jenkinson^{49,50} Teemu Kuulasmaa⁵¹ Johanna Kuusisto^{51,52} Alisa Manning⁴ Maggie C Y Ng^{53,54} Nicholette D Palmer^{53,54,55} Beverley Balkau⁵⁶ Alena Stančáková⁵¹ Hanna E Abboud⁴⁹ Heiner Boeing⁵⁷ Vilmantas Giedraitis⁵⁸ Dorairaj Prabhakaran⁵⁹ Omri Gottesman⁶⁰ James Scott⁶¹ Jason Carey⁴ Phoenix Kwan¹ George Grant⁴ Joshua D Smith⁶² Benjamin M Neale^{4,63,64} Shaun Purcell^{4,64,65} Adam S Butterworth⁶⁶ Joanna M M Howson⁶⁶ Heung Man Lee⁶⁷ Yingchang Lu⁶⁰ Soo-Heon Kwak⁶⁸ Wei Zhao⁶⁹ John Danesh^{13,66,70} Vincent K L Lam⁶⁷ Kyong Soo Park^{68,71} Danish Saleheen^{72,73} Wing Yee So⁶⁷ Claudia H T Tam⁶⁷ Uzma Afzal⁴⁴ David Aguilar⁷⁴ Rector Arya⁷⁵ Tin Aung^{38,39,40} Edmund Chan⁷⁶ Carmen Navarro^{77,78,79} Ching-Yu Cheng^{30,38,39,40} Domenico Palli⁸⁰ Adolfo Correa⁸¹ Joanne E Curran⁸² Denis Rybin¹⁷ Vidya S Farook⁸³ Sharon P Fowler⁴⁹ Barry I Freedman⁸⁴ Michael Griswold⁸⁵ Daniel Esten Hale⁷⁵ Pamela J Hicks^{53,54,55} Chiea-Chuen Khor^{3038,39,86,87} Satish Kumar⁸² Benjamin Lehne⁴⁴ Dorothée Thuillier⁸⁸ Wei Yen Lim³⁰ Jianjun Liu^{30,87} Yvonne T van der Schouw⁸⁹ Marie Loh^{44,90,91} Solomon K Musani⁹² Sobha Puppala⁸³ William R Scott⁴⁴ Loïc Yengo⁸⁸ Sian-Tsung Tan^{45,61} Herman A Taylor Jr⁸¹ Farook Thameem⁴⁹ Gregory Wilson Sr⁹³ Tien Yin Wong^{38,39,40} Pål Rasmus Njølstad^{94,95} Jonathan C Levy¹² Massimo Mangino¹¹ Lori L Bonnycastle¹⁹ Thomas Schwarzmayer⁹⁶ João Fadista⁹⁷ Gabriela L Surdulescu¹¹ Christian Herder^{98,99} Christopher J Groves¹² Thomas Wieland⁹⁶ Jette Bork-Jensen²⁶ Ivan Brandslund^{100,101} Cramer Christensen¹⁰² Heikki A Koistinen^{103,104,105,106} Alex S F Doney¹⁰⁷ Leena Kinnunen¹⁰³ Tõnu Esko^{4,108,109,110} Andrew J Farmer¹¹¹ Liisa Hakaste^{104,112,113} Dylan Hodgkiss¹¹ Jasmina Kravic⁹⁷ Valeriya Lyssenko⁹⁷ Mette Hollensted²⁶ Marit E Jørgensen¹¹⁴ Torben Jørgensen^{115,116,117} Claes Ladvall⁹⁷ Johanne Marie Justesen²⁶ Annemari Käräjämäki^{118,119} Jennifer Kriebel^{99,120,121} Wolfgang Rathmann¹²² Lars Lannfelt⁵⁸ Torsten Lauritzen¹²³ Narisu Narisu¹⁹ Allan Linneberg^{115,124,125} Olle Melander¹²⁶ Lili Milani¹⁰⁸ Matt Neville^{12,127} Marju Orho-Melander¹²⁸ Lu Qi^{129,130} Qibin Qi^{129,131} Michael Roden^{98,99,132} Olov Rolandsson¹³³ Amy Swift¹⁹ Anders H Rosengren⁹⁷ Kathleen Stirrups¹³ Andrew R Wood⁹ Evelin Mihailov¹⁰⁸ Christine Blancher¹³⁴ Mauricio O Carneiro⁴ Jared Maguire⁴ Ryan Poplin⁴ Khalid Shakir⁴ Timothy Fennell⁴ Mark DePristo⁴ Martin Hrabé de Angelis^{99,135,136} Panos Deloukas^{137,138} Anette P Gjesing²⁶ Goo Jun^{1,29} Peter Nilsson¹³⁹ Jacquelyn Murphy⁴ Robert Onofrio⁴ Barbara Thorand^{99,120} Torben Hansen^{26,140} Christa Meisinger^{99,120} Frank B Hu^{31,129} Bo Isomaa^{112,141} Fredrik Karpe^{12,127} Liming Liang^{20,31} Annette Peters^{25,99,120} Cornelia Huth^{99,120} Stephen P O'Rahilly¹⁴² Colin N A Palmer¹⁴³ Oluf Pedersen²⁶ Rainer Rauramaa¹⁴⁴ Jaakko Tuomilehto^{103,145,146,147,148} Veikko Salomaa¹⁴⁸ Richard M Watanabe^{149,150,151} Ann-Christine Syvänen¹⁵² Richard N Bergman¹⁵³ Dwaipayan Bharadwaj¹⁵⁴ Erwin P Bottinger⁶⁰ Yoon Shin Cho¹⁵⁵ Giriraj R Chandak¹⁵⁶ Juliana C N Chan^{67,157,158} Kee Seng Chia³⁰ Mark J Daly⁶³ Shah B Ebrahim⁵⁹ Claudia Langenberg¹⁰ Paul Elliott^{44,159} Kathleen A Jablonski¹⁶⁰ Donna M Lehman⁴⁹ Weiping Jia³⁷ Ronald C W Ma^{67,157,158} Toni I Pollin¹⁶¹ Manjinder Sandhu^{13,66} Nikhil Tandon¹⁶² Philippe Froguel^{88,163} Inês Barroso^{13,142} Yik Ying Teo^{30,164,165} Eleftheria Zeggini¹³ Ruth J F Loos⁶⁰ Kerrin S Small¹¹ Janina S Ried²² Ralph A DeFronzo⁴⁹ Harald Grallert^{99,120,121} Benjamin Glaser¹⁶⁶ Andres Metspalu¹⁰⁸ Nicholas J Wareham¹⁰ Mark Walker¹⁶⁷ Eric Banks⁴ Christian Gieger^{22,120,121} Erik Ingelsson^{6,168} Hae Kyung Im²⁷ Thomas Illig^{121,169,170} Paul W Franks^{35,129,133} Gemma Buck¹³⁴ Joseph Trakalo¹³⁴ David Buck¹³⁴ Inga Prokopenko^{6,12,163} Reedik Mägi¹⁰⁸ Lars Lind¹⁷¹ Yossi Farjoun¹⁷² Katharine R Owen^{12,127} Anna L Gloyn^{6,12,127} Konstantin Strauch^{22,24} Tiinamaija Tuomi^{104,112,113,173} Jaspal Singh Kooner^{4561,174} Jong-Young Lee³² Taesung Park^{28,41} Peter Donnelly^{6,8} Andrew D Morris^{175,176} Andrew T Hattersley¹⁷⁷ Donald W Bowden^{53,54,55} Francis S Collins¹⁹ Gil Atzmon^{46,178} John C Chambers^{44,45,174} Timothy D Spector¹¹ Markku Laakso^{51,52} Tim M Strom^{96,179} Graeme I Bell¹⁸⁰ John Blangero⁸² Ravindranath Duggirala⁸³ E Shyong Tai^{30,76,181} Gilean McVean^{6,182} Craig L Hanis²⁹ James G Wilson¹⁸³ Mark Seielstad^{184,185} Timothy M Frayling⁹ James B Meigs¹⁸⁶ Nancy J Cox²⁷ Rob Slade^{15,42,187} Eric S Lander¹⁸⁸ Stacey Gabriel⁴ Noël P Burt⁴ Karen L Mohlke¹⁸⁹ Thomas Meitinger^{96,179} Leif Groop^{97,173} Goncalo Abecasis¹ Jose C Florez^{4,64,190,191} Laura J Scott¹ Andrew P Morris^{6,108,192} Hyun Min Kang¹ Michael Boehnke¹ David Altshuler^{4,5,109,190,191,193} and Mark I McCarthy^{6,12,127}

- 1 Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, USA.
- 2 Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
- 3 Center for Biomedicine, European Academy of Bolzano/Bozen (EURAC), affiliated with the University of Lübeck, Bolzano, Italy.
- 4 Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.
- 5 Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- 6 Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- 7 Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
- 8 Department of Statistics, University of Oxford, Oxford, UK.
- 9 Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK.
- 10 MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
- 11 Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
- 12 Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
- 13 Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
- 14 School of Computer Science, McGill University, Montreal, Quebec, Canada.
- 15 McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada.
- 16 Human Genetics Center, The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
- 17 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
- 18 National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA.
- 19 Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
- 20 Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA.
- 21 Chronic Disease Epidemiology, Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.
- 22 Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
- 23 Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany.
- 24 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany.
- 25 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
- 26 The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- 27 Department of Medicine, Section of Genetic Medicine, The University of Chicago, Chicago, Illinois, USA.
- 28 Department of Statistics, Seoul National University, Seoul, Republic of Korea.
- 29 Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
- 30 Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore.
- 31 Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.
- 32 Center for Genome Science, Korea National Institute of Health, Chungcheongbuk-do, Republic of Korea.
- 33 The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
- 34 Departments of Computational Medicine & Bioinformatics and Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.
- 35 Department of Clinical Sciences, Lund University Diabetes Centre, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden.

36 Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, Colorado, USA.

37 Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

38 Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.

39 Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore.

40 The Eye Academic Clinical Programme, Duke-NUS Graduate Medical School, Singapore.

41 Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Republic of Korea.

42 Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

43 Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.

44 Department of Epidemiology and Biostatistics, Imperial College London, London, UK.

45 Department of Cardiology, Ealing Hospital NHS Trust, Southall, Middlesex, UK.

46 Departments of Medicine and Genetics, Albert Einstein College of Medicine, New York, USA.

47 Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

48 Department of Genetics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

49 Department of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA.

50 Research, South Texas Veterans Health Care System, San Antonio, Texas, USA.

51 Faculty of Health Sciences, Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.

52 Kuopio University Hospital, Kuopio, Finland.

53 Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

54 Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

55 Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

56 Centre for Research in Epidemiology and Population Health, Inserm U1018, Villejuif, France.

57 German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.

58 Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, Sweden.

59 Centre for Chronic Disease Control, New Delhi, India.

60 The Charles Bronfman Institute for Personalized Medicine, The Icahn School of Medicine at Mount Sinai, New York, USA.

61 National Heart and Lung Institute, Cardiovascular Sciences, Hammersmith Campus, Imperial College London, London, UK.

62 Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington, USA.

63 Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

64 Center for Human Genetic Research, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

65 Department of Psychiatry, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, USA.

66 Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

67 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

68 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

69 Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

70 NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

71 Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Republic of Korea.

72 Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

73 Center for Non-Communicable Diseases, Karachi, Pakistan.

74 Cardiovascular Division, Baylor College of Medicine, Houston, Texas, USA.

75 Department of Pediatrics, University of Texas Health Science Center, San Antonio, Texas, USA.

76 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore.

77 Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.

78 CIBER Epidemiología y Salud Pública (CIBERESP), Spain.

79 Unit of Preventive Medicine and Public Health, School of Medicine, University of Murcia, Spain.

80 Cancer Research and Prevention Institute (ISPO), Florence, Italy.

81 Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.

82 South Texas Diabetes and Obesity Institute, Regional Academic Health Center, University of Texas Rio Grande Valley, Brownsville, Texas, USA.

83 Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, USA.

84 Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

85 Center of Biostatistics and Bioinformatics, University of Mississippi Medical Center, Jackson, Mississippi, USA.

86 Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore.

87 Division of Human Genetics, Genome Institute of Singapore, A*STAR, Singapore.

88 CNRS-UMR8199, Lille University, Lille Pasteur Institute, Lille, France.

89 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.

90 Institute of Health Sciences, University of Oulu, Oulu, Finland.

91 Translational Laboratory in Genetic Medicine (TLGM), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.

92 Jackson Heart Study, University of Mississippi Medical Center, Jackson, Mississippi, USA.

93 College of Public Services, Jackson State University, Jackson, Mississippi, USA.

94 KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway.

95 Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.

96 Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

97 Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malmö, Sweden.

98 Institute of Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.

99 German Center for Diabetes Research (DZD), Neuherberg, Germany.

100 Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

101 Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark.

102 Department of Internal Medicine and Endocrinology, Vejle Hospital, Vejle, Denmark.

103 Department of Health, National Institute for Health and Welfare, Helsinki, Finland.

104 Abdominal Center: Endocrinology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

105 Minerva Foundation Institute for Medical Research, Helsinki, Finland.

106 Department of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

107 Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, UK.

108 Estonian Genome Center, University of Tartu, Tartu, Estonia.

109 Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.

110 Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.

111 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

112 Folkhälsan Research Centre, Helsinki, Finland.

113 Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland.

114 Steno Diabetes Center, Gentofte, Denmark.

115 Research Centre for Prevention and Health, Capital Region of Denmark, Glostrup, Denmark.

116 Department of Public Health, Institute of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

117 Faculty of Medicine, Aalborg University, Aalborg, Denmark.

118 Department of Primary Health Care, Vaasa Central Hospital, Vaasa, Finland.

119 Diabetes Center, Vaasa Health Care Center, Vaasa, Finland.

120 Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

121 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

122 Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.

123 Department of Public Health, Section of General Practice, Aarhus University, Aarhus, Denmark.

124 Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark.

125 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

126 Department of Clinical Sciences, Hypertension and Cardiovascular Disease, Lund University, Malmö, Sweden.

127 Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, UK.

128 Department of Clinical Sciences, Diabetes and Cardiovascular Disease, Genetic Epidemiology, Lund University, Malmö, Sweden.

129 Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA.

130 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

131 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, USA.

132 Department of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.

133 Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

134 High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

135 Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

136 Center of Life and Food Sciences Weihenstephan, Technische Universität München, Freising-Weihenstephan, Germany.

137 William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

138 Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia.

139 Department of Clinical Sciences, Medicine, Lund University, Malmö, Sweden.

140 Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

141 Department of Social Services and Health Care, Jakobstad, Finland.

142 Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

143 Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.

144 Foundation for Research in Health, Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, Finland.

145 Center for Vascular Prevention, Danube University Krems, Krems, Austria.

146 Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.

147 Instituto de Investigacion Sanitaria del Hospital Universitario LaPaz (IdiPAZ), University Hospital LaPaz, Autonomous University of Madrid, Madrid, Spain.

148 National Institute for Health and Welfare, Helsinki, Finland.

149 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

150 Department of Physiology & Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

151 Diabetes and Obesity Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

152 Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

153 Cedars-Sinai Diabetes and Obesity Research Institute, Los Angeles, California, USA.

154 Functional Genomics Unit, CSIR-Institute of Genomics & Integrative Biology (CSIR-IGIB), New Delhi, India.

155 Department of Biomedical Science, Hallym University, Chuncheon, Republic of Korea.

156 CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India.

157 Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.

158 Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, China.

159 MRC-PHE Centre for Environment and Health, Imperial College London, London, UK.

160 The Biostatistics Center, The George Washington University, Rockville, Maryland, USA.

161 Department of Medicine, Division of Endocrinology, Diabetes and Nutrition, and Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

162 Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.

163 Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK.

164 Life Sciences Institute, National University of Singapore, Singapore.

165 Department of Statistics and Applied Probability, National University of Singapore, Singapore.

166 Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

167 The Medical School, Institute of Cellular Medicine, Newcastle University, Newcastle, UK.

168 Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

169 Hannover Unified Biobank, Hannover Medical School, Hanover, Germany.

170 Institute for Human Genetics, Hannover Medical School, Hanover, Germany.

171 Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

172 Data Sciences and Data Engineering, Broad Institute, Cambridge, Massachusetts, USA.

173 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

174 Imperial College Healthcare NHS Trust, Imperial College London, London, UK.

175 Clinical Research Centre, Centre for Molecular Medicine, Ninewells Hospital and Medical School, Dundee, UK.

176 The Usher Institute to the Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.

177 University of Exeter Medical School, University of Exeter, Exeter, UK.

178 Department of Natural Science, University of Haifa, Haifa, Israel.

179 Institute of Human Genetics, Technische Universität München, Munich, Germany.

180 Departments of Medicine and Human Genetics, The University of Chicago, Chicago, Illinois, USA.

181 Cardiovascular & Metabolic Disorders Program, Duke-NUS Medical School Singapore, Singapore.

182 Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.

183 Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, USA.

184 Department of Laboratory Medicine & Institute for Human Genetics, University of California, San Francisco, San Francisco, California, USA.

185 Blood Systems Research Institute, San Francisco, California, USA.

186 General Medicine Division, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

187 Division of Endocrinology and Metabolism, Department of Medicine, McGill University, Montreal, Quebec, Canada.

188 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

189 Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.

190 Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

191 Diabetes Research Center (Diabetes Unit), Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

192 Department of Biostatistics, University of Liverpool, Liverpool, UK.

193 Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

The EPIC InterAct Consortium

Claudia Langenberg(1), Robert A Scott(1), Stephen J Sharp(1), Nita G Forouhi(1), Nicola D Kerrison(1), Matt Sims(1), Debora ME Lucarelli(1), Inês Barroso(2,3), Panos Deloukas(2), Mark I McCarthy(4,5,6), Antonio Agudo(7), Beverley Balkau(8), Aurelio Barricarte(9,10,11), Heiner Boeing(12), Miren Dorransoro(13,14,11), Paul W Franks(15,16), Sara Grioni(17), Rudolf Kaaks(18), Timothy J Key(19), Carmen Navarro(20,11,21), Peter M Nilsson(15), Kim Overvad(22,23), Domenico Palli(24), Salvatore Panico(25), J. Ramón Quirós(26), Olov Rolandsson(16), Carlotta Sacerdote(27,28), María-José Sánchez(29,11,30), Nadia Slimani(31), Annemieke MW Spijkerman(32), Anne Tjønneland(33), Rosario Tumino(34,35), Yvonne T van der Schouw(36), Elio Riboli(37), Nicholas J Wareham(1)

(1) MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom, (2) The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, (3) University of Cambridge Metabolic Research Laboratories, Cambridge, UK, (4) Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, UK, (5) Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, (6) Oxford NIHR Biomedical Research Centre, Oxford, UK, (7) Catalan Institute of Oncology (ICO), Barcelona, Spain, (8) CESP, University Paris-South, Faculty of Medicine, University Versailles-St Quentin, Inserm U1018, University Paris- Saclay, Villejuif, France, (9) Navarre Public Health Institute (ISPN), Pamplona, Spain, (10) Navarra Institute for Health Research (IdiSNA) Pamplona, Spain, (11) CIBER de Epidemiología y Salud Pública (CIBERESP), Spain, (12) German Institute of Human Nutrition Potsdam-Rehbruecke, Germany, (13) Public Health Division of Gipuzkoa, San Sebastian, Spain, (14) Instituto BIO-Donostia, Basque Government, San Sebastian, Spain, (15) Lund University, Malmö, Sweden, (16) Umeå University, Umeå, Sweden, (17) Epidemiology and Prevention Unit, Milan, Italy, (18) Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, (19) University of Oxford, United Kingdom, (20) Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain, (21) Unit of Preventive Medicine and Public Health, School of Medicine, University of Murcia, Spain, (22) Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark, (23) Aalborg University Hospital, Aalborg, Denmark, (24) Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Florence, Italy, (25) Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy, (26) Public Health Directorate, Asturias, Spain, (27) Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital- University of Turin and Center for Cancer Prevention (CPO), Torino, Italy, (28) Human Genetics Foundation (HuGeF), Torino, Italy, (29) Andalusian School of Public Health, Granada, Spain, (30) Instituto de Investigación Biosanitaria de Granada (Granada.ibs), Granada (Spain), (31) International Agency for Research on Cancer, Lyon, France, (32) National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, (33) Danish Cancer Society Research Center, Copenhagen, Denmark, (34) ASP Ragusa, Italy, (35) AIRE - ONLUS, Ragusa, Italy, (36) Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands, (37) School of Public Health, Imperial College London, UK

INTERVAL Study

Di Angelantonio E1, Thompson SG2, Kaptoge S2, Moore C2, Walker M2, Armitage J3, Ouweland WH4, Roberts DJ5, Danesh J6

1 NHS Blood and Transplant, Cambridge, UK; NHS Blood and Transplant, Oxford, UK; Department of Public Health and Primary Care, Strangeways Research Laboratory, Cambridge, UK; NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Strangeways Research Laboratory, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK; British Heart Foundation Cambridge Centre for Research Excellence, Addenbrooke's Hospital, Cambridge, UK.

2 Department of Public Health and Primary Care, Strangeways Research Laboratory, Cambridge, UK; NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Strangeways Research

Laboratory, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK; British Heart Foundation Cambridge Centre for Research Excellence, Addenbrooke's Hospital, Cambridge, UK.

3 Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; MRC Population Health Research Unit, University of Oxford, Oxford, UK.

4 NHS Blood and Transplant, Cambridge, UK; NHS Blood and Transplant, Oxford, UK; British Heart Foundation Cambridge Centre for Research Excellence, Addenbrooke's Hospital, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

5 NHS Blood and Transplant, Cambridge, UK; NHS Blood and Transplant, Oxford, UK; NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Strangeways Research Laboratory, Cambridge, UK; NIHR Oxford Biomedical Research Centre-Haematology Theme and Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.

6 Department of Public Health and Primary Care, Strangeways Research Laboratory, Cambridge, UK; NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Strangeways Research Laboratory, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK; British Heart Foundation Cambridge Centre for Research Excellence, Addenbrooke's Hospital, Cambridge, UK

ReproGen Consortium

Felix R Day^{1,163}, Deborah J Thompson^{2,163}, Hannes Helgason^{3,4,163}, Daniel I Chasman^{5,6}, Hilary Finucane^{7,8}, Patrick Sulem³, Katherine S Ruth⁹, Sean Whalen¹⁰, Abhishek K Sarkar^{11,12}, Eva Albrecht¹³, Elisabeth Altmaier^{14,15}, Marzyeh Amini¹⁶, Caterina M Barbieri¹⁷, Thibaud Boutin¹⁸, Archie Campbell¹⁹, Ellen Demerath²⁰, Ayush Giri^{21,22}, Chunyan He^{23,24}, Jouke J Hottenga²⁵, Robert Karlsson²⁶, Ivana Kolcic²⁷, Po-Ru Loh^{7,28}, Kathryn L Lunetta^{29,30}, Massimo Mangino^{31,32}, Brumat Marco³³, George McMahon³⁴, Sarah E Medland³⁵, Ilja M Nolte¹⁶, Raymond Noordam³⁶, Teresa Nutile³⁷, Lavinia Paternoster^{34,38}, Natalia Perjakova³⁹, Eleonora Porcu⁴⁰, Lynda M Rose⁵, Katharina E Schraut^{41,42}, Ayellet V Segrè⁴³, Albert V Smith^{44,45}, Lisette Stolk⁴⁶, Alexander Teumer⁴⁷, Irene L Andrusis^{48,49}, Stefania Bandinelli⁵⁰, Matthias W Beckmann⁵¹, Javier Benitez^{52,53}, Sven Bergmann^{54,55}, Murielle Bochud⁵⁶, Eric Boerwinkle⁵⁷, Stig E Bojesen^{58–60}, Manjeet K Bolla², Judith S Brand²⁶, Hiltrud Brauch^{61–63}, Hermann Brenner^{63–65}, Linda Broer⁴⁶, Thomas Brüning⁶⁶, Julie E Buring^{5,6}, Harry Campbell⁴², Eulalia Catamo⁶⁷, Stephen Chanock⁶⁸, Georgia Chenevix-Trench⁶⁹, Tanguy Corre^{54–56}, Fergus J Couch⁷⁰, Diana L Cousminer^{71,72}, Angela Cox⁷³, Laura Crisponi⁴⁰, Kamila Czene²⁶, George Davey Smith^{34,38}, Eco J C N de Geus²⁵, Renée de Mutsert⁷⁴, Immaculata De Vivo^{7,75}, Joe Dennis², Peter Devilee^{76,77}, Isabel dos-Santos-Silva⁷⁸, Alison M Dunning⁷⁹, Johan G Eriksson⁸⁰, Peter A Fasching^{51,81}, Lindsay Fernández-Rhodes⁸², Luigi Ferrucci⁸³, Dieter Flesch-Janys^{84,85}, Lude Franke⁸⁶, Marika Gabrielson²⁶, Ilaria Gandin³³, Graham G Giles^{87,88}, Harald Grallert^{14,15,89}, Daniel F Gudbjartsson^{3,4}, Pascal Guénel⁹⁰, Per Hall²⁶, Emily Hallberg⁹¹, Ute Hamann⁹², Tamara B Harris⁹³, Catharina A Hartman⁹⁴, Gerardo Heiss⁸², Maartje J Hoening⁹⁵, John L Hopper⁸⁸, Frank Hu^{75,96}, David J Hunter^{7,75,96}, M Arfan Ikram⁹⁷, Hae Kyung Im⁹⁸, Marjo-Riitta Järvelin^{99–103}, Peter K Joshi⁴², David Karasik^{6,104}, Manolis Kellis^{11,12}, Zoltan Kutalik^{54,56}, Genevieve LaChance³¹, Diether Lambrechts^{105,106}, Claudia Langenberg¹, Lenore J Launer⁹³, Joop S E Laven¹⁰⁷, Stefania Lenarduzzi⁶⁷, Jingmei Li²⁶, Penelope A Lind³⁵, Sara Lindstrom¹⁰⁸, YongMei Liu¹⁰⁹, Jian'an Luan¹, Reedik Mägi³⁹, Arto Mannermaa^{110–112}, Hamdi Mbarek²⁵, Mark I McCarthy^{113–115}, Christa Meisinger^{14,116}, Thomas Meitinger¹¹⁷, Cristina Menni³¹, Andres Metspalu³⁹, Kyriaki Michailidou^{2,118}, Lili Milani³⁹, Roger L Milne^{87,88}, Grant W Montgomery¹¹⁹, Anna M Mulligan^{120,121}, Mike A Nalls¹²², Pau Navarro¹⁸, Heli Nevanlinna¹²³, Dale R Nyholt¹²⁴, Albertine J Oldehinkel¹²⁵, Tracy A O'Mara⁶⁹, Sandosh Padmanabhan¹²⁶, Aarno Palotie^{28,127–131}, Nancy Pedersen²⁶, Annette Peters^{14,89}, Julian Peto⁷⁸, Paul D P Pharoah^{2,79}, Anneli Pouta¹³², Paolo Radice¹³³, Iffat Rahman¹³⁴, Susan M Ring^{34,38}, Antonietta Robino⁶⁷, Frits R Rosendaal⁷⁴, Igor Rudan⁴², Rico Rueedi^{54,55}, Daniela Ruggiero³⁷, Cinzia F Sala¹⁷, Marjanka K Schmidt^{135,136}, Robert A Scott¹, Mitul Shah⁷⁹, Rossella Sorice³⁷, Melissa C Southey¹³⁷, Ulla Sovio^{99,138}, Meir Stampfer^{7,75}, Maristella Steri⁴⁰, Konstantin Strauch^{13,139}, Toshiko Tanaka⁸³, Emmi Tikkanen^{131,140}, Nicholas J Timpson^{34,38}, Michela Traglia¹⁷, Thérèse Truong⁹⁰, Jonathan P Tyrer⁷⁹, André G Uitterlinden^{46,97}, Digna R Velez Edwards^{22,141,142}, Veronique Vitart¹⁸, Uwe Völker¹⁴³, Peter Vollenweider¹⁴⁴, Qin Wang², Elisabeth Widen¹³¹, Ko Willems van Dijk^{77,145,146}, Gonneke Willemsen²⁵, Robert Winqvist^{147,148}, Bruce H R Wolffenbuttel¹⁴⁹, Jing Hua Zhao¹, Magdalena Zoledziewska⁴⁰, Marek Zygmunt¹⁵⁰, Behrooz Z Alizadeh¹⁶, Dorret I Boomsma²⁵, Marina Ciullo³⁷,

Francesco Cucca^{40,151}, Tõnu Esko^{28,39}, Nora Franceschini⁸², Christian Gieger^{14,15,89}, Vilmundur Gudnason^{44,45}, Caroline Hayward¹⁸, Peter Kraft^{7,152}, Debbie A Lawlor^{34,38}, Patrik K E Magnusson²⁶, Nicholas G Martin³⁵, Dennis O Mook-Kanamori^{74,153}, Ellen A Nohr¹⁵⁴, Ozren Polasek²⁷, David Porteous¹⁹, Alkes L Price^{7,8,28}, Paul M Ridker^{5,6}, Harold Snieder¹⁶, Tim D Spector³¹, Doris Stöckl^{14,155}, Daniela Toniolo¹⁷, Sheila Ulivi⁶⁷, Jenny A Visser⁴⁶, Henry Völzke⁴⁷, Nicholas J Wareham¹, James F Wilson^{18,42}, The LifeLines Cohort Study¹⁵⁶, The InterAct Consortium¹⁵⁶, kConFab/AOCS Investigators¹⁵⁶, Endometrial Cancer Association Consortium¹⁵⁶, Ovarian Cancer Association Consortium¹⁵⁶, PRACTICAL consortium¹⁵⁶, Amanda B Spurdle⁶⁹, Unnur Thorsteindottir^{3,44}, Katherine S Pollard^{10,157}, Douglas F Easton^{2,79}, Joyce Y Tung¹⁵⁸, Jenny Chang-Claude^{159,160}, David Hinds¹⁵⁸, Anna Murray⁹, Joanne M Murabito^{30,161}, Kari Stefansson^{3,44,164}, Ken K Ong^{1,162,164} & John R B Perry^{1,164}

1MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK. 2Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. 3deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. 4School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland. 5Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. 6Harvard Medical School, Boston, Massachusetts, USA. 7Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. 8Department of Mathematics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 9Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK. 10Gladstone Institutes, San Francisco, California, USA. 11Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 12Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. 13Institute of Genetic Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. 14Institute of Epidemiology II, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. 15Research Unit of Molecular Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. 16Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 17Genetics of Common Disorders Unit, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy. 18Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. 19Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. 20Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA. 21Division of Epidemiology, Institute for Medicine and Public Health, Vanderbilt University, Nashville, Tennessee, USA. 22Vanderbilt Genetics Institute, Vanderbilt University, Nashville, Tennessee, USA. 23Department of Epidemiology, Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, Indiana, USA. 24Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA. 25Department of Biological Psychology, VU University Amsterdam, Amsterdam, the Netherlands. 26Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 27Faculty of Medicine, University of Split, Split, Croatia. 28Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA. 29Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. 30NHLBI's and Boston University's Framingham Heart Study, Framingham, Massachusetts, USA. 31Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. 32National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' Foundation Trust, London, UK. 33Department of Clinical Medical Sciences, Surgical and Health, University of Trieste, Trieste, Italy. 34School of Social and Community Medicine, University of Bristol, Bristol, UK. 35QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 36Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands. 37Institute of Genetics and Biophysics, CNR, Naples, Italy. 38MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. 39Estonian Genome Center, University of Tartu, Tartu, Estonia. 40Institute of Genetics and Biomedical Research, National Research Council, Cagliari, Italy. 41Centre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK. 42Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. 43Cancer Program, Broad Institute, Cambridge, Massachusetts,

USA. 44Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 45Icelandic Heart Association, Kopavogur, Iceland. 46Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands. 47Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. 48Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada. 49Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. 50Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy. 51Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany. 52Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. 53Centro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain. 54Swiss Institute of Bioinformatics, Lausanne, Switzerland. 55Department of Computational Biology, University of Lausanne, Lausanne, Switzerland. 56Institute of Social and Preventive Medicine, University Hospital of Lausanne, Lausanne, Switzerland. 57Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas, USA. 58Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark. 59Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark. 60Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 61Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. 62University of Tübingen, Tübingen, Germany. 63German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. 64Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. 65Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. 66Institute for Prevention and Occupational Medicine of German Social Accident Insurance, Institute of Ruhr University Bochum (IPA), Bochum, Germany. 67Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. 68Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA. 69Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 70Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 71Division of Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 72Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 73Academic Unit of Molecular Oncology, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. 74Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. 75Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 76Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. 77Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands. 78Non-Communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London, UK. 79Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. 80Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland. 81David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California, USA. 82Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA Nicholas J Timpson34,38, Michela Traglia17, Thérèse Truong90, Jonathan P Tyrer79, André G Uitterlinden46,97, Digna R Velez Edwards22,141,142, Veronique Vitart18, Uwe Völker143, Peter Vollenweider144, Qin Wang2, Elisabeth Widen131, Ko Willems van Dijk77,145,146, Gonneke Willemsen25, Robert Winqvist147,148, Bruce H R Wolffenbuttel149, Jing Hua Zhao1, Magdalena Zoledziewska40, Marek Zygmunt150, Behrooz Z Alizadeh16, Dorret I Boomsma25, Marina Ciullo37, Francesco Cucca40,151, Tõnu Esko28,39, Nora Franceschini82, Christian Gieger14,15,89, Vilmundur Gudnason44,45, Caroline Hayward18, Peter Kraft7,152, Debbie A Lawlor34,38, Patrik K E Magnusson26, Nicholas G Martin35, Dennis O Mook-Kanamori74,153, Ellen A Nohr154, Ozren Polasek27, David Porteous19, Alkes L Price7,8,28, Paul M Ridker5,6, Harold Snieder16, Tim D Spector31, Doris Stöckl14,155, Daniela Toniolo17, Sheila Ulivi67, Jenny A Visser46, Henry Völzke47, Nicholas J Wareham1, James F Wilson18,42, The LifeLines Cohort Study156, The InterAct Consortium156, kConFab/AOCS Investigators156, Endometrial Cancer Association Consortium156, Ovarian Cancer Association Consortium156, PRACTICAL consortium156, Amanda B Spurdle69, Unnur Thorsteindottir3,44, Katherine S Pollard10,157, Douglas F Easton2,79, Joyce Y Tung158, Jenny Chang-Claude159,160, David Hinds158, Anna Murray9, Joanne M Murabito30,161, Kari Stefansson3,44,164, Ken K Ong1,162,164 & John R B Perry1,1641MRC Epidemiology Unit, University of Cambridge School of

Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK. 2Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. 3deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. 4School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland. 5Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. 6Harvard Medical School, Boston, Massachusetts, USA. 7Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. 8Department of Mathematics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 9Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK. 10Gladstone Institutes, San Francisco, California, USA. 11Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 12Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. 13Institute of Genetic Epidemiology, Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany. 14Institute of Epidemiology II, Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany. 15 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany. 16Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 17Genetics of Common Disorders Unit, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy. 18Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. 19 Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. 20Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA. 21Division of Epidemiology, Institute for Medicine and Public Health, Vanderbilt University, Nashville, Tennessee, USA. 22Vanderbilt Genetics Institute, Vanderbilt University, Nashville, Tennessee, USA. 23Department of Epidemiology, Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, Indiana, USA. 24Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA. 25Department of Biological Psychology, VU University Amsterdam, Amsterdam, the Netherlands. 26Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 27Faculty of Medicine, University of Split, Split, Croatia. 28Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA. 29Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. 30NHLBI's and Boston University's Framingham Heart Study, Framingham, Massachusetts, USA. 31Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. 32National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' Foundation Trust, London, UK. 33Department of Clinical Medical Sciences, Surgical and Health, University of Trieste, Trieste, Italy. 34School of Social and Community Medicine, University of Bristol, Bristol, UK. 35QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 36Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands. 37Institute of Genetics and Biophysics, CNR, Naples, Italy. 38MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. 39Estonian Genome Center, University of Tartu, Tartu, Estonia. 40Institute of Genetics and Biomedical Research, National Research Council, Cagliari, Italy. 41Centre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK. 42Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. 43Cancer Program, Broad Institute, Cambridge, Massachusetts, USA. 44Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 45Icelandic Heart Association, Kopavogur, Iceland. 46Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands. 47Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. 48Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada. 49Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. 50Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy. 51Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany. 52Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. 53Centro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain. 54Swiss Institute of Bioinformatics, Lausanne, Switzerland. 55Department of Computational Biology, University of Lausanne, Lausanne, Switzerland. 56Institute of Social and Preventive Medicine, University Hospital of Lausanne, Lausanne, Switzerland. 57Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas, USA.

58Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark. 59Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark. 60Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 61Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. 62University of Tübingen, Tübingen, Germany. 63German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. 64Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. 65Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. 66Institute for Prevention and Occupational Medicine of German Social Accident Insurance, Institute of Ruhr University Bochum (IPA), Bochum, Germany. 67Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. 68Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA. 69Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 70Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 71Division of Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 72Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 73Academic Unit of Molecular Oncology, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. 74Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. 75Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 76Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. 77Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands. 78Non-Communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London, UK. 79Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. 80Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland. 81David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California, USA. 82Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA

The MAGIC Investigators

Eleanor Wheeler¹, Aaron Leong^{2,3}, Ching-Ti Liu⁴, Marie-France Hivert^{5,6}, Rona J. Strawbridge^{7,8}, Clara Podmore^{9,10}, Man Li^{11,12,13}, Jie Yao¹⁴, Xueling Sim¹⁵, Jaeyoung Hong⁴, Audrey Y. Chu^{16,17}, Weihua Zhang^{18,19}, Xu Wang²⁰, Peng Chen^{15,21,22,23}, Nisa M. Maruthur^{11,24,25}, Bianca C. Porneala², Stephen J. Sharp⁹, Yucheng Jia¹⁴, Edmond K. Kabagambe²⁶, Li-Ching Chang²⁷, Wei-Min Chen²⁸, Cathy E. Elks^{9,29}, Daniel S. Evans³⁰, Qiao Fan³¹, Franco Giulianini¹⁷, Min Jin Go³², Jouke-Jan Hottenga³³, Yao Hu³⁴, Anne U. Jackson³⁵, Stavroula Kanoni³⁶, Young Jin Kim³², Marcus E. Kleber³⁷, Claes Ladvall^{38,39}, Cecile Lecoeur⁴⁰, Sing-Hui Lim⁴¹, Yingchang Lu^{42,43}, Anubha Mahajan⁴⁴, Carola Marzi^{45,46}, Mike A. Nalls^{47,48}, Pau Navarro⁴⁹, Ilja M. Nolte⁵⁰, Lynda M. Rose¹⁷, Denis V. Rybin^{4,51}, Serena Sanna⁵², Yuan Shi⁴¹, Daniel O. Stram⁵³, Fumihiko Takeuchi⁵⁴, Shu Pei Tan⁴¹, Peter J. van der Most⁵⁰, Jana V. Van Vliet- Ostaptchouk^{50,55}, Andrew Wong⁵⁶, Loic Yengo⁴⁰, Wanting Zhao⁴¹, Anuj Goel^{44,57}, Maria Teresa Martinez Larrad⁵⁸, Doerte Radke⁵⁹, Perttu Salo^{60,61}, Toshiko Tanaka⁶², Erik P. A. van Iperen^{63,64}, Goncalo Abecasis³⁵, Saima Afaq¹⁸, Behrooz Z. Alizadeh⁵⁰, Alain G. Bertoni⁶⁵, Amelie Bonnefond⁴⁰, Yvonne Bottcher⁶⁶, Erwin P. Bottinger⁴², Harry Campbell⁶⁷, Olga D. Carlson⁶⁸, Chien-Hsiun Chen^{27,69}, Yoon Shin Cho^{32,70}, W. Timothy Garvey⁷¹, Christian Gieger⁴⁵, Mark O. Goodarzi⁷², Harald Grallert^{45,46}, Anders Hamsten^{7,8}, Catharina A. Hartman⁷³, Christian Herder^{74,75}, Chao Agnes Hsiung⁷⁶, Jie Huang⁷⁷, Michiya Igase⁷⁸, Masato Isono⁵⁴, Tomohiro Katsuya^{79,80}, Chia-Chuen Khor⁸¹, Wieland Kiess^{82,83}, Katsuhiko Kohara⁸⁴, Peter Kovacs⁶⁶, Juyoung Lee³², Wen-Jane Lee⁸⁵, Benjamin Lehne¹⁸, Huaixing Li³⁴, Jianjun Liu^{15,81}, Stephane Lobbens⁴⁰, Jian'an Luan⁹, Valeriya Lyssenko³⁹, Thomas Meitinger^{86,87,88}, Tetsuro Miki⁷⁸, Iva Miljkovic⁸⁹, Sanghoon Moon³², Antonella Mulas⁵², Gabriele Muller⁹⁰, Martina Müller-Nurasyid^{91,92,93}, Ramaiah Nagaraja⁹⁴, Matthias Nauck⁹⁵, James S. Pankow⁹⁶, Ozren Polasek^{97,98}, Inga Prokopenko^{44,99,100}, Paula S. Ramos¹⁰¹, Laura Rasmussen-Torvik¹⁰², Wolfgang Rathmann⁷⁵, Stephen S. Rich¹⁰³, Neil R. Robertson^{99,104}, Michael Roden^{74,75,105}, Ronan Roussel^{106,107,108}, Igor Rudan¹⁰⁹, Robert A. Scott⁹, William R. Scott^{18,19}, Bengt Sennblad^{7,8,110}, David S. Siscovick¹¹¹, Konstantin Strauch^{91,112}, Liang Sun³⁴, Morris Swertz¹¹³, Salman M. Tajuddin¹¹⁴, Kent D. Taylor¹⁴, Yik-Ying Teo^{15,20,81,115,116}, Yih Chung Tham⁴¹, Anke Teijssen¹¹⁷, Nicholas J. Wareham⁹, Gonneke Willemsen³³, Tom Wilsgaard¹¹⁸, Aroon D.

Hingorani119, Josephine Egan68, Luigi Ferrucci68, G. Kees Hovingh120, Antti Jula60, Mika Kivimaki121, Meena Kumari121,122, Inger Njølstad118, Colin N. A. Palmer123, Manuel Serrano Ríos58, Michael Stumvoll117, Hugh Watkins44,57, Tin Aung41,124,125,126, Matthias Bluher117, Michael Boehnke35, Dorret I. Boomsma33, Stefan R. Bornstein127, John C. Chambers18,19,128, Daniel I. Chasman17,129,130, Yii-Der Ida Chen14, Yduan-Tsong Chen27, Ching-Yu Cheng41,124,125,126, Francesco Cucca52,131, Eco J. C. de Geus33, Panos Deloukas36,132, Michele K. Evans114, Myriam Fornage133, Yechiel Friedlander134, Philippe Froguel100,135, Leif Groop39,136, Myron D. Gross137, Tamara B. Harris138, Caroline Hayward139, Chew-Kiat Heng140,141, Erik Ingelsson142,143, Norihiro Kato54, Bong-Jo Kim32, Woon-Puay Koh15,144, Jaspal S. Kooner19,128,145, Antje Körner82,83, Diana Kuh56, Johanna Kuusisto146, Markku Laakso146, Xu Lin34, Yongmei Liu147, Ruth J. F. Loos42,43,148, Patrik K. E. Magnusson149, Winfried März37,150,151, Mark I. McCarthy99,104,152, Albertine J. Oldehinkel73, Ken K. Ong9, Nancy L. Pedersen149, Mark A. Pereira96, Annette Peters45, Paul M. Ridker17,153, Charumathi Sabanayagam41,124, Michele Sale103, Danish Saleheen154,155, Juha Saltevo156, Peter EH. Schwarz127, Wayne H. H. Sheu157,158,159, Harold Snieder50, Timothy D. Spector160, Yasuharu Tabara161, Jaakko Tuomilehto162,163,164,165, Rob M. van Dam15, James G. Wilson166, James F. Wilson49,67, Bruce H. R. Wolffenbuttel55, Tien Yin Wong41,124,125,126, Jer-Yuarn Wu27,69, Jian-Min Yuan89,167, Alan B. Zonderman168, Nicole Soranzo1,169,170, Xiuqing Guo14, David J. Roberts171,172, Jose C. Florez3,173,174, Robert Sladek175, José Dupuis4,16, Andrew P. Morris104,176, E-Shyong Tai15,144,177, Elizabeth Selvin11,24,25, Jerome I. Rotter14, Claudia Langenberg9, Inês Barroso1,178, James B. Meigs2,3,174

1 Department of Human Genetics, Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge, United Kingdom, **2** Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, United States of America, **3** Harvard Medical School, Boston, MA, United States of America, **4** Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America, **5** Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA, United States of America, **6** Massachusetts General Hospital, Boston, MA, United States of America, **7** Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, **8** Centre for Molecular Medicine, Karolinska Universitetsjukhuset, Solna, Sweden, **9** MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, **10** Department of Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland, **11** Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America, **12** Division of Nephrology, University of Utah, Salt Lake City, UT, United States of America, **13** Department of Human Genetics, University of Utah, Salt Lake City, UT, United States of America, **14** Institute for Translational Genomics and Population Sciences, Department of Pediatrics, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, United States of America, **15** Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, **16** National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, United States of America, **17** Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America, **18** Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom, **19** Department of Cardiology, Ealing Hospital NHS Trust, Southall, Middlesex, United Kingdom, **20** Life Sciences Institute, National University of Singapore, Singapore, Singapore, **21** Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, United States of America, **22** Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China, **23** College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China, **24** Division of General Internal Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, **25** Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins University, Baltimore, MD, United States of America, **26** Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States of America, **27** Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, **28** University of Virginia Center for Public Health Genomics, Charlottesville, VA, United States of America, **29** Personalised Healthcare & Biomarkers, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom, **30** California Pacific Medical Center Research Institute, San Francisco, CA, United States of America, **31** Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore, **32** Division of Structural and Functional Genomics, Center for Genome Science, Korean National Institute of Health,

Osong, Chungchungbuk-do, South Korea, **33** Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, **34** The Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, People's Republic of China, **35** Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, United States of America, **36** William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, **37** Vth Department of Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, **38** Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, **39** Lund University Diabetes Centre, Lund University, Lund, Sweden, **40** University of Lille, CNRS, Institut Pasteur of Lille, UMR 8199—EGID, Lille, France, **41** Singapore Eye Research Institute, The Academia Level 6, Discovery Tower, Singapore, Singapore, **42** The Charles Bronfman Institute for Personalized Medicine, The Icahn School of Medicine at Mount Sinai, New York, NY, United States of America, **43** The Genetics of Obesity and Related Metabolic Traits Program, The Icahn School of Medicine at Mount Sinai, New York, NY, United States of America, **44** Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, **45** Institute of Epidemiology II, Research Unit of Molecular Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany, **46** German Center for Diabetes Research (DZD e.V.), Partner Munich, Munich, Germany, **47** Data Tecnica International, Glen Echo, MD, United States of America, **48** Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, United States of America, **49** MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, Scotland, **50** Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, **51** Data Coordinating Center, Boston University School of Public Health, Boston, MA, United States of America, **52** Istituto di Ricerca Genetica e Biomedica (IRGB), CNR, Monzerrato, Italy, **53** Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States of America, **54** Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, **55** Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, **56** MRC Unit for Lifelong Health & Ageing, London, United Kingdom, **57** Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom, **58** Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Instituto de Investigació n Sanitaria del Hospital Clí nico San Carlos (IdISSC), Madrid, Spain, **59** Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, **60** National Institute for Health and Welfare (THL), Helsinki, Finland, **61** University of Helsinki, Institute for Molecular Medicine, Finland (FIMM) and Diabetes and Obesity Research Program, Helsinki, Finland, **62** Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, United States of America, **63** Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, **64** Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, Netherlands, **65** Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, United States of America, **66** Integrated Research and Treatment (IFB) Center Adiposity Diseases, University of Leipzig, Leipzig, Germany, **67** Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, **68** Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, United States of America, **69** School of Chinese Medicine, China Medical University, Taichung City, Taiwan, **70** Department of Biomedical Science, Hallym University, Chuncheon, Gangwon-do, South Korea, **71** Department of Nutrition Sciences, University of Alabama at Birmingham and the Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States of America, **72** Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America, **73** Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, **74** Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University Dusseldorf, Dusseldorf, Germany, **75** German Center for Diabetes Research (DZD), München-Neuherberg, Germany, **76** Division of Endocrinology, Diabetes, Metabolism, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH, United States of America, **77** Boston VA Research Institute, Inc., Boston, MA, United States of America, **78** Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Ehime, Japan, **79** Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Japan, **80** Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of

Medicine, Suita, Japan, **81** Genome Institute of Singapore, Agency for Science Technology and Research, Singapore, Singapore, **82** Center of Pediatric Research, University Hospital for Children & Adolescents, Dept. of Women's & Child Health, University of Leipzig, Leipzig, Germany, **83** LIFE Child, LIFE Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany, **84** Faculty of Collaborative Regional Innovation, Ehime University, Ehime, Japan, **85** Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, **86** Institute of Human Genetics, Technische Universität München, München, Germany, **87** Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany, **88** Munich Cluster for Systems Neurology (SyNergy), Munich, Germany, **89** Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States of America, **90** Center for Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, Dresden, Germany, **91** Institute of Genetic Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany, **92** Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, München, Germany, **93** DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, München, Germany, **94** Laboratory of Genetics, National Institute on Aging, Baltimore, MD, United States of America, **95** Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany, **96** Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, United States of America, **97** University of Split, Split, Croatia, **98** Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom, **99** Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom, **100** Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, United Kingdom, **101** Department of Medicine, Medical University of South Carolina, Charleston, SC, United States of America, **102** Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America, **103** Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, United States of America, **104** Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, **105** Department of Endocrinology and Diabetology, University Hospital Düsseldorf, Düsseldorf, Germany, **106** INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France, **107** Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, Paris, France, **108** Assistance Publique Hôpitaux de Paris, Bichat Hospital, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Paris, France, **109** University of Edinburgh, Edinburgh, United Kingdom, **110** Science for life laboratory, Karolinska Institutet, Solna, Sweden, **111** The New York Academy of Medicine, New York, NY, United States of America, **112** Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, München, Germany, **113** Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, **114** Health Disparities Unit, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States of America, **115** Department of Statistics and Applied Probability, National University of Singapore, Singapore, Singapore, **116** NUS Graduate School for Integrative Science and Engineering, National University of Singapore, Singapore, Singapore, **117** Department of Medicine; University of Leipzig, Leipzig, Germany, **118** Dept of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway, **119** Institute of Cardiovascular Science, University College London, London, United Kingdom, **120** Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands, **121** Department of Epidemiology and Public Health, University College London, London, United Kingdom, **122** Institute for Social and Economic Research, University of Essex, Colchester, United Kingdom, **123** Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom, **124** Ophthalmology and Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore, **125** Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, **126** Singapore National Eye Centre, Singapore, Singapore, **127** Dept of Medicine III, University of Dresden, Medical Faculty Carl Gustav Carus, Dresden, Germany, **128** Imperial College Healthcare NHS Trust, London, United Kingdom, **129** Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America, **130** Broad Institute of MIT and Harvard, Cambridge, MA, United States of America, **131** Dipartimento di Scienze Biomediche, Università di Sassari, Italy, **132** Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia, **133** Brown Foundation Institute of Molecular Medicine, Division of Epidemiology, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, United States of America, **134** Braun School of Public Health,

Hebrew University-Hadassah Medical Center, Jerusalem, Israel, **135** CNRS 8199-Lille University, France, **136** Finnish Institute for Molecular Medicine (FIMM), Helsinki, Finland, **137** Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States of America, **138** National Institute on Aging, Bethesda, MD, United States of America, **139** Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom, **140** Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, **141** Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore, **142** Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, **143** Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, United States of America, **144** Duke-NUS Medical School Singapore, Singapore, **145** National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom, **146** Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, **147** Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, United States of America, **148** The Mindich Child Health Development Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, United States of America, **149** Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, **150** Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria, **151** Synlab Academy, Synlab Services GmbH, Mannheim, Germany, **152** Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, United Kingdom, **153** Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America, **154** Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, United States of America, **155** Center for Non-Communicable Diseases, Karachi, Pakistan, **156** Department of Medicine, Central Hospital, Central Finland, Jyväskylä, Finland, **157** Division of Endocrine and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, **158** School of Medicine, National Yang-Ming University, Taipei, Taiwan, **159** School of Medicine, National Defense Medical Center, Taipei, Taiwan, **160** Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom, **161** Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, **162** Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland, **163** Dasman Diabetes Institute, Dasman, Kuwait, **164** Centre for Vascular Prevention, Danube-University Krems, Krems, Austria, **165** Saudi Diabetes Research Group, King Abdulaziz University, Fahd Medical Research Center, Jeddah, Saudi Arabia, **166** Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, United States of America, **167** Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States of America, **168** Laboratory of Epidemiology & Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States of America, **169** Department of Haematology, University of Cambridge, Cambridge, United Kingdom, **170** The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge, United Kingdom, **171** Biomedical Research Centre Oxford Haematology Theme and Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Headley Way, Headington, Oxford, United Kingdom, **172** NHS Blood and Transplant, Headington, Oxford, United Kingdom, **173** Diabetes Unit and Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, United States of America, **174** Programs in Metabolism and Medical & Population Genetics, Broad Institute, Cambridge, MA, United States of America, **175** Department of Medicine, McGill University, Montreal, Quebec, Canada, **176** Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom, **177** Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, **178** Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom

Understanding Society Scientific Group

Michaela Benzeval¹, Jonathan Burton², Nicholas Buck, Annette Jäckle², Meena Kumari¹, Heather Laurie², Peter Lynn², Stephen Pudney³, Birgitta Rabe, Dieter Wolke⁴

¹ Institute for Social and Economic Research, University of Essex, Wivenhoe Park, Colchester, Essex UK

² University of Essex

³ School of Health and Related Research University of Sheffield

⁴ University of Warwick

